

## INDEX

# Category Index

## Acute Liver Failure and Artificial Liver Support

### Acute Liver Failure and Artificial Liver Support

Pre-emptive Administration of Continuous Renal Replacement Therapy in Patients with Acute Liver Failure with Cerebral Edema improves outcomes- A randomized controlled trial.	11
Safety and efficacy of nafamostat mesylate anticoagulation in centrifugal artificial liver support system for ALF and ACLF patients at high risk of bleeding	64
DDX3X Regulates the Functional Transition of Endoplasmic Reticulum Stress During Progression of Liver Failure	103
Acylcarnitines are promising indicators of infection and mortality associated in in patients with acute liver failure.	110
Cryopreserved human alternatively activated macrophages promote the resolution of acetaminophen-induced liver injury	131
Selective ablation of FXR in neurons is neuroprotective in a mouse model of acute liver failure	226
Plasma lipidomic and fungal peptide-based community analysis identifies distinct signatures of early mortality in acute liver failure	229
Safety and efficacy of centrifugal separation plasma exchange with ACD-A on acute liver failure and acute on chronic liver failure: a single center retrospective study	4023
Artificial liver support systems is associated with improved short-term and medium-term outcomes in Patients with hepatitis B-related acute-on-chronic liver failure: A retrospective cohort study	4024
Activation of hepatocyte p53 triggers acute liver failure with multiple organ injury.	4025
Effect of plasma adsorption plus half-volume plasma exchange on intracranial pressure in acute-on-chronic liver failure	4026
Association between systemic immune-inflammation index and short-term prognosis of acute-on-chronic liver failure	4027
Association between platelet levels and bleeding events in patients with acute-on-chronic liver failure treated with artificial liver support system	4028
Therapeutic dosing of double plasma molecular adsorption system in the treatment of severe liver disease	4029
Mortality and Outcomes of Acute Liver injury in Critically ill patients: An Observational Study	4030
Enhancing ASPP2 Promotes Acute Liver Injury through Inflammatory Immunoregulatory Mechanism	4031
Characteristics of Acute Liver Failure in the Elderly in Japan: A Cross-sectional Study	4032
Melatonin mitigates sleep deprivation-exacerbated acute liver injury through Per2-mediated endoplasmic reticulum stress	4033
Expandable and Functional Hepatocytes Derived from Primary Cells with Robust Liver Repopulation Capacity	4034
Cost-effectiveness analysis of double plasma molecular adsorption system with sequential low volume plasma exchange versus plasma exchange in early HBV-ACLF	4035

Racial Disparities in Clinical Outcomes of Acute Liver Failure and Hepatic Encephalopathy: A Nationwide Population Study	4036
Lyophilized Mesenchymal Stem Cell-Derived Extracellular Vesicles Improve Acute Liver Failure Models	4037
Incidence of Acute Liver Failure and Its Associated Mortality in Patients with Dengue Infection: A Systematic Review and Meta-analysis	4038
Therapeutic plasma exchange improves 90-day transplant free survival by 2 folds in Fulminant Wilson disease with NWI > 10	4039
Role of Continuous renal replacement therapy (CRRT) in management of Pediatric Acute Liver Failure	4040
Improved outcomes of Acute Liver Failure with extracorporeal liver support- A more than a decade of experience from a tertiary centre.	4041
Endotoxin-tolerant dendritic cell-derived biomimetic exosomes loaded with iridium nanozymes for the treatment of acute liver failure.	4042
ALF listed for urgent liver transplantation in Switzerland: results of a 12-year retrospective cohort study.	4043
RBP4 Regulates APAP-Induced Liver Injury by Targeting Mitochondria	4044
Prevalence, characteristics and outcomes of infections in pediatric acute liver failure	4045
Mesenchymal stromal cell encapsulation in modified alginate affects their function, improves their cytokine production and hepatocyte support	4046
Outcomes of Plasma-Exchange and Continuous Renal Replacement Therapy in a Viral Hepatitis Predominant Cohort of Acute Liver Failure: A Multicentric Study	4047
Concerning Rise in Mortality Trends from Acute and Subacute Hepatic Failure in the United States: A 24-year Analysis of National Epidemiologic Data	4048
Risk Factors for Prolonged Length of Stay in Patients with ALF: Nationwide Analysis	4049
Programmed cell death factor 4 aggravates sepsis-induced liver damage through disturbed mitochondrial quality control system	4050
Outcomes of combination of therapeutic plasma exchange (TPE) and steroids in patients with acute severe autoimmune hepatitis with acute liver failure	4051
NextGeneration Extracorporeal Albumin Detoxification and Dialysis (ECAD) is more effective in removing toxic bile acids than Plasma Exchange (PE)	4052
Predictors of in-hospital and post-discharge mortality among acute liver failure recipients in the U.S.	4053

## Acute on Chronic Liver Failure

### Acute on Chronic Liver Failure

Optimal mean arterial pressure targets in the management of critically ill patients with decompensated cirrhosis and septic shock	3
★ Inhibition of necroptosis reduces inflammation, neutrophil activation, liver fibrosis and improves multiorgan damage	29

★, Foundation Award Recipient

Copyright © 2024 American Association for the Study of Liver Diseases.

(kidney function and neuroinflammation) in a murine model of alcohol-induced ACLF		Predicting Mortality and Cirrhosis-Related Complications with MELD3.0: An Analysis of a Multicenter Cohort	1601
Initiation of renal replacement therapy in critically ill patients with cirrhosis/chronic liver disease: a secondary analysis of STARRT-AKI trial	73	The Etiology of Chronic Liver Disease is an Independent Prognostic Factor in Patients with Acutely Decompensated Chronic Liver Disease.	1602
Autologous macrophage therapy decreases major clinical outcomes in patients with compensated cirrhosis: extended data from a randomized controlled Phase 2 trial	95	Effect of VS-01 on Acute-on-Chronic Liver failure-related toxins such as lipopolysaccharide and hydrophobic bile acids in vitro	1603
Phenotypes, natural course, and outcomes of acute kidney injury (AKI) in patients with acute-on-chronic liver failure (ACLF): Results from the ICA-Global AKI Study.	117	Mesenchymal Stem Cell Promote Macrophage Efferocytosis in The Context of ACLF Via Arid3a/Mertk Axis	1604
Serum albumin-binding capacity correlates with serum albumin structural alterations and clinical outcomes in patients with acutely decompensated cirrhosis and acute-on-chronic liver failure	127	Comparative Efficacy of Mycophenolate Mofetil vs. Azathioprine in Autoimmune Hepatitis: A Systematic Review and Meta-Analysis	1605
Individual nutrition support in patients with HBV-ACLF at nutrition risk: preliminary results of a randomized controlled clinical trial	243	Early Inpatient Paracentesis Associated With Lower Inpatient Mortality Compared to The Late Paracentesis	1606
Neutrophil Extracellular Trap Scores Predict 90-Day Mortality in Hepatitis B-related Acute-on-Chronic Liver Failure	1581	AARC Liver failure score based on registry of 10,994 patients is a better prognostic model for ACLF patients justifying global application and expansion of AARC database	1607
Actein Inhibits NETosis in Acute-on-Chronic Liver Failure by Targeting the Mac-1/RhoA GTPase/PAD4 Axis	1582	Drivers of organ failures and patient trajectories favoring the development of acute-on-chronic liver failure among hospitalized patients with acute decompensation of cirrhosis: a multi-centric cohort study	1608
Dissecting liver inflammation ecosystem identifies annexin A1 as a pro-resolving target for liver failure	1583	Resource utilization following liver transplantation for acute on chronic liver failure in alcohol associated liver disease.	1609
The Use of Sodium-glucose Cotransporter-2 Inhibitors (SGLT2-i) in Addition to Furosemide and Spironolactone in Patients with Decompensated Cirrhosis: An International Analysis	1584	Evolving role and outcome of liver transplantation for acute-on-chronic liver failure: a 20-year single-center experience.	1610
Shifting of PBMC Transcriptomic Landscape from Acute Decompensation to Acute-on-Chronic Liver Failure	1585	Nutrition care in acute on chronic liver failure in the intensive care unit	1611
Monocyte/macrophages-derived RESISTIN is a potential therapeutic target for acute-on-chronic liver failure	1586	Designation of Acute-on-Chronic Liver Failure in Patients with Severe Alcoholic Hepatitis	1612
A new prognostic method for acute-on-chronic liver failure: a machine learning prognostic model based on elastography	1587	Hepatic irradiated pigs develop radiation induced veno-occlusive liver disease with ferroptosis	1613
Malnutrition Impact on Patients with Cirrhosis; A Nationwide Analysis	1588	Use of continuous renal replacement therapy in critically ill patients with cirrhosis/acute-on-chronic liver failure: the Multicentre CRRNet substudy	1614
Argonaute-2 Autoantibodies Reveal Prognosis in HBV-Related Acute-on-Chronic Liver Failure Patients with Cirrhosis	1589	Cirrhotic Cardiomyopathy Independently Increases Post-Transplant Mortality in Patients Transplanted For Acute on Chronic Liver Failure: The MODEL Consortium Experience	1615
Development and patterns of acute-on-chronic liver failure in cirrhotic patients with acute kidney injury: implications for prognosis and therapeutic approaches	1590	The Echocardiographic Markers of Cirrhotic Cardiomyopathy Can Independently Predict Circulatory Failure and Posttransplant Death in Patients with Acute on Chronic Liver Failure: 15 Centers Experience	1616
Single-cell multimodal analysis reveals the dynamic immunopathogenesis of HBV-ACLF progression	1591	Albumin Reprograms the B cell Transcriptional Landscape and Rescues Neutrophil Dysfunction in Immunocompromised Patients with Advanced Cirrhosis	1617
SEMA6B accelerates acute-on-chronic liver failure by triggering systemic inflammation and hepatocyte apoptosis	1592	Deep Learning Model for Prediction of Prognosis in Patients with Acute-on-Chronic Liver Failure	1618
Comparative analysis of Liver cirrhosis and Acute Coronary Syndrome (STEMI and NSTEMI) and their outcomes: Case Control Study of an In-patient analysis	1593	Clinical Characteristics of Recurrent Bacteremia in End-stage Liver Disease: 10-year Experience in a Single Center in Southwest China	1619
HIV patients with Low CD4 counts and the development of Acute Liver Injury and Cirrhosis: An In Patient Analysis Study from 2016-2020	1594	Platelet count, liver and spleen stiffness-based model identifies high risk esophageal varices in Acute-on-chronic liver failure	1620
Panose, an intestinal microbial derived prebiotic reduces the risk of bacterial infection during acute-on-chronic liver failure by repairing the oxidative stress-induced intestinal barrier disruption	1595	Pharmacokinetics and Safety of Tenofovir Alafenamide in Chinese Patients with Acute-on-Chronic Liver Failure	1621
Integrating prior decompensation in ACLF definitions for simplified clinical management	1596	Hemoadsorption with continuous renal replacement therapy reduces catecholamine requirements and hypercytokinemia in ACLF patients with septic shock and stage 3 AKI- A prospective cohort study.	1622
Intravenous administration with the ASK1 inhibitor SRT-015 alleviates liver injury and systemic inflammation in disease models of liver failure	1597	Role of Notch Mediated Hepatocyte Reprogramming in Sepsis Induced Liver Failure	1623
MSC-derived Extracellular Vesicles Alleviate Ischemia Liver Injury via Inhibiting NETs Formation	1598	Predictors of one-year transplant-free survival of patients with acute-on-chronic liver failure after hospital discharge	1624
Natural killer cell-derived extracellular vesicles alleviate CD8+ T cell exhaustion in acute-on-chronic liver failure via TGF- $\beta$ /Smad pathway	1599	Evaluating the Impact of Pre-Liver Transplant Acute-on-Chronic Liver Failure on Post-Liver Transplant Prognosis in Patients with Alcohol-Associated Liver Disease	1625
A Nation-wide Retrospective Cohort study of the Outcomes, Prevalence and Comparative analysis of Liver Cirrhosis and Pulmonary Hypertension	1600	How Does the Presence of Pre-Transplant Acute-on-Chronic Liver Failure Affect Post-Liver Transplant Outcomes Among	1626

Patients with Metabolic Dysfunction-associated Steatotic Liver Disease		★ Gastrointestinal and liver adverse effects of medical treatments of alcohol use disorder: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database	69
Serum Galectin-3 as a Predictor of Infections and Mortality in Acute-on-Chronic Liver Failure	1627	★ Absence of intestinal Mucin-2 Promotes Goblet Cell-associated Antigen Passages Formation to Prevent Ethanol-induced Steatohepatitis in mice.	80
The Influence of Geographical Differences and COVID-19 on Hepatic-Failure Related Mortality Rates	1628	★ Alpha diversity analysis of hepatic transcriptome reveals distinct signatures and predicts novel pathways in alcohol-related hepatitis.	145
How Important is Acute-on-Chronic Liver Failure Grade for Post-Liver Transplant Outcomes? A Single-Center Analysis	1629	Video-Based Multi-Center Collaboration with County Public Health Department to Enhance Delivery of Alcohol-Associated Liver Disease Care by Community Providers	148
Novel Role of Lsecs in Hepatic Immune Function During Sepsis	1630	Role of FAF2, Fas associated factor family member 2, in the pathogenesis of alcohol-associated liver disease	150
Predictors of Reversal of Acute on Chronic Liver Failure and need for therapeutic goals to extend timelines beyond 90 days	1631	The Lipidomic Profile discriminates between metabolic dysfunction-associated steatotic liver disease and combined metabolic dysfunction- and alcohol-related steatotic liver disease	156
Longitudinal Trajectories and Outcomes in Acute Decompensation and Acute-on-Chronic Liver Failure	1632	Artificial intelligence-derived granular histological markers of inflammation and fibrosis associate with progression in patients with alcohol-related steatohepatitis	163
<b>Advanced Practice Providers (NP, PA, RN, PharmD, etc.)</b>		★ Ahead, A Novel Validated Machine Learning Model for Clinical Diagnosis of Alcohol-associated Hepatitis	171
<b>Behavioral and Quality Issues</b>		Initiation of naltrexone is associated with lower rates of AKI, SBP, and mortality in patients with decompensated alcohol-associated cirrhosis and ascites	175
Rapid Start-up of A Field-based Hepatitis C Elimination Program Enabled by State Funded 340B Initiative	244	★ Variable Treatment and Access to Liver Transplantation for Alcohol Associated Liver Disease: The California Liver Network	179
Impact of Health Coaching for patients with MASLD in a community-based liver center	2216	Alcohol Behavior Change in Veterans with Unhealthy Alcohol Use: Assessing the Short Term Impact of Personalized Liver Biofeedback Using FibroScan with Brief Intervention	194
<b>Advanced Practice Providers (NP, PA, RN, PharmD, etc.)</b>		Effects of Timely Treatment on Outcomes of Larsucosterol for Severe Alcohol-associated Hepatitis (AHFIRM Trial)	198
<b>Practice Issues</b>		Alcohol-associated hepatitis remains a highly fatal condition: Results from a contemporary prospective multicenter cohort study from the United States	206
Pharmacist-Driven Strategies Improve Hepatitis C CURES in a Variety of Practice Settings	149	Therapeutic Efficacy of Varenicline Tartrate in Attenuating Alcohol Craving in Patients Suffering from Alcohol Use Disorder and Met-ALD.	210
★ Enhanced Patient Knowledge and Confidence in Managing Metabolic Dysfunction-Associated Steatotic Liver Disease Through Behavioral Resources and Intervention Through Digital Group Education (BRIDGE): A Shared Medical Appointment Program	181	★ Long-term Outcomes of Bariatric Surgery in Patients with Combined Metabolic Dysfunction and Increased Alcohol Consumption (MetALD)	216
Evaluation of Pharmaceutical Care Service (PCS) for Liver Cirrhosis Patients in Acute Tertiary Hospital in Singapore	2214	Use of pharmacological therapies for alcohol-associated hepatitis in Alberta: impact of shifting evidence and guideline-based recommendations	236
Transplanting Hepatitis C NAT positive solid organs into HCV negative recipients; an Advanced Practice Provider (APP) led clinic, 4-year real world outcomes	2215	Evolving Trends and Outcomes for Alcohol-Associated Hepatitis Patients with severely High MELD Scores on the US Liver Transplant Waitlist	3001
<b>Alcohol-Associated Liver Diseases: Clinical and Experimental</b>		In-hospital Outcomes for Acute Alcohol Associated Cirrhosis and Major Cardiac Arrhythmias	3002
<b>Alcohol-Associated Liver Diseases: Clinical and Experimental</b>		Mortality From Alcohol-associated Liver Disease and Alcohol Use Disorder is Decreasing Globally yet Increasing in the United States	3003
★ Impact of Glucagon-like Peptide-1 Receptor Agonists on the Risk of Adverse Liver Outcomes among Patients with Alcohol-associated Liver Disease and Type 2 Diabetes.	9	Vitamin D deficiency exacerbates alcohol-associated liver disease via gut barrier dysfunction and hepatic overload of endotoxin in mice	3004
Fecal Microbiota Therapy is a safe and effective option in Steroid Ineligible Alcoholic Hepatitis (FEMTAH Trial): a RCT	13	Targeting mitochondrion-nucleus PDH1 transfer suppresses self-renewal and epigenetic NANOG reprogramming of liver tumor-initiating cells induced by alcohol Western diet	3005
★ Fecal proteomics links neutrophil degranulation with mortality in patients with alcohol-associated hepatitis	38	Administration of polyethylene glycol ameliorates inflammation of liver and gut, and hangovers against acute alcohol consumption	3006
Pyruvate dehydrogenase kinase 4 Promotes Mitochondrial Dysfunction in Alcohol-Associated Liver Disease by Regulating ER-Mitochondria Interaction	51	Cognitive Interviewing of Experts and Patients to Develop an Alcohol Insight Scale for Patients with Alcohol-Associated Liver Disease	3007

ATP-Binding Pocket Inhibitor for Mixed Lineage Kinase Domain-like Protein (MLKL) Attenuated Alcoholic Liver Disease via Necroptosis-independent Pathway	3008	Obesity and acute alcohol-associated hepatitis: adding insult to injury	3034
Comprehensive profiling of infiltrated circulating immune cell types and their subset responsible for alcoholic steatohepatitis by scRNAseq analysis	3009	Bile Acid Induces Retinol Metabolism in Hepatic Stellate Cells to Activate Glutathione Synthetic Machinery for Protection against Alcohol-associated Steatohepatitis	3035
Clinical Outcomes of Alcohol-Associated Liver Disease in a Medical Center in Taiwan	3010	Influence of the COVID-19 pandemic and alcohol on hospitalizations for decompensated liver disease	3036
Trends in Hospitalizations for Alcohol Related Hepatitis in the Pre-COVID, COVID, and Post-COVID Era: A National Database Study	3011	Incorporating Sarcopenia to Enhance Mortality Prediction in Severe Alcoholic Hepatitis	3037
Impacts of smoking on alcoholic liver disease: A nationwide cohort study	3012	Incidence and Predictors of Long-Term Risks of Cirrhosis Among Veterans with Alcohol-Associated Liver Disease	3038
Prevalence and impact of cardiometabolic risk factors in alcohol-related liver disease and MetALD	3013	Development of an EHR-based Algorithm to Identify Recompensation in Alcohol-Associated Liver Disease	3039
Distinct neutrophil phenotypes infiltrate the liver in different liver diseases	3014	A Balancing Act: The Life-Saving Potential and Dilemma of Liver Transplantation as an Endpoint in Alcohol-Associated Hepatitis Trials	3040
Targeted Breath Biopsy profiling of induced biomarkers unveils a metabolic adaptation in cirrhosis toward alcohol production	3015	Combination of high-fat diet with chronic ethanol consumption in mice results in early-stage alcohol-associated liver disease.	3041
The impact of integrated care on clinical outcomes in patients with alcohol-associated liver disease: early outcomes from a multidisciplinary clinic.	3016	A Novel Role of STARD10 In ERBB2-mediated Lipogenesis in Alcohol-associated Liver Disease	3042
Autophagy deficiency induces the expression of interferon-stimulated genes in mouse livers	3017	A Novel Role of Phosphorylated Ubiquitin Conjugating Enzyme 9 on Lipogenesis in Alcohol-associated Liver Disease	3043
Sympathetic nervous system-beta 3 adrenergic receptor-mediated lipolysis in binge drinking-induced fatty liver disease	3018	A role for the C5 complexosome in Kupffer Cell polarization in Alcohol Associated Liver Disease	3044
Beer Consumption is Associated with Low Dietary Quality Among Alcohol Users	3019	Trends in Alcohol-Associated Hepatitis Among U.S. Veterans: Exploring Alternative Definitions Beyond Solely Using ICD-9/10 Codes to Improve Accurate Estimates of Disease Burden	3045
Cardiolipin Treatment in hepatocyte specific Ptpmt1-/- mice is Hepatoprotective in an Animal Model of Alcohol-associated Hepatitis	3020	UBC9 Phosphorylation Regulates Cytokine Secretory Signaling in Alcoholic Associated Liver Disease	3046
Patients Receiving Liver Transplantation for Acute on Chronic Liver Failure and Known Alcohol Related Liver Disease have Equivalent Relapse Risk Compared to those Transplanted for First Presentation of Severe Alcohol Related Hepatitis	3021	Engagement with addiction medicine post-liver transplant increases treatment for alcohol use disorder	3047
Effect of diabetes on mortality and liver transplantation in alcoholic liver cirrhotic patients with acute decompensation	3022	The Histologic Features of Severe Alcohol-Associated Hepatitis Undergoing Liver Transplantation: An Explant Study	3048
Body mass index influences liver-related mortality after the first decompensation event in patients with alcohol-related liver disease	3023	Global landscape of skeletal muscle mitochondrial functional and structural perturbations in sarcopenia of alcohol related liver disease	3049
Potential Use of Ipsc-derived Hepatocyte-like Cells to Develop Precision Medicine for Ash	3024	The Role of Psychotherapy Alone in Reducing Alcohol Return to Drinking in Patients with Chronic Liver Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials	3050
The role of C/EBP $\beta$ -SAA1/2 axis in alcohol-associated liver disease resolution.	3025	Hepatic Stellate Cells and Alcohol: Investigating Canonical Wnt/ $\beta$ -catenin Signaling in Models of Alcohol-associated Liver Disease	3051
Prevalence of Infection in Alcohol-Associated Hepatitis and Impact on Mortality	3026	Naltrexone Use in Patients with Combined Metabolic and Alcohol-associated Liver Disease (MetALD), Propensity Score Matched Study	3052
Clinical impact of harm reduction in patients with chronic liver disease and alcohol use disorder by brief intervention in a hepatology outpatient unit	3027	Predictors of survival and hepatic recompensation in patients with ALD referred for early liver transplantation	3053
Cardiometabolic Comorbidities are Associated with Lower Rates of Recompensation and Transplant Free Survival in Patients with Acute Alcohol Associated Liver Disease	3028	Brewing Bias: Alcohol biomarker testing trends for patients on the liver transplantation waitlist	3054
Early pharmacologic treatment of alcohol use disorder and psychiatry consultation are associated with improved overall survival in severe alcohol-associated hepatitis	3029	Using a human liver-on-a-chip model to study alcohol-associated liver disease by targeting LSECs and ALDH2	3055
Treatment of Alcohol Use Disorder With Medications and With Integrated Care Model Benefit Patients With Alcohol-associated Liver Disease	3030	Population Based Screening For Alcohol Associated Liver Disease Using the Electronic Health Record	3056
Survival benefit from corticosteroids in severe alcohol-associated hepatitis attributed to clinical and treatment differences in a large multicenter cohort	3031	Cirrhosis is Associated With Worse Outcomes in Hospitalizations for Alcohol Withdrawal	3057
Prognostic significance of skeletal muscle mass in patients with alcoholic cirrhosis	3032	Subcutaneous Injection of Galanin Attenuates Alcoholic Hepatitis and Abdominal Adipose Tissue Inflammation Induced by Ethanol Binge in OB/OB Mice	3058
Screening of compensated alcohol-related liver disease: efficacy of a holistic approach (hepatology visit, brief intervention, and non-invasive test) on alcohol abstinence and relapses	3033	Statin therapy may protect against variceal bleeding in patients with alcohol-associated liver disease	3059
		Real-world Evidence of Emerging Health Disparities in Severe Alcoholic Hepatitis Incidence in the Post-COVID Era	3060

What is the correlation between AUDIT score and phosphatidylethanol level both taken on admission to a tertiary liver unit? A cirrhosis registry study Skladany L1,2, Ciefova J1, Adamcova Selcanova S1, Zilincanova D1, Havaj D1, Sulejov&aacute; KK1, Gazda J2, Laffers L3, Arab JP4,5	3061	Assessment of Early Return to Drinking in Patients with Alcohol-Associated Hepatitis	3089
Short-term Costs of Alcohol-associated Hepatitis Care in Different Clinical Settings	3062	National Trends in Metabolic Risk Factors and Alcohol Use from 1999 to 2018 in Emerging Adults Aged 20-25	3090
Impact of Steroids and Infection on Mortality in Alcohol-related Hepatitis	3063	Plasma cell-free mtDNA is released in alcohol-related liver disease and correlates with liver injury	3091
Growth Differentiation Factor 15 and Adrenergic Receptor $\beta$ 2 Regulates Anti-Inflammatory Adipose Foamy Macrophages in Alcohol-Associated Liver Disease	3064	Sex differences in characteristics and outcomes of Veterans with alcohol-associated hepatitis	3092
Development of alcohol-associated hepatocellular carcinoma mouse model	3065	Comparative Analysis of Prognostic Models in Alcohol-Associated Hepatitis	3093
Gene isoform transcript usage is associated with higher alcohol-associated hepatitis susceptibility in females than males	3066	Identification of Alcohol-associated Hepatitis Using Electronic Medical Records	3094
Prognostic Utility of Systemic Inflammatory Response Syndrome Criteria in Acute Alcoholic Hepatitis	3067	GLP-1 Receptor Agonism Reduces Injury, Hepatic CYP2E1 Activity and Increases Antioxidant Activity in A Mouse Model of Alcohol-induced Acute Hepatitis	3095
Ethanol induced skeletal muscle senescence contributes to sarcopenia in alcohol related liver disease.	3068	Prevalence, Risk Factors, and Outcomes of Fungal Infections in Patients with Severe Alcohol-Associated Hepatitis	3096
Retinoic Acid Pathway Protects Against Oxidative Stress in Alcohol-Associated Liver Diseases	3069	Molecular targets of PXR-dependent ethanol-induced hepatotoxicity in female mice	3097
Cholesterol toxicity and PON-1 levels in alcohol-associated hepatitis correlate with severity and survival	3071	Impact of Social Determinants of Health on Transplant Candidacy for Alcohol-Associated Liver Disease	3098
US Trends in Alcohol Use after the COVID-19 Pandemic: A National Cross-Sectional Study	3072	Comparative Effectiveness of Different Corticosteroids in Predicting 30-Day Mortality and Clinical Outcomes in Severe Alcohol-Associated Hepatitis	3099
Longitudinal Outcomes And Recovery In Patients With Decompensated Alcohol Associated Liver Disease	3073	Alcohol Use Disorder Treatment During Evaluation in Patients with ALD Referred for Early Liver Transplant	3100
Biased agonism of FPR1 signaling in neutrophils mitigates alcohol-associated liver disease	3074	Demographic Disparities in The Outcomes of Patients Admitted with Alcohol-Associated Hepatitis: A Cross-Sectional Study	3101
Alcohol binge drinking impairs lipid metabolism in healthy hamsters and aggravates liver lesions in diet-induced obese MASH hamsters	3075	Development of Alcohol-associated Liver Disease in Young Indian Adults: An Observational Study of Clinical and Socio-Demographic Correlates and opportunities for early intervention	3102
Deciphering the impact of myeloid cell-derived osteopontin in alcohol-associated liver disease	3076	Impact of COVID-19 on Alcoholic-Related Hepatitis Admissions at a Midwest Tertiary Care Hospital	3103
Dysregulated Lysosome Biogenesis and Abnormal Lysosomal Activity Potentially Drive Human Alcohol-Associated Liver Disease	3077	Cardiometabolic Comorbidities Influence Early Mortality in Patients with Alcohol-associated Hepatitis (AH)	3104
Biochemical and Histological clues in Metabolic Dysfunction and Alcoholic Associated Liver Disease (MetALD)	3078	Initiation of naltrexone is associated with lower rates of SBP and mortality than acamprosate in patients with decompensated alcohol-associated cirrhosis	3105
The Impact of Type 2 Diabetes (T2D) on the Outcomes of Liver Transplantation (LT) Among Patients with Alcohol-associated Liver Disease (ALD) In the United States	3079	Performance of urine rapid Ethyl glucuronide testing to characterize recent and unhealthy alcohol use at HIV clinics in Zambia	3106
Prior Diagnosis of Decompensated Alcohol-Associated Liver Disease Does Not Increase Risk of Alcohol Relapse During Transplant Evaluation and May Increase Risk of Post-Transplant Alcohol Relaps	3080	Therapeutic inhibition of Bruton's tyrosine kinase (BTK) acts on both immune cells and hepatocytes to attenuate immune cell activation and steatosis in a mouse model of alcohol-associated hepatitis	3107
Alcohol-associated liver disease (ALD) is associated with less adverse outcomes compared to non-alcohol-associated liver disease (NAALD) in hospitalized patients with COVID-19	3081	Elevated systemic IgM antibodies targeting malondialdehyde adducts promote alcohol-associated liver disease via complement activation.	3108
Understanding the immune landscape of alcohol-related liver disease through fibro-inflammatory serological biomarkers	3082	Single-cell RNA sequencing analysis reveals specific cell subpopulations in alcohol-associated hepatitis characterized by inflammatory, angiogenic and fibrogenic profile	3109
The Association of Dysregulated Sphingolipid Metabolism and microRNAs with Alcohol-associated Liver Diseases	3083	Survival Outcomes in Patients with Severe Alcohol-Associated Hepatitis Receiving Dialysis	3110
A Nationwide Analysis of the Outcomes among Hospitalized Cardiogenic Shock Patients with Alcoholic Cirrhosis: A United States Population-Based Cohort Study	3084	Modulation Of MAIT Cells By FMT Ameliorates the Intestinal and Hepatic Inflammatory Milieu, Improves Gut Barrier Function and Clinical Outcomes in Severe Alcohol Associated Hepatitis	3111
Non-enzymatic Targeting of Metabolic-Alcohol-Associated Liver Disease and Cancer associated with ALDH2 deficiency and altered TGF-beta Signaling	3085	Predictive value of NLR in short-term prognosis of patients with severe alcoholic hepatitis	3112
Formoterol promotes mitochondrial biogenesis and decreases liver injury after chronic-binge ethanol (CBE) treatment in mice	3086	Liver-related Complications are Associated with Worse Outcomes in Patients with Severe Alcohol-Associated Hepatitis	3113
Post-liver transplant PETH monitoring: Potential as an early Biomarker for Rejection and Graft Failure	3087	Complement activation is associated with lower eGFR and markers of kidney injury in patients with severe alcohol hepatitis.	3114
Liver injury in heavy drinking individuals is associated with elevated levels of plasma soluble epoxide hydrolase	3088	Chronic ethanol insult damages hepatocellular lysosomes	3115

Impact of area-level income and residence on in-hospital mortality and intensive care unit admissions among patients with cirrhosis and alcohol-related hepatitis hospitalizations: A population-based study.	3116	Role of ghrelin hormone in the development of alcohol-associated liver disease via dysregulating GLP-1 receptor-mediated signal transduction	
The effect of area-level material and social deprivation on cirrhosis and alcohol-related hepatitis hospitalization rates during the COVID-19 pandemic: A population-based study.	3117	Drinking Behavior in the AHFIRM trial as measured by Phosphatidyl Ethanol	3140
Engineered Human Liver Co-cultures to Model Hepatic Dysfunctions in MetALD	3118	Sustaining A-Kinase Anchoring Protein-12 Expression During Alcohol Exposure Maintains PKA Signaling And Regulates Steatosis	3141
Impact of Pre-Transplant Steroid Therapy on Early Post-Transplant Infections in Alcohol-Associated Hepatitis Patients Undergoing Liver Transplantation	3119	Integrated hepatology and addiction medicine consultation for hospitalized patients with alcohol use disorder reduces future liver-related decompensating events.	3142
Rising Trends of Concurrent Mood Disorders in Hospitalized Patients with Alcohol-Associated Liver Disease Between 2014 and 2023: A Nationwide Study of Insured and Uninsured Populations	3120	Phosphodiesterase 4 inhibition mitigates alcohol-induced intestinal dysfunction and the development of alcohol-associated steatohepatitis (ASH)	3143
Post-Transplantation Outcomes in Alcohol-Related Liver Disease: Higher Relapse Rates Associated with Alcohol-Associated Hepatitis	3121	IL-17 signaling coordinates TNFR1-dependent NF- $\kappa$ B activation in hepatocytes during ALD.	3144
The forever chemical, perfluorooctane sulfonate (PFOS), alters hepatic metabolism and worsens alcohol-associated liver disease severity in a chronic-binge ethanol feeding model	3122	The Development, Feasibility, and Usability of an Artificial Intelligence-Enabled Conversational Agent in Virtual Reality for Patients with Alcohol-Associated Cirrhosis	3145
Risk Reduction is Possible in Patients with High-Risk SIPAT Scores Undergoing Liver Transplantation for Alcohol-Related Liver Disease	3123	Sociodemographic disparities in access to liver transplantation waitlist in patients with Alcohol associated liver diseases: A single center study.	3146
Trends in Post-Discharge Pharmacological Alcohol Cessation Therapy and Psychiatric Referrals for Hospitalized Patients with Alcohol-Associated Liver Disease (ALD) Between 2014 to 2023: A Nationwide Study	3124	Post-transplant Outcomes in Patients With and Without Alcohol Relapse Following Liver Transplantation for Alcohol Associated Liver Disease	3147
The role of Kupffer cell-derived Let7a-5p in regulating hepatocyte differentiation during alcohol-associated liver disease.	3125	Abstinence triggers site-specific metabolomic changes in the resolution of Alcohol-related Liver Disease	3148
The role for Keratin18 M30 as a Companion Diagnostic for Glucocorticoid Therapy in Severe Alcohol-associated Hepatitis (sAH)	3126	The Clinical Significance of Homelessness on the Hospital Outcomes of Patients Admitted with Alcohol-associated Liver Disease	3149
A novel MetALD spheroid model reveals differential effects of ethanol and metabolic stressors on mitochondrial respiration and synergistic increases in lipid accumulation	3127	National Trends in the Costs of Patients Admitted with Alcohol-associated Liver Disease Stratified by Patient Demographics: Analysis of National Hospital Database	3150
Alcohol-induced liver injury is mediated via $\alpha$ 4 nicotinic acetylcholine receptors expressed in hepatocytes	3128	National trends in the Costs of Patients admitted with Alcohol Associated Liver Disease Stratified by Psychiatric Comorbidities and Substance Use: Analysis of National Hospital Database	3151
Identification of environmental pollutants and metabolic pathways in human subjects with alcohol-associated hepatitis	3129	Identifying Risk Factors for Return to Alcohol Use in Post-Liver Transplant: The Role of Sobriety Duration and Age	3152
Acute-on-Chronic Liver Failure (ACLF) criteria in Alcohol-associated Hepatitis: Implications for Liver Transplantation	3130	Integrated hepatology and addiction care for hospitalized patients with alcohol use disorder improves medical alcohol therapy engagement at discharge	3153
Precision cut liver slice disease model recapitulates human liver disease biology for preclinical drug developmentSofia Izunza Barba, Denisse Rubio-Cruz, Hua Xu, Susmita Bhattacharai, Z. Gordon Jiang	3131	Feasibility of Radiomics in Prediction of Overall Mortality in Severe Alcoholic Hepatitis: A Pilot Study	3154
Inflammation during alcohol associated hepatitis is mediated by liver sinusoidal endothelial cell production of Galectin-9 and PD-L1	3132	Hepatocyte-specific deletion of betaine homocysteine methyltransferase promotes age-dependent progression of liver disease	3155
Thirty-Day Readmissions Among Patients with Alcoholic Hepatitis, Risk factors, Impact on Mortality and Healthcare Resource Utilization: A Nationwide Analysis	3133	Exploring the interplay of graded alcohol use and excess weight on atherogenic lipid profiles among Latinos with underlying chronic liver disease	3156
Prevalence and outcome of Concomitant Hepatitis B or C infection in Alcohol associated Liver Disease	3134	Differences in Alcohol Use Disorder Treatment and Return to Drinking According to Severity of Alcohol-Associated Hepatitis	3157
IL17 signaling in liver sinusoidal endothelial cells mediates inflammation in alcohol associated hepatitis	3135	A Prospective Study Evaluating the Prevalence of Steatotic Liver Disease and Advanced Fibrosis and Cirrhosis in Overweight and Obese Individuals in the United States	3158
Perturbations in the Peripheral T Cell Niche of Patients with Alcohol-Associated Hepatitis Provide Mechanistic Insights into Immune Paralysis	3136	The care of acute alcohol associated hepatitis at a large tertiary care and liver transplant center: assessing knowledge gaps	3159
Hepatic Methyltransferase Proteins Mediate PNPLA3-I148M-Driven Lipid Droplet Dynamics in Fatty Liver	3137	Real-World Outcomes of Corticosteroid Use in Severe Alcoholic Hepatitis Post-STOPAH Trial: A propensity matched cohort study	3160
Medications for AUD in Patients with Alcohol-associated Cirrhosis or Hepatitis: No hepatotoxicity, but side-effect risks and decompensation	3138	Hepatocyte-specific deletion of betaine homocysteine methyltransferase promotes alcohol-induced liver injury	3161
	3139	Psychiatric Comorbidities and Risk of Return to Drinking Amongst Liver Transplant Recipients	3162
		Altered lipids in patients and humanized mice with alcoholic hepatitis modulate liver immune responses	3163



Impact of Alcohol Use Disorder Remission on Outcomes Post-TIPS Procedure: A Retrospective Cohort Study	3164	Abcb4/Mdr2 haploinsufficiency predisposes mice to biliary injury and secondary cholestasis and defines a translational model of toxic bile induced hepatobiliary injury in human cholangiopathy	4018
Liver Transplantation in Alcoholic Hepatitis and ACLF: Redefining Selection and Sobriety Criteria	3165	Hepatobiliary-restricted Dcdc2 deletion serves as a genetic mouse model of cholangiopathy and rapidly progressive liver fibrosis	4019
Alcohol intervention after acute variceal bleeding: reduces alcohol consumption, but remains underutilized in real-world setting	3166		

## Biliary Physiology, Transport, Cholangiocyte Biology, and Experimental Cholestasis

### Cholangiocyte Biology

Deletion of biliary atresia candidate gene Pkd111 in isolated murine cholangiocytes cultures leads to enhanced basal and reactive pro-inflammatory gene expression	18
Aramchol, a stearoyl-CoA desaturase inhibitor, attenuates the TGF $\beta$ -stimulated fibroinflammatory signals in cholangiocyte models of primary sclerosing cholangitis	4012
Novel etiology for cholestatic cholangiopathies caused by MRP9 deficiency	4021

## Biliary Physiology, Transport, Cholangiocyte Biology, and Experimental Cholestasis

### Experimental Cholestasis

★ snRNAseq and GeoMx spatial transcriptomics elucidate the cell-type-specific roles of lncRNA H19 in cholestatic liver injury	118
Notch signaling disruption and cellular crosstalk: dissecting the pathophysiology of bile duct paucity in Alagille syndrome using human liver organoids.	238
The competing role of hepatic X-box binding protein 1 (Xbp1) in bile acid metabolism and bile-acid induced injury in murine chronic cholestasis	245
Histone deacetylase inhibitor MS-275 reduces liver injury, inflammation, and fibrosis in a mouse model of cholestatic liver disease	4002
The PPAR-delta agonist seladelpar normalizes primary biliary cholangitis-like features in human cholangiocytes and reduces pathological immune activation	4004
Experimental sclerosing cholangitis: paradoxical effects of an anti-fibrotic strategy	4006
Cholesterol-dependent Mitochondrial GSH Status Determine the Hepatotoxicity of Bile Acids in Cholestasis	4007
Reducing neutrophil infiltration is protective in Primary Sclerosing Cholangitis	4009
Altered expression of tight junction proteins Claudin 2 and 3 protects the liver from cholestatic injury	4010
Thalamic volume reduction and neural circuit alterations in cholestatic mice parallel changes in patients with primary biliary cholangitis	4011
The involvement of LECT2 in the fibrosis mechanism of primary sclerosing cholangitis	4014
AGMB-101, a full agonistic antibody of MET, achieves deep suppression of cholestatic disease in Mdr2 KO mice through a pleiotropic mechanism of action	4015
PPAR $\delta$ ; activation with seladelpar regulates multiple inflammatory checkpoints in the human cholangiocyte cell line H69	4017

## Biliary Physiology, Transport, Cholangiocyte Biology, and Experimental Cholestasis

### Transport, Bilirubin, Cholesterol, Lipids, and Bile Salts

★ Heterozygous Knockout of Bile Salt Export Pump Induces Alterations in the Gut-Liver Axis Including Gut Microbiota in Mice Fed a High-fat Diet	59
Hydrophobic secondary bile acids induce primary sclerosing cholangitis through the liver-large intestine axis in a Cyp2c70 $^{-/-}$ /Cyp2a12 $^{-/-}$ mouse with human-type bile acid composition	4001
3D reconstruction of biliary system in the bioengineered livers using decellularized scaffolds	4003
Regulation of hepatic multidrug resistance-associated protein 3/ATP-binding cassette subfamily C member 3 (MRP3/ABCC3) by peroxisome proliferator-activated receptor (PPAR): a novel mechanism to reduce bile acid injury during cholestasis	4005
Regeneration of bile duct by replacing artificial bile duct made of Gelatine Hydrogel Nonwoven Fabric (GHNF) in pig	4008
Alcohol Consumption in Mice Lacking the Bile Acid Receptor Tgr5	4013
Increased Incidence of Rectal Prolapse in FGF15 Transgenic Mice is Caused by Chronic Diarrhea and Electrolyte Imbalance	4016
Protectin DX exerts promising anti-inflammatory, antioxidant and anti-fibrotic properties in liver cells	4020

## Cell and Molecular Biology

### Cell Structure and Function

Autophagy impairment leads to multiple forms of cell death in the liver	77
★ Hepatic lymphangiogenesis regulates biliary cell proliferation during liver regeneration after partial hepatectomy	220
Regulation of Lipid Droplets by Endosomal Sorting Complexes in Liver Steatosis	4232
Identifying novel peri-droplet-mitochondrial interface proteins of oleic acid-treated HepG2 cells using microscopy-guided subcellular spatial protein purification	4235
Fuzheng Jiedu Xiaoji formula inhibits the STAT3 pathway of hepatocellular carcinoma cells to improve CD8 $^{+}$ T cell function	4237
KDM4C represses liver fibrosis by regulating H3K9me3 methylation of ALKBH5 and m6A methylation of snail1 mRNA	4239
Hypoxic Inducible Factor 2-Alpha Regulates Ureagenesis in a Murine Model	4248
Citrullinated histone in neutrophil extracellular traps is an endogenous danger signal sensed by NLRP3 and it induces stellate cell and macrophage activation in MetALD	4250

- Aberrant levels of the hydroxysteroid enzyme HSD17b13 increases lipid droplet accumulation by blocking cellular lipophagy in hepatocytes 4256
- Hepato-biliary transdifferentiation contributes to liver repair during cholestatic injury caused by acute loss of adherens junctions from cholangiocytes. 4263

## Cell and Molecular Biology

### Cell Structure and Function

- ★ In vivo screening for targets to block immune escape in hepatocellular carcinoma 237
- β2-adrenergic receptor promotes early hepatocyte proliferation mediated by tumor necrosis factor-α production in neutrophils after partial hepatectomy 4227
- Repurposing Protonix to enhance efficiency of doxorubicin in HCC treatment . 4229
- miR-122 Delivered by Hepatocyte Extracellular Vesicles Promotes Ferroptosis In Hepatic Stellate Cells 4233
- BMP9 promotes protein lactylation modification in hepatocellular carcinoma 4234
- A novel metabolic dysfunction-associated gene, DPYSL2, is implicated in hepatocellular carcinoma through the cAMP pathway 4242
- KIF20A inhibitors enhance the efficacy of PD-1 inhibitors by enhancing c-Myc ubiquitination and breaking immune escape in hepatocellular carcinoma 4243
- Verification of gene expression composition in pathological liver tissue of primary sclerosing cholangitis using spatial transcriptome analysis 4245
- Skeletal muscle mitochondrial dysfunction during hyperammonemia in cirrhosis is mediated via a MyD88-PGC1α axis. 4246
- Inhibition of P2RX7 contributes to cytotoxicity by suppression of HK2-mediated glycolysis and AKT activation in human hepatocellular carcinoma cells. 4251
- miR-22 Regulates Tumor Immunity During HCC Development 4252
- Expression of SGLT2 in Human Hepatocellular Carcinoma Tissues and Its Relationship with Prognosis, as well as the Hepatocarcinoma Inhibitory Effects and Mechanisms of SGLT2 Inhibitors 4253
- Ectopic Wnt-β-catenin Activation and Zone 2 Expansion in Early Liver Regeneration 4257
- Multomics analyses of skeletal muscle responses in a mouse model of hyperammonemia of cirrhosis. 4258
- MARCO-Positive Macrophage Cell Therapy Reduces Carbon Tetrachloride-Induced Fibrosis. 4259
- Chaperone protein MyD88 mediated activation of ATP citrate lyase-lysine acetyl transferase (GCN5) axis in skeletal muscle results in mitochondrial dysfunction in hyperammonemia of cirrhosis. 4260
- Different metabolic flux patterns show four molecular types of hepatocellular carcinoma 4261
- The Significance of Galectin-1 in Contributing to the Anti-HCC Effects of miR-22 4262
- Identification of Alcoholic associated Hepatitis-related and Mesenchymal Stem Cell treatment Target Genes 4264

## Cell and Molecular Biology

### Cell Structure and Function

- X-box binding protein 1 (XBP1) transcriptionally regulates small heterodimer partner (SHP) expression in the liver. 205

- ★ The role of Sirt2 and downstream signaling in hepatocellular carcinoma progression 234
- Novel Mechanisms of TFEB Nuclear Import and Export by cAMP Signaling 4228
- Schistosoma mansoni egg antigens drive hepatic and colonic metabolic activity via the Insulin/IGF-1R receptor 4231
- Development of extraction technology for extracellular vesicles derived from liver tissue in mouse chronic liver disease model and analysis of factors encapsulating extracellular vesicles 4238
- Autophagy can protect the liver against Nrf2-independent stress 4241
- Increased Oxidative Stress in Cirrhosis Induces a Pro-angiogenic State in Adipose Tissue 4247
- Acyl-CoA Thioesterase 12-Mediated Suppression of PPARα and PPARγ Activities Limits Hepatic Glucose Production and Glycerolipid Biosynthesis: Implications for Health and Metabolic Dysfunction-Associated Steatotic Liver Disease 4249
- Acceleration of Human Hepatocyte Engraftment in Humanized Liver Mice Through Reactivating Signal Pathways Critical in Liver Regeneration 4254

## Cell and Molecular Biology

### Cell Structure and Function

- Bioactive Hydrogel Microcapsules for Scalable Differentiation of Pluripotent Cells into Hepatocyte-Like Cells 4236
- Mesenchymal Stem Cell-derived secretomes inhibit hepatic stellate cell activation and mitigate liver fibrosis 4240
- DDX3 Participates in Regulating Exosome Release to Inhibit the Development of Hepatocellular Carcinoma 4244
- Mesenchymal stem cell-derived exosomes targeting liver sinusoid endothelial cells in hepatic fibrosis 4255

## Genomics and Precision Medicine

### Genomics and Precision Medicine

- Novel genetic architecture and metabolic interactions for all-cause cirrhosis and hepatocellular carcinoma defined in multi-ancestry meta-analyses 8
- Clinical and Genetic Characteristics of Patients with Histologic Steatosis Defined by Natural Language Processing in the MVP Liver Biopsy Cohort 71
- Multimodal single-nuclei atlas of MASLD progression identifies a link to insulin resistance 135
- LNP delivered Prime editors restore glycemic control in humanized rodent models of Glycogen Storage Disease Type 1b (GSD1b) 191
- Differential Impacts of GLP1R Gene Variants on Disease Risk and Treatment Efficacy in African Americans 209
- The dual role of let-7 microRNAs in hepatitis C virus-related hepatocellular carcinoma: A biomarker for risk stratification and a potential therapeutic target in inflammation-driven cancers 4479
- Novel combination approaches to the comprehensive genome profiling and ICI-combined chemotherapy for advanced intrahepatic cholangiocarcinoma. 4480
- Lipid Droplet Morphology Justifies Discordances between Hepatic Steatosis Grades and MRI Proton Density Fat Fraction 4481
- PNPLA3 p.I148M variant affects lipid droplets number and size in patient-derived liver organoids 4482



In vivo expansion of gene-targeted hepatocytes through transient inhibition of an essential gene	4483	Prioritization of icosapent ethyl for the potential reversal of metabolic dysfunction associated fatty liver disease using a genetically informed drug repurposing pipeline.	4508
High Inherited Risk by Polygenic Score More Than Doubles Age-Associated Increases in Fibrosis in Mid-Life in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)	4484	Fatty Acid Oxidation Impairment and Metabolic Changes in Liver Disease	4509
Association of genetic alterations with treatment efficacy of systemic therapy for unresectable hepatocellular carcinoma: analysis with national genomic database in Japan	4485		
Steatotic liver disease in lean patients is associated with diabetes, but not PNPLA3	4486		
Integration of Bulk RNA-Seq and scRNA-Seq reveals molecular mechanisms and tumor microenvironment behind differences in clinicopathologic characteristics of hepatocellular carcinoma patients with different tumor marker combinations	4487		
Deep-learning based virtual staining of liver tissue sections	4488		
Cas9 3-base & Pam Offset (C3PO) detection increases deletion efficiency to help study PNPLA3 mutant knockouts in Huh7 cells	4489		
Genome-wide CRISPR knockout genetic screen in liver cell lines to identify genes affecting hepatic steatosis.	4490		
Metabolic dysfunction-associated steatotic liver disease associated allele GCKR (P446L) promotes FGF21 secretion via up-regulating transcription factor ChREBP in Huh-7 cell line	4491		
Genetic studies of steatotic liver disease, steatohepatitis in Geisinger Histology cohort replicates known loci	4492		
Genetics Informed Steatosis Prediction outperforms existing Steatosis Indices in the UK Biobank	4493		
Development of Mutated b-catenin Gene Signature (MBGS) to identify CTNNB1 mutations from whole and spatial transcriptomic data in patients	4494		
Full liver cell atlas of FHF mouse model reveals HsPCs as regulatory hub promoting hepatic micro-environment rebuilding during MSC treatment	4495		
Developing a Machine Learning Universal Predictor for Liver Fibrosis Progression	4496		
Framework to stratify the SNPs associated with MASLD activity score (MAS) and fibrosis and development of a candidate gene polygenic risk score (CGS) in patients with MASLD	4497		
Pathogenic variants associated with monogenic disorders of dyslipidemia in patients with well characterized MASLD	4498		
Exploring the Protective Role of LYPLAL1 Loss-of-Function in Metabolic Dysfunction-Associated Steatotic Liver Disease	4499		
Lenvatinib Inhibits the Efficacy of Chimeric Antigen Receptor Macrophage (CAR-M) Therapy in Treating Hepatocellular Carcinoma	4500		
HSD17B13 loss-of-function splice variant delays onset of incident metabolic-dysfunction-related and alcohol-related liver disease, slows progression of established liver disease, and lowers risk of liver-related mortality	4501		
Molecular events underlying adverse prognosis of liver fibrosis following antiviral therapy in patients with chronic hepatitis B virus infection	4502		
Proliferation-competent T Cells Predict Liver Fibrosis Regression During Viral Clearance in Chronic HBV Infection	4503		
Genome-wide association tests between individuals with alcoholic hepatitis and heavy drinkers without known liver diseases from the GenomALC cohort.	4504		
Study of the safety and preliminary efficacy of Exosomes secreted by menstrual blood-derived mesenchymal stem cells (MenSCs-Exos) in the treatment of liver cirrhosis: preclinical studies and clinical studies	4505		
Comparative assay of barcoded Transposon Vector Systems In Vivo reveals advantages of PiggyBac	4506		
Predicting MASLD Risk Using Patient-Derived Induced Pluripotent Stem Cells	4507		

## Gut Liver Axis and Microbiome

### Gut Liver Axis and Microbiome

The Role of Regulating Gut Tryptophan Metabolism on Anti-Tumor Immunity in Liver Cancer and its Mechanism	86
Gut microbiome pattern impacts treatment response in primary biliary cholangitis	102
Metabonomics and metagenomics for diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease	111
Diminished Enteric High-Density Lipoprotein 3 and Low LPS and Spingosine-1-Phosphate Binding in Portal Blood Associated with High Mortality in Alcoholic Cirrhosis	113
Pasteurized Akkermansia muciniphila Suppresses Hepatocellular Carcinoma Growth by Regulating the CD8 Memory Response and Treg Cells Through Modulation of STING Expression	122
Ultradeep sequencing of the Gut Microbiome shows Progressive Weaponization of Enterobacteriaceae with Cirrhosis progression through Mobile Genetic Elements which may not recover after FMT	159
A large-scale metabolomics screen to define pathways for microbiome-derived small molecules	2239
Chronic stress promotes intrahepatic cholangiocarcinoma progression via T-cell exhaustion induced by Lactobacillus_sp. and tryptophan metabolism	2240
Chronic stress-mediated taurine enterohepatic circulation imbalance shapes the immunosuppressive microenvironment of hepatocellular carcinoma	2241
Evolution of Ruminococcus gnavus in cirrhosis facilitates its patho-adaptation to Mucous	2242
Intestinal Colonization by A Gut Pathobiont Accelerates Metabolic Dysfunction Associated Steatotic Liver Disease: Implications of the Gut Immune Response in Shaping the Liver Cellular Landscape	2243
Microbiota Driven Inflammation Contained to the Intestines is Averted by IL10 Producing Kruppel-like Factor 2 CD4+ T Cells	2245
Sulfasalazine ameliorates hepatic fibrosis by regulating the BSH bacteria-CDCA-FXR axis in rats	2246
Assessment of bacterial involvement in the stagnation of secondary bile acid production and deacidification in the gut environment after HCV elimination	2247
Gut commensal bacteria exert anti-inflammatory and anti-fibrotic effects by regulating macrophage polarization through secondary bile acids	2248
Gut Microbe-Produced Indole-3-Propionic Acid Alleviates Hepatitis B-Related Fibrosis by Regulating Th17 Cell Differentiation through Glucose Metabolism Reprogramming	2250
Analysis for gut microbial profile changes by Japanese diet identified specific species that reflect MASLD progression	2251
Prevalence, risk factors, and outcomes of Clostridioides difficile infection in liver transplant recipients	2252
SMP30 deficiency accelerates gut-liver nanoplastic accumulation via disrupted intestinal barrier mediated by alcohol consumption	2253
Duodenal Mitochondrial Oxidative Phosphorylation Worsens with Disease Progression and is Ameliorated After FMT in Patients with Cirrhosis	2254

- Leveraging Machine Learning to Explore Microbiome Variations in Response to Nutrition and Genetic Variation 2255
- Alcohol Administration Disrupts Intestinal Autophagy to Exacerbate Liver Injury 2256
- Oral Cannabidiol treatment ameliorated Alcohol-associated liver disease in mice by reducing gut permeability 2257
- C. difficile* Colitis Dysregulates Hepatic Lipid Metabolism, Inducing a Pro-Steatotic and Pro-Inflammatory State 2258
- Comprehensive profiles of the microbiome and metabolome within the gut-liver axis in Western diet-fed MC4R knockout mice. 2259
- Identification of *Ruminococcus gnavus* and Its Neurotoxic Role in Hepatic Encephalopathy through Phenylalanine/Tryptophan Decarboxylase Pathway 2260
- Bacterial genetic determinants of species adaption in cirrhosis The Role of Gut Microbiota-Derived Phenylethylamine in Hepatic Encephalopathy Pathogenesis: Beyond the Ammonia Hypothesis 2261
- Association between the gut microbiota and primary biliary cholangitis: A two-sample Mendelian randomization study 2263
- Salivary Microbiome is Independently Associated with Hospitalizations in a Multi-Center Prospective Cohort of Outpatients with Cirrhosis: NACSELD3 Experience. 2264
- Dietary intervention improves intestinal permeability and reduces colon fibro-inflammation in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH 2265
- Acyl-CoA thioesterase 12-mediated PPAR $\gamma$  activation preserves gut barrier integrity by suppressing intestinal epithelial cell necroptosis: Protective role in metabolic dysfunction-associated steatohepatitis 2266
- Reduced Bacteroides Thetaiotaomicron Contributes to the Disordered Metabolism of Bile Acids in MASLD Patients 2267
- Fecal microbiota transplant donor exposed to high protein diet improves the remission in murine model of alcohol-associated liver disease 2268
- Fecal cell free transplantation is effective in remission of alcohol associated liver disease in mice model. 2269
- Clostridium spp. cocktail alleviates hepatocellular carcinoma progression by modulating HIF1a-derived lipid profiling. 2270
- Gut Microbiome-Nitrogen Metabolic Imbalance in Hepatic Encephalopathy Restored by *Dacus Carota* Exosomes 2271
- Impact of Fibrosis Severity on Clinical and Metagenomic Profiles in MASH (Metabolic dysfunction-associated steatohepatitis) Patients 2272
- Cryptogenic Pyogenic Liver Abscess: A Sentinel Marker for Colorectal Cancer? 2273
- Lactulose is associated with increased risk of disseminated infection from intestinal pathogens 2274
- Intra-Tumoral Microbiome Promote Hepatocellular Carcinoma Cell Proliferation and Is Associated with Prognosis 2275
- Iron regulatory protein 2 contributes to antimicrobial immunity by preserving lysosomal function in macrophages 2276
- Dissecting causal links of the gut microbiome, gut microbiota-associated metabolites on portal vein thrombosis: a Mendelian randomization study 2277
- Acute alcohol binges alter colonic mucosal architecture to cause transient changes in defecation 2278
- Gut bacteria associated with mortality after fecal microbiota transplant in severe alcohol associated hepatitis patients: An approach to understand pathways for improved survival 2279
- Western diet contributes to MASH by remodeling gut microbiota and metabolite 2-OG 2280
- Differences in gut microbiome diversity in patients with MASLD associate with response to fecal microbiota transplant (FMT) defined by plasma metabolic profiles 2281
- Growth hormone reshapes the gut microbial profile in individuals with metabolic dysfunction-associated steatotic liver disease after six months of treatment 2282
- 'From Abscess to Tumor: Tracking the Prevalence of Colon Cancer Among Pyogenic Liver Abscess Patients (2016-2020)' 2283

## Health Disparities/Health Equity Research

### Social Determinants of Health

- ★ Applying Large Language Models to Better Understand Psychosocial Factors Contributing to Liver Transplant Waiting List Decisions 12
- Representation of Gender, Racial, and Ethnic Minorities In Hepatology Clinical Trials Kin Li, DO1, Muhammed Bouso, MD1, Malik Mushannen, MD1, Carla Pellergrino, MD1, Joshua Harroch, MD1, Gres Karim, MD2, Nicholas Brown, MD2,3,4, Ilan Weisberg, MD2,31 New York Presbyterian - Brooklyn Methodist, Department of Medicine, Brooklyn, NY 112152 New York Presbyterian - Brooklyn Methodist, Department of Gastroenterology, Brooklyn, NY 112153 Weill Cornell Medicine, Department of Gastroenterology, New York, NY 100214 Columbia University Irving Medical Center, Department of Gastroenterology, New York, NY 10032 97
- Acceptability of and Experience with Health Related Social Needs Screening Among Patients with Chronic Liver Disease: A Qualitative Study 178
- High Mortality at Safety-Net Hospitals for Patients with Cirrhosis 2140
- Racial disparities impact access to and outcomes of liver transplantation in Black Patients with Hepatocellular Carcinoma: A Systematic Review 2142
- Significant Racial/Ethnic Disparities in Liver Transplant Waitlist Outcomes Among U.S. Adults with End-Stage Liver Disease Due to Steatotic Liver Disease 2145
- A nationwide retrospective study: the association of race with clinical outcomes in hospitalized patients with hepatorenal syndrome 2146
- ★ Health Literacy and Education Level are Determinants of Disease Severity in Metabolic Dysfunction Associated Steatotic Liver Disease 2149
- Disparities in Primary Biliary Cholangitis: A retrospective study using real-world data from a single hepatology clinic in the greater Los Angeles area 2151
- Temporal Trends in Deaths from Alcohol Use Disorder, Alcoholic Liver Disease, and Hepatocellular Carcinoma in the United States from 1999-2020 2152
- Social isolation is higher among people with chronic liver disease and associated with increased psychological distress and all-cause mortality 2153
- Hospitalized Patients With Cirrhosis, Especially Those Not in High Income countries Continue to Have Worse Outcomes Regardless of Whether Outcomes Were Studied During and After the Covid Pandemic 2155
- Disparities and Barriers in Improving Oral Health in Cirrhosis: The ORACLE (Oral Health In Cirrhosis of the Liver) study 2158
- A Cross-Sectional Analysis of Disparities for Acute Liver Failure-Related Mortality in the United States 2159
- Social Vulnerability (SV) is Associated with Higher Premature Mortality from Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in the United States (US) 2160
- The Association Between Food Environment and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Socioeconomically Developed (SED) Countries: A Global Study of the United Nations and the Global Burden of Disease (GBD) Data 2161

Trends in Alcohol-Associated Cirrhosis: Incidence and Mortality Disparities Between Men and Women, and Young and Older Individuals in a Central Canadian Province (2010-2020)	2162	Racial and Ethnic Differences in Self-Reported Dietary and Health Behaviors in a Large Cohort of Patients with Cirrhosis	2205
Social Drivers of Health Prevalence and Screening Acceptability Among Patients with Chronic Liver Disease	2163	Characterizing Non-Medical Referral and Evaluation Drop-offs in Adult Liver Transplantation: A California Liver Network Study	2206
Disparities and Outcomes of Physical Restraint Use in Hepatic Encephalopathy: A National Inpatient Assessment	2164	Racial and Ethnic Disparities in Barriers to Care, Social Support and Housing Stability in a Prospective Cohort of Patients with Cirrhosis	2207
Outcomes in a Multidisciplinary MASLD Clinic Are Affected by Race	2166	Global disparities in Liver Transplantation Outcomes: Extensive Study utilising Global Registry data	2211
Neighborhood Social Support Associated with Increased Mortality Among Adults with Liver Disease	2167	Dissecting Racial Disparities in HCC: Mortality Rates and Access to Treatment: A Multicenter Retrospective Analysis	2212
Unequal Burden: Unveiling Racial and Regional Disparities in Hepatocellular Carcinoma Mortality in the United States (2018 to 2022)	2168	Socioeconomic deprivation is an independent risk factor for liver fibrosis in fatty liver disease: a community-based propensity-score matched case-control study	2213
Mental Health Diagnoses are Associated with Disparities in Hepatocellular Carcinoma among Veterans	2169		
Exploring the Role of Social Determinants in Early Liver Transplantation Relapse Rates and Outcomes: A Multicenter Analysis	2171		
Disparities in Alcohol-associated Liver Disease: Trends in Liver Transplantation and Listing to Death Ratio	2177	<b>Health Disparities/Health Equity Research</b>	
The Impact of Housing Insecurity on Hospitalized Patients with Diagnosis of Cirrhosis: A Comparative Analysis Using Data from the National Inpatient Sample (2016-2019)	2178		
The Effect of Socioeconomic Factors on Outcomes of Variceal Hemorrhage	2179	<b>Special Populations</b>	
Social Determinants of Health and Metabolic Dysfunction-associated Steatotic Liver Disease in Children With Overweight or Obesity	2180	Racial/Ethnic and S+D27+A27:B2666+A27:B2668+A27:B1082 +A27:B1083+A27:B1087+A27:B1088	26
High Prevalence and Low Awareness of Markers of Chronic Liver Disease Among Men Who Have Sex with Men in Los Angeles	2182	Jail Length of Stay Does Not Account for Gender Differences in Hepatitis C Treatment Initiation in the New York City Jail System, 2019-2023	66
Community Resilience Estimates (CRE) can predict patient outcomes related to end-stage liver disease and liver transplantation in the United State	2183	Equitable and Inclusive Policies Towards Sexual and Gender Minoritized Patients at Liver Transplant Centers	119
An exploration of socio-economic and medical factors influencing the low cervical cancer screening uptake among liver transplant recipients - A high volume single-center retrospective cohort study	2184	People of African/African American ancestry harbor fewer liver disease-related risk alleles than European (White) ancestry	162
Bridging Gaps in Vibration Controlled Transient Elastography (VCTE) Usage for Metabolic Dysfunction-Associated Steatotic Liver Disease/Steatohepatitis (MASLD/MASH) Patients: Insights on Sociodemographic Influences and Care Connections	2187	Shifting Burdens: Gender Disparities and Evolving Trends in Liver Cirrhosis Across Low SDI Countries	2141
Disparities in Waitlist Outcomes for Hepatocellular Carcinoma: Insurance Status and Access to Locoregional Therapies	2190	Analysis of the distribution and severity of liver fibrosis stages among the local population within the Rio Grande Valley: identification of risk factors and accuracy of non-invasive diagnostic tools.	2143
Equity in Liver Transplant Access for Critically Ill Patients	2191	Real-world experience with FibroScan in a tribal specialty liver clinic	2144
Adverse social determinants of health contribute to worse clinical outcomes in sarcopenic patients with cirrhosis	2192	Racial/Ethnic Disparities in Liver Transplant Outcome	2147
Liver Transplantation Disparities in Listing to Death Ratio and Mortality from 1999-2021	2193	Racial/Ethnic Disparities in Liver Transplantation: The Unintended Consequence of Disparate Alcohol-Associated Liver Disease	2148
Subgroup disparities in patients with cirrhosis that received palliative/hospice care and discussion: Findings from a large, single-center study	2194	Evaluating Gaps and Disparities in Hepatitis B Treatment among US Adults: A Real-World Analysis using a Nationwide Electronic Health Records Database	2150
Antiviral use among immigrants with chronic hepatitis B (HBV) in Metropolitan-DC	2195	Disparities in the AANHPI Population with Intrahepatic Cholangiocarcinoma: A Disaggregated Survival Study of the SEER Database	2154
Revealing Disparities: Native Americans Are Deferred and Denied for Liver Transplant At a Higher Rate Due to Psychosocial Reasons	2197	Racial/Ethnic Disparities in Risks of Cirrhosis Among Veterans with Metabolic Dysfunction Associated Steatotic Liver Disease in the United States	2156
Racial Differences in Progression through Living Donor Liver Transplant Donor Candidacy Evaluation	2198	Gaps and Disparities in Hepatocellular Carcinoma Surveillance Among a Multi-Center Safety-Net Cohort of Adults with Cirrhosis	2157
Health Disparities in Autoimmune Hepatitis	2199	Sex Differences in Disease Severity at Diagnosis of Cirrhosis in a National Cohort	2165
Food Insecurity and Neighborhood Disparities: Correlation with MASLD and Alcohol-Associated Liver Disease Rates in Chicago's Liver Transplant Patients	2201	Palliative Care Consultation Can Improve End of Life Care for Patients with Cirrhosis Removed from the Liver Transplant List Compared to Patients with Pancreatic Adenocarcinoma	2170
Exploring multilevel risk factors for metabolic-dysfunction-associated steatotic liver disease (MASLD) in a racially, ethnically, and socioeconomically diverse cohort	2202	Elevated Rates of Liver and Intrahepatic Duct Cancer in Native American and Alaskan Native Females Versus Males When Compared to Their White Counterparts: A 5-Year Regional Analysis	2172

## Health Disparities/Health Equity Research

### Special Populations

Racial/Ethnic and S+D27+A27:B2666+A27:B2668+A27:B1082 +A27:B1083+A27:B1087+A27:B1088	26
Jail Length of Stay Does Not Account for Gender Differences in Hepatitis C Treatment Initiation in the New York City Jail System, 2019-2023	66
Equitable and Inclusive Policies Towards Sexual and Gender Minoritized Patients at Liver Transplant Centers	119
People of African/African American ancestry harbor fewer liver disease-related risk alleles than European (White) ancestry	162
Shifting Burdens: Gender Disparities and Evolving Trends in Liver Cirrhosis Across Low SDI Countries	2141
Analysis of the distribution and severity of liver fibrosis stages among the local population within the Rio Grande Valley: identification of risk factors and accuracy of non-invasive diagnostic tools.	2143
Real-world experience with FibroScan in a tribal specialty liver clinic	2144
Racial/Ethnic Disparities in Liver Transplant Outcome	2147
Racial/Ethnic Disparities in Liver Transplantation: The Unintended Consequence of Disparate Alcohol-Associated Liver Disease	2148
Evaluating Gaps and Disparities in Hepatitis B Treatment among US Adults: A Real-World Analysis using a Nationwide Electronic Health Records Database	2150
Disparities in the AANHPI Population with Intrahepatic Cholangiocarcinoma: A Disaggregated Survival Study of the SEER Database	2154
Racial/Ethnic Disparities in Risks of Cirrhosis Among Veterans with Metabolic Dysfunction Associated Steatotic Liver Disease in the United States	2156
Gaps and Disparities in Hepatocellular Carcinoma Surveillance Among a Multi-Center Safety-Net Cohort of Adults with Cirrhosis	2157
Sex Differences in Disease Severity at Diagnosis of Cirrhosis in a National Cohort	2165
Palliative Care Consultation Can Improve End of Life Care for Patients with Cirrhosis Removed from the Liver Transplant List Compared to Patients with Pancreatic Adenocarcinoma	2170
Elevated Rates of Liver and Intrahepatic Duct Cancer in Native American and Alaskan Native Females Versus Males When Compared to Their White Counterparts: A 5-Year Regional Analysis	2172



The Wall Within: Understanding Racial Disparities in Liver Transplant Outcomes in the US Southwestern Region Centre	2173	Evaluating the Role of Palliative Care in Hepatocellular Carcinoma Using the National Inpatient Sample: Cost Savings, Reduced Interventions, and Racial Disparities	3324
Representation of Women in Liver Disease Clinical Trials	2174	Optimal treatment duration of resmetirom for metabolic dysfunction-associated steatotic liver disease: a cost-effectiveness analysis	3329
Racial and ethnic disparities in liver cancer risk by birth cohort: An electronic health record (EHR)-based epidemiologic cohort study	2175	Cost-Effectiveness of the HepQuant DuO Test for the Management of Patients at Risk for Large Esophageal Varices	3341
Safety and Efficacy of Contraceptive Agents After Liver Transplantation	2176	Affordable Hepatology: Exploring the Potential Benefits of the Mark Cuban Cost Plus Drug Company Model for Liver Disease Treatments	3349
Navigating behavioral change: The lived experience of Mexican and Central American patients with MASLD	2181		
The Burden of Steatotic Liver Disease in Croatian Veterans Three Decades After the War	2185		
Characteristics of Patients with Primary Biliary Cholangitis that Received Transient Elastography at a Tertiary Liver Transplant Center in Northern California	2186		
Psychological Burdens, System Distrust, and Financial Constraints Among the Barriers Facing Marginalized Groups Referred for Liver Transplantation for Hepatocellular Carcinoma: A Qualitative Study	2188		
Global Disparities in Liver Diseases Research Funding: A Root Cause of Health Disparities	2189		
A Pregnant Pause - Room for Improvement in Fertility Discussions with End Stage Liver Disease Patients	2196		
Seven-year follow-up of a predominantly Hispanic patients with Significant Steatosis at a Primary Care Clinic: Update on the South Bay Cohort	2200		
Alcohol Relapse After Liver Transplantation Among Patients with Alcohol-Associated Liver Disease in the Mountain West	2203		
Temporal Trends in Liver Diseases in Pregnancy: Data from a Tertiary Care Center	2204		
Hepatic osteodystrophy in cirrhosis, etiological spectrum, and outcome.	2208		
Enrollment of minority groups in clinical trials of liver diseases in the US	2209		
Racial Disparities in Hepatitis C Prevalence, Treatment and Long-term Outcomes Among Patients with Concurrent Substance Use Disorder	2210		
<b>Health Services and Public Health Research</b>			
<b>Cost-Effectiveness and Economics of Care</b>			
Value-based pricing of resmetirom for the treatment of metabolic dysfunction-associated steatotic liver disease: a cost-effectiveness analysis	228		
Annual Out-of-Pocket Medical Costs and Financial Burden Among Transplant Recipients in the United States	3265		
The Cost of DILI: Exploring How Drug Induced Liver Injury Burdens the U.S. Healthcare System	3278		
Cost-effectiveness of expanding eligibility for antiviral prophylaxis to all HBsAg-positive pregnant women inaccessible to HBV DNA or HBeAg testing in China	3286		
Assessing Economic Burden Among Unique Patient Segments in an HDV-infected Population	3294		
Terlipressin Is Associated with Decreased Healthcare Resource Utilization Compared with Midodrine/Octreotide Among Patients with Hepatorenal Syndrome	3307		
Cost-effectiveness of Universal Pediatric Screening of Hepatitis C Virus in the United States	3310		
To achieve functional cure for chronic hepatitis B infection- new therapy vs expanding the existing therapy	3312		
Patients With Hepatitis Delta Virus Incur Increased Healthcare Resource Utilization and Costs Postdiagnosis: Results From a Large Healthcare Provider in Israel	3316		
		<b>Health Services and Public Health Research</b>	
		<b>Health Care Delivery/Access/Quality</b>	
		A Health IT Intervention with Caregiver Engagement Significantly Reduces Avoidable Readmissions in A Multi-Center Randomized Clinical Trial of >450 participants: The HEROIC Trial	124
		★ Outcomes of the alcohol-associated hepatitis Bridge clinic at a safety-net hospital: a prospective pilot study	232
		Surge in incidence and prevalence of autoimmune hepatitis since the COVID-19 pandemic	3234
		Patient Perceptions of Undergoing Routine Viral Hepatitis Screening and Receiving a Hepatitis C (HCV) Diagnosis While Incarcerated: A Qualitative Study	3237
		Early palliative care (PC) in end-stage liver disease (ESLD) patients significantly improves health-related quality of life (HRQoL)	3242
		Liver Cirrhosis and Its Impact on Clinical Outcomes in Adult Respiratory Syncytial Virus Pneumonia: A Retrospective Analysis of the National Inpatient Sample	3243
		Activity Metrics Measured by Wearable Technology Correlates with Patient-Reported Wellbeing in Cirrhosis	3244
		Psychometric Properties of a Novel Tool to Measure Goal Concordant Care (GCC) From Patients with End Stage Liver Disease, and their Caregivers.	3245
		A Qualitative Inquiry into the Experiences of Participants and Nurses in the Australian Liver Failure Trial	3248
		Patients with Non-alcoholic Fatty Liver Disease (NAFLD) and Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) have Similar Clinical, Non-invasive Tests (NITs) and Patient-Reported Outcomes (PROs) Profile	3251
		The long-term follow-up status of 3,643 patients achieving SVR after DAAs, managed by Specialists in hepatology; Nationwide survey	3252
		Effectiveness of polyene phosphatidylcholine in improving liver function for patients with non-hepatitis B chronic liver disease: a real-world study	3256
		Population-based hepatitis C screening in country with moderate seroprevalence: 21-month results of the program in Lithuania.	3259
		Caregivers of Liver Transplantation Recipients Experience Significant Anxiety Pre-Transplant and Decreased Informational Support Post-Transplant	3269
		Immunogenicity of SARS-CoV-2 Vaccine in Patients with Chronic Liver Disease	3271
		The Supportive Needs Assessment tool in Cirrhosis is a feasible tool for Identifying Unmet Needs in a US academic cohort	3273

Symptom burden and management in patients with end stage liver disease versus pancreatic cancer: a comparative analysis.	3279	Clinical Utility of Two-Step Hepatitis E Virus IgM Antibody Testing in a Low-Prevalence Setting: A 10-year Retrospective Multicenter Study	1144
Patient Voice in MASH Initiative: Foundational Principles for the Conduct of Patient-Centric MASH Research	3285	★ Successful development of a loop-mediated isothermal amplification assay (LAMP-PCR) for detection HDV-RNA	1145
New diagnosis of cirrhosis is common in the Emergency Department and associated with higher healthcare utilization.	3288	Performance Characteristics of a New Open-Source Case-Finding Algorithm for HDV and a Survey of Provider Knowledge	1146
Increasing Readiness and Self-efficacy for Serious Illness Communication Engagement in Patients with ESLD	3291	Efficacy and safety of BLV monotherapy for chronic hepatitis delta: post treatment results through 48 weeks after the end of treatment from an interim analysis of a randomized Phase 3 study MYR301	1147
Development of a sexual function assessment tool in men and women with liver disease and liver transplantation	3297	The Viral Envelope Glycoprotein gp120 Facilitates a Profibrotic Program Following HIV Exposure in the Liver	1148
Caregiver Involvement and Characteristics are Associated with Patient Quality of Life: Baseline Analyses from the PAL LIVER Trial	3302	The prevalence and clinical characteristics of concurrent hepatitis D infection in chronic hepatitis B patients in Xinjiang region: A multicenter, retrospective, cross-sectional study.	1149
The Self-Rating Scale Item Is a Valid Measure of Lactulose Adherence in Patients With Hepatic Encephalopathy	3305	Characteristics and Antiviral Treatment Patterns Among US Adults With Laboratory-Confirmed Hepatitis Delta Virus vs Hepatitis B Virus Mono-infection	1150
The Hospital Frailty Risk Score Predicts Outcomes in Patients with Hepatic Fibrosis or Cirrhosis	3306	Summary of clinical features of 1800 cases of bacterial liver abscesses	1151
Association Between Cirrhosis and Liver Injury and Toxic Metals Exposures	3308	Barodelta study : Real world data (RWD) of 498 unique patients with chronic hepatitis Delta treated with bulevirtide (BLV) 2 mg. Analysis from the French National Health Data System (SNDS).	1152
Advance Care Planning Completion Rates and Perceptions Among Adults with End-Stage Liver Disease in a Population-Based Cohort	3314	Healthcare Resource Utilization and Costs Across Varying Disease States Among Adults With Hepatitis Delta Virus or Hepatitis B Virus Mono-infection in the Inpatient and Outpatient Setting in Italy	1153
Etiological transitions in patients with liver cirrhosis and hepatocellular carcinoma: a single-center study from an institution located in a district with a high prevalence of viral hepatitis	3315	Pharmacokinetics, Pharmacodynamics, and Safety of Bulevirtide 2 mg Once-Daily for 6 Days in Participants with Moderate and Severe Hepatic Impairment and in Matched Control Participants with Normal Hepatic Function	1154
A nationwide cross-sectional survey in viral hepatitis screening for Japanese workers and consultation behavior of positive patients for HCV antibody -13.7 million general checkup applicants	3318	Real world outcomes of Hepatitis Delta patients with mild or moderate fibrosis	1155
Exploring Campaign Preference Styles and Trusted Information Sources regarding Hepatitis B and Hepatocellular carcinoma among Adults in the Midwest: A Cross-Sectional Survey with Visual Aids	3319	Utility of the fungal biomarker beta-D-glucan (BDG) for diagnosis of invasive fungal infections, antifungal prescription and correlation with mortality for critically ill patients in a liver intensive care unit	1156
Premature Mortality for the Spectrum of Steatotic Liver Disease (SLD) in the US populations	3320	Recent seroprevalence and epidemiological characteristics of HDV infection among HBsAg-positive inpatients in China	1157
PRISMA (Patient Resonance Intelligence Supporting Medical Analysis): An AI Algorithm in de-ciphering lifestyle factors effects on liver disease	3326	Establishment and application of a new method for dual detection of HDV RNA and HBV DNA based on CRISPR technology	1158
Opioid Use after Adult Liver Transplantation: Predicting Incidence, High-Risk Use, and Opioid-Related Complications in a National Cohort	3327	A novel SPR assay detects specifically anti-HDV in human serum samples	1159
Quality of Life Among Veterans with Cirrhosis	3344	Effect of Sex Steroid Hormones on HEV replication - Clinical Implication	1160
Liver Frailty Index, Not Six-Minute Walk Distance, is Associated with Liver Transplant Waitlist Dropout	3345	Delta Describe, the French collaborative project: Profile and management of hepatitis delta patients in metropolitan France	1161
<b>Hepatitis - Other Infections</b>		Natural History and Liver Related Outcomes due to Chronic Hepatitis Delta Virus from North America	1162
<b>Hepatitis - Other Infections</b>		Sero-prevalence and genotype distribution of HDV among 67 HBsAg-positive pregnant women in Siem Reap, Cambodia, using in-house direct ELISA test method.	1163
Association of Hepatitis Delta Virus Infection and Hepatocellular Carcinoma, Hepatic Decompensation, All-cause and Liver-Related Death in a U.S National Cohort	21	Establishment of BALB/cAJcl-nu/nu Mice Xenograft Model and Drug Screening Platform for Acute Hepatitis A	1164
Efficacy and safety of tobevibart (VIR-3434) alone or in combination with elebsiran (VIR-2218) in participants with chronic hepatitis delta virus infection: Week 24 primary endpoint analysis from the Phase 2 SOLSTICE trial	74	Clinical characteristics and prognosis of HEV hepatitis: a retrospective study of 628 Chinese patients	1165
A Prospective / Retrospective Provincial and National Laboratory Serosurvey of HDV Antibody Prevalence in Referred and Non-Referred Samples in Canada.	104	Bulevirtide monotherapy may reduce liver decompensation in patients with HDV-related compensated cirrhosis: a case control study with propensity score weighted analysis	1166
Long-term Bulevirtide monotherapy in patients with HDV-related compensated cirrhosis: effectiveness, safety and clinical outcomes from the retrospective multicenter european study (SAVE-D)	139	Epidemiologic and Clinical Characteristics of Acute Viral Hepatitis in South Korea: A Prospective, Nationwide Multicenter Study	1167
Syphilitic Hepatitis: A Rare Case of Hepatic Injury from a Commonly Transmitted Venereal Disease	1143		



Hepatitis B surface antigen (HBsAg) response in patients with chronic hepatitis delta receiving bulevirtide with or without pegylated interferon alfa-2a in MYR204	1168	Pharmacokinetics, Pharmacodynamics, and Safety of Bulevirtide 2 mg Once-Daily for 6 Days in Participants With Normal and Severely Impaired Renal Function	1194
Effect of Bulevirtide treatment on the HDV induced antiviral state and cell damage in infected humanized mice and patients with chronic hepatitis D	1169	Hepatitis A infection decreases amino acid and SCFA metabolism by gut bacteria, compromising gut barrier integrity and contributing to acute liver failure	1195
Association of Socioeconomic Status on the Prevalence of Hepatitis D Co-infection in patients with Chronic Hepatitis B in San Diego County.	1170	Hepatitis E virus induced metabolomic and immune shift in acute liver failure is associated with obstetric complications during pregnancy	1196
Hepatitis D virus (HDV) screening program in a single tertiary liver center in the United States	1171	Pyogenic Liver Abscess: National Findings on Demographics, Interventions, and Outcomes	1197
Similar Rates of Biochemical Response Are Observed Across Virologic Response Categories Over 96 Weeks of Bulevirtide Monotherapy in Patients With Chronic Hepatitis Delta	1172	Hepatitis delta virus awareness and screening among immigrants in the Metropolitan-DC area	1198
Day 3 MELD Score as a reliable guide for early liver transplant in Autoimmune hepatitis - A prospective study	1173	Spectrum of Hepatitis A viral infection and related mortality from a tertiary care centre in South East Asia region : Time for a new era	1199
Review of evidence to Support the Use of Surrogate Endpoints and Fibroscan in Hepatitis D Infection	1174	Management and Care of Patients with HDV Differs Across Specialties	1200
Associations Between Liver Biomarkers and Clinical Events in Patients with Hepatitis D Virus infection: A Retrospective Real-world Study	1175		
Prevalence and Clinical Characteristics of Hepatitis Delta Virus (HDV) Infected Individuals in British Columbia and Ontario: A Multi-centre Update.	1176		
Evidence for an Oncogenic Role of the Small Hepatitis Delta Antigen in Hepatocellular Carcinoma (HCC)	1177		
Defining the data requirement to improve hepatitis D co-infection detection in the United Kingdom: the Somerset Liver Improvement Project	1178		
Seroprevalence and genotype distribution of hepatitis A and E viruses among general residents in Binh Thuan Province, Southern Vietnam	1179		
A Systematic Review and Meta-analysis Assessing the Safety and Efficacy of Hepatitis E Virus Vaccine.	1180		
Zinc acetate inhibits hepatitis A virus replication in vitro	1181		
Autoimmune Hepatitis Triggered by Acute Hepatitis A Infection	1182		
Development and implementation of an hepatitis D detection and linkage to care program in Catalonia. Preliminary results.	1183		
Differential placental estrogen receptor expression is responsible for the adverse clinical outcomes in Hepatitis E virus and COVID-19 infected pregnant women	1184		
Bulevirtide for patients with chronic Hepatitis D (CHD) in Italy: a multicenter prospective nationwide real-life study (D-SHIELD)	1185		
HBcrAg mirrors HDV RNA decline and ALT normalisation during bulevirtide therapy in patients with chronic hepatitis delta	1186		
Vibration-Controlled Transient Elastography-based Scores in Autoimmune Hepatitis for Predicting Liver Fibrosis Stage and Liver-Related Events	1187		
Quantification of plasma HDV RNA in untreated and Bulevirtide-treated patients with CHD: a comparison between Robogene 2.0, Eurobioplex and Altostar	1188		
Patient Characteristics and Disease Progression in Adults With Hepatitis Delta Virus in the Inpatient and Outpatient Setting in Italy	1189		
Patients With Hepatitis Delta Virus Have a Higher Risk of Disease Progression Than Patients With Hepatitis B Virus Mono-infection: Results From a Large Healthcare Provider in Israel	1190		
Evaluation of COVID-19-related Decompensation and long-term assessment of Post COVID Condition in Patients with Cirrhosis (Eva-Long COVID study)	1191		
The asymmetry of the liver and spleen stiffness measures between patients with chronic hepatitis B and D reflects important clinic-pathologic differences	1192		
Patient-reported Outcomes Among Patients With Chronic Hepatitis Delta Treated With Bulevirtide 2 mg: A Long-term Analysis of the Phase 3 MYR301 Trial at 144 Weeks	1193		
		<b>Hepatitis B</b>	
		<b>Diagnostics and Biomarkers - Hep B</b>	
		Highly sensitive hepatitis B core-related antigen (HBcrAg) measurements can predict hepatocellular carcinoma (HCC) risk and hepatitis B surface antigen (HBsAg) loss in HBeAg-negative chronic hepatitis B patients	90
		★ Performance of the CAGE-B and SAGE-B scores for prediction of hepatocellular carcinoma in chronic hepatitis B patients with advanced fibrosis	96
		HBs isoforms as innovative biomarkers in predicting virological response to bulevirtide monotherapy in patients with chronic hepatitis delta	213
		Non-Linear Association Between Liver Fibrosis Scores and Viral Load in Patients with Chronic Hepatitis B	1204
		Anti-HBs immune complex levels: A novel biomarker of hepatitis flare in patients with HBeAg-negative chronic hepatitis B who stop nucleos(t)ide analogue therapy	1222
		Longitudinal profile of serum HBV RNA in patients with chronic hepatitis B infection on long-term nucleoside analogues	1247
		Longitudinal profile of HBsAg isoforms and HBsAg-antibody immune complex in natural history of chronic hepatitis B infection	1248
		The role of steatosis and fibrosis parameters in predicting hepatocellular carcinoma recurrence in chronic hepatitis B patients	1275
		Early off-treatment HBcrAg and anti-HBc levels identify patients at high risk of severe ALT flares after nucleos(t)ide analogue withdrawal - A pooled analysis of two prospective studies	1286
		Core biomarkers for early detection of primary liver cancer	1289
		HBV antigen-guided switching strategy from nucleos(t)ide analogue to interferon: avoid virologic breakthrough and improve functional cure	1294
		Residual hepatitis B viremia detected by a high-sensitivity droplet digital-PCR assay predicts hepatocellular carcinoma risk and prognosis in patients on antiviral therapy	1300
		Hepatitis B Virus Genotype Influences Quantitative Surface Antigen Level	1301
		New Transient Elastography (TE) Device Hepatus Shows Superior Efficiency and Strong Comparable to a Conventional TE Device in Liver Stiffness Measurement for CHB and NAFLD Patients	1316
		Increased Hepatitis D Virus (HDV) Detection in Hepatitis B Virus (HBV) Patients Utilizing a Modified HDV Reflex Testing Protocol	1323

Complete determination of hepatitis B virus genotype in all participants with chronic HBV infection receiving nucleos(t)ide analog therapy using multi-method analysis to better understand clinical outcomes: Phase 2b B-Clear study	1326	without postpartum cessation of nucleos(t)ide analogs therapy	
Accurate HBsAg Testing is Associated with HBsAg Seroreversion Outcomes	1329	Dismantling Barriers to Hepatitis B and Delta Screening, Prevention, and Linkage to Care Among the PWUD Community in Philadelphia	1219
Evaluation of PAGE-B Score and Machine Learning Enhanced Prediction of Hepatocellular Carcinoma Development in Chronic Hepatitis B patients using Conditional Survival Forest: a multicenter study	1331	Role of healthcare providers in recruitment of minority populations living with hepatitis B in clinical trials	1225
Male sex, high $\gamma$ -GTP, high AFP, high GDF15 and high FIB-4 index were high risk factors for the occurrence of primary HCC in CHB patients under NUC treatment.	1351	Stratification of HBeAg-negative chronic hepatitis B patients through longitudinal monitoring of HBV DNA levels	1229
Development of a low-cost diagnostics platform for the identification of HBV DNA using CRISPR/Cas13a system	1355	Risk factors associated with hepatocellular carcinoma occurrence in chronic hepatitis B patients on long-term nucleos(t)ide analogues	1233
Apply HBV RNA and HBcrAg to Follow-up of Patients with Chronic Hepatitis B Receiving Nucleos(t)ide Analogs	1367	Can Primary Care Health Centers Manage Chronic Hepatitis B? Clinical Care Characteristics of Hepatitis B Registry Patients at a Federally Qualified Health Center in the San Francisco Bay Area	1236
Serum ESPL1 Protein as an Early Warning Biomarker for the Initial Occurrence and Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma	1373	Factors associated with MASLD and liver fibrosis in foreign-born Asian-Americans with chronic hepatitis B seen in two non-academic hepatology clinics in Southern California: impact of metabolic features, MASLD and time spent living in the US	1241
Superior Diagnostic Efficacy of PRO-C3 and GP73 Compared with FIB-4, FAST, Agile 3+, and LSM for Detection of Fibrosis in Chronic Hepatitis B	1379	Customized screening strategy for Hepatocellular Carcinoma demonstrates good cost-effectiveness in patients with HBsAg-positive in China.	1249
The Impact of Concurrent Chronic Hepatitis B Infection on the Diagnostic Accuracy of FIB-4 in Individuals with Metabolic-Associated Steatotic Liver Disease (MASLD)	1384	Current management and treatment indications of baseline grey-zone (GZ) patients with HBeAg-negative chronic hepatitis B virus infection (CHBVe-) in Greece	1250
Differential HBV replicative markers and covalently closed circular DNA transcription in immune-active chronic hepatitis B with and without HBeAg	1413	Long-term outcomes of baseline grey-zone (GZ) patients with HBeAg-negative chronic hepatitis B virus infection (CHBVe-) in Greece	1251
<b>Hepatitis B</b>		The Impact of Superimposed Metabolic-dysfunction Associated Steatotic Liver Disease (MASLD) on Clinical and Patient-Reported Outcomes (PROs) Profile of Patients with Chronic Hepatitis B (CHB) and C (CHC)	1253
<b>Epidemiology, Prevention, Natural History - Hep B</b>		Risk of advanced liver disease among individuals with hepatitis B virus infection with low level viremia compared to individuals with no evidence of hepatitis B virus infection	1260
Association between viral replication activity and recurrence of HBV-associated hepatocellular carcinoma after curative resection	19	All-cause and cause-specific mortality in non-steatotic chronic hepatitis B patients with cardiometabolic risk factors	1262
Clinical outcomes of inactive hepatitis B surface antigen carriers with undetectable HBV DNA levels and low-level viremia	189	Higher risk of disease progression in the grey zone relative to inactive Chronic hepatitis B	1268
Impact of HBV Integration Events in HBV-Related Hepatocellular Carcinoma after Long-Term Antiviral Therapy on Clinical Indicators and Human Chromosomal Structure	202	The relationship between reproductive history and clinical characteristics in HBeAg-negative chronic HBV-infected women of childbearing age	1271
★ Alanine Aminotransferase Flares During Pregnancy or Postpartum Predict Increased HBeAg Seroclearance in Highly Viremic HBV-Infected Women	214	Management and outcome of baseline grey-zone (GZ) patients among the French HEPATHER cohort: is it different from HBeAg negative chronic hepatitis B infection (CHBVe-) or HBeAg negative chronic hepatitis (CHBVHe-)?	1272
Optimizing Hepatitis B Virus Seroprotection in Thoracic Organ Transplantation: The Role of Heplisav-B Vaccination Schedule	1206	The Impact of hepatitis b virus infection on assisted reproductive technology outcomes a systematic review and meta-analysis.	1276
The proportion of serum HBsAg-negative patients in hepatitis B virus-associated glomerulonephritis was as high as 70%—A retrospective cohort study from China	1208	Long-term follow up identifies a higher incidence of functional cure following nucleos(t)ide analogue discontinuation in HBeAg-negative Chronic Hepatitis B	1277
Serum total cholesterol is a predictor of end-stage renal disease in patients with hepatitis B virus-associated glomerulonephritis: a retrospective cohort study from China	1209	Performance of hepatocellular carcinoma predictive scores in an Australian cohort with chronic hepatitis B infection	1279
Gender-Specific Disparities in Receiving Antiviral Therapy Among Treatment-Eligible Adults with Chronic Hepatitis B Infection Across Three Safety-Net Health Systems in the United States	1211	Hepatitis B Screening and Vaccination Rates at Rush Hepatology Clinic: A Retrospective Review	1280
Gaps in Hepatitis B Laboratory Monitoring Among an Ethnically Diverse Cohort of Adults with Treatment-Naïve Chronic Hepatitis B Infection in the United States	1212	Assessment of clinical outcomes in HBsAg positive individuals compared to patients who achieved HBsAg loss as determined by conventional or ultrasensitive testing for HBsAg	1285
HBeAg-positive pregnant mothers with higher HBV DNA decline rate from mid-pregnancy to delivery are more likely to achieve HBeAg seroconversion after delivery	1217	Impact and cost-effectiveness of a hospital-based hepatitis B screening and management program in China: a mathematical modelling prediction	1293
		Alternative HBV Vaccination Strategies for Both Compensated and Decompensated Cirrhotics	1302



transaminase and positive hepatitis B virus DNA: a 48-week multicenter retrospective study from China		Effectiveness and safety of tenofovir alafenamide for chronic hepatitis B patients with decompensated cirrhosis: a real-world study in China	1292
A Comparative Analysis of Adverse Event Incidence Rates between Intermittent and Continuous Regimen of Peginterferon alpha-2b Based on Exposure-Response Analysis	1237	Comparative analysis of clinical efficacy and safety of combined pegylated interferon a-2b in 489 patients with chronic hepatitis B	1297
Safety and Efficacy Assessment of Tenofovir Alafenamide (TAF) Antiviral Therapy Commenced Preconception or During Early/Mid-Trimester of Pregnancy in Hepatitis B Virus (HBV) Infection	1239	Study on the correlation between HLA-DR+CD38+CD8+ T cell changes and efficacy in the treatment of hepatitis B virus with interferon	1298
Short-term efficacy and safety after switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with suboptimal response or intolerant to entecavir	1240	Tenofovir alafenamide to prevent hepatitis B virus reactivation in patients with 'resolved' infection receiving rituximab-based chemotherapy: A randomized controlled trial	1299
Nucleotide analogs reduced 3-year recurrence rate after curative radiofrequency ablation therapy in HBV-related HCC patients	1243	Factors predictive of improvement of renal function after switching to Tenofovir alafenamide from Tenofovir disoproxil fumarate in patients with chronic hepatitis B	1306
The efficacy and safety of prophylactic tenofovir alafenamide to prevent HBsAg-positive cancer patients undergoing chemotherapy from HBV reactivation- An interim report of a prospective trial	1244	Lower Alanine Aminotransferase Normalization During Antiviral Treatment Is Associated with lower risk of Hepatocellular Carcinoma in Chronic Hepatitis B	1309
Comparative Analysis of Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Treated with Tenofovir Alafenamide (TAF), Tenofovir Disoproxil Fumarate (TDF), and Entecavir (ETV): A Systematic Review and Meta-Analysis with GRADE Assessment	1246	Comparison of denosumab and bisphosphonates for tenofovir-induced osteoporosis in patients with chronic hepatitis B	1310
Effectiveness and Safety of Tenofovir Alafenamide in Chronic Hepatitis B Patients with Suboptimal Response to Antiviral Therapy	1252	Efficacy of Peg-IFN $\alpha$ -2b in Combination with NAs in the Treatment of Chronic Hepatitis B Patients With/Without Non-alcoholic Fatty Liver Disease: A Multicenter Study	1312
Efficacy and safety of tenofovir amibufenamide in chronic hepatitis B virus infection patients with normal alanine aminotransferase: a multicenter, open-label, randomized controlled trial	1256	Virologic outcome of peginterferon for HBeAg-positive chronic hepatitis B - a 20-year follow-up, entecavir-matched study	1313
Anti-PD-1 antibody combined with ETV and Peg-IFN- $\alpha$ safely enhances anti-HBV efficacy and T cell response in AAV-HBV mice	1257	Renal function comparison between entecavir and tenofovir alafenamide in treatment-naïve chronic hepatitis B	1315
Metabolic dysfunction-associated fatty liver disease improves response to peginterferon alpha-2b therapy in patients with chronic hepatitis B	1258	Kinetics and Prediction of HBsAg Seroclearance during Long-Term Treatment with Nucleos(t)ide Analogues in Patients with Chronic Hepatitis B	1318
Effects of different antiviral treatments on liver inflammation and fibrosis in patients with chronic hepatitis B	1261	The Effects of Tenofovir Alafenamide or Tenofovir Disoproxil Fumarate on Lipid Profiles in Chronic Hepatitis B Patients with Metabolic Associated Steatotic Liver Disease	1321
'BeNEG-DO': A Study of Clinical Outcomes, Immunologic Correlates and Genetic Predictors after NUC Treatment Withdrawal in e-Antigen Negative Chronic Hepatitis B	1263	Characterization of Changes in Noninvasive Fibrosis Markers Over 8 years of Tenofovir-based Treatment in Patients With Chronic Hepatitis B Enrolled in Two Phase 3 Trials	1337
FDA approved drug library screening to identify compounds that reduce HBs antigen	1267	Tenofovir Alafenamide Fumarate in Treatment-naïve Chronic Hepatitis B Patients with Liver Fibrosis: a preliminary non-invasive results of 96 weeks	1347
A simple model for predicting HBsAg loss using baseline HBsAg in chronic hepatitis B patients who received PEG-IFN $\alpha$ -2b therapy	1269	Outcomes of Nucleos(t)ide Analog Discontinuation in HBeAg-Positive Chronic Hepatitis B Patients Without Achieving HBeAg Loss	1350
Safety of PegIFN $\alpha$ -2b in patients with compensated hepatitis B cirrhosis	1278	A twenty years tailored treatment history of an italian cohort patients with HBV/HDV chronic hepatitis: from multiple pegylated interferon-alpha (Peg-IFN) cycles through entecavir/tenofovir to bulevirtide treatment.	1356
Peginterferon alpha-2b based antiviral therapy as an effective treatment option for functional cure in inactive hepatitis B surface antigen carriers: A prospective, multicenter, randomized controlled trial	1281	Eliminating viral hepatitis one island at a time - the Hainan experience	1358
Higher Circulating CCR7/loPD-1hi Follicular Helper T Cells and Lower HBcrAg Indicate durable clinical cure after PegIFN $\alpha$ -2b-based therapy in patients with CHB	1282	32.2% of Inactive HBsAg Carriers Achieved Clinical Cure at 48 Weeks with Pegylated Interferon Alpha-2b Therapy: A Multicenter Real-World Study (STARHB Project in China) - 2-Year Data Update	1359
Little liver disease progression after long-term drug withdrawal in HBeAg positive postpartum women	1283	The effect of tenofovir alafenamide on the risk of hepatocellular carcinoma in different risk groups defined by mPAGE-B score	1360
Functional cure and prediction analysis of pegylated interferon alpha-2b in HBeAg negative chronic hepatitis B patients with normal ALT (Ice-breaking Project in China): an interim analysis update	1284	Factors and prediction model of HBsAg relapse after achieving clinical cure in CHB patients with PEG IFN $\alpha$ -2b	1362
Plasma Haptoglobin and Haptoglobin concentration predicts pegylated interferon a-2b treatment response in HBeAg-negative chronic hepatitis B patients	1287	Comparable Outcomes Between Besifovir and Other Antiviral Therapies in Hepatocellular Carcinoma Development Among Patients with Chronic Hepatitis B	1365
Relationship between the clinical efficacy and lymphocyte subsets in the clinical cure advantage population of chronic hepatitis B with pegylated interferon alpha	1291	Effects of tenofovir alafenamide fumarate versus tenofovir disoproxil fumarate on serum lipid profiles in patients with chronic hepatitis B	1371
		The rapid reduction rate was significantly lower in grey zone HBeAg-negative patients who started antiviral therapy compared to those with active hepatitis	1377
		Leveraging in silico clinical trials of the Everest study to obtain mechanistic insights into determinants of functional cure with	1381



standard-of-care therapies in chronically infected hepatitis B patients		A Phase 1, double-blinded, randomized, placebo-controlled, multicenter global study evaluating the safety, tolerability, antiviral activity and pharmacodynamic responses of DF-006 in chronic hepatitis B, virologically-suppressed subjects	1235
Risks of discontinuation and benefits of continuation of TDF after interruption of mother-to-child transmission in immunotolerant pregnant women	1382	Efficacy and Safety of PD-L1 Antibody ASC22 (Envafohimab) in Patients with Low Baseline HBsAg Levels: a randomized Phase IIb Expansion Cohort	1264
Higher Sustained Response rate and Partial cure in NUC Experienced Pegylated Interferon-Treated Patients Compared to NUC Na&iuml;ve Pegylated Interferon Monotherapy Patients	1386	Capsid Assembly Modulators Such as ALG-001075 Induce Profound HBV DNA Knockdown and Directly Target HBeAg In Vitro	1266
Effectiveness and Safety of 48-Week Tenofovir Amibufenamide vs Tenofovir Alafenamide Fumarate for Patients with Chronic Hepatitis B: A Retrospective Real-World Study	1388	Pharmacokinetics, Safety, and Tolerability of the siRNA TQA3038 in Healthy Chinese Volunteers	1270
Second line treatment with bulevirtide in HDV patients from the ANRS-MIE French multicentre real-life cohort ANRS HD EP01 Buledelta	1390	First-In-Human Study to Assess the Safety, Tolerability and Pharmacokinetics of an oral Toll-like Receptor 8 Agonist in Healthy Subjects	1274
Impact of metabolic disease on treatment response in chronic hepatitis B patients with nucleos(t)ide analogues therapy: a multicenter REAL-B study	1392	Pharmacokinetic/pharmacodynamic modelling of RG6084 effects on hepatitis B surface antigen and alanine transaminase to inform Phase 2 dosing regimen selection	1288
Investigation of the reference value of ALT for the initiation of nucleic acid analogs for chronic hepatitis B.	1399	Combination therapy with TLR7 agonist TQ-A3334 and anti-PD-L1 TQ-B2450 enhance HBsAg decline in virally-suppressed patients with chronic hepatitis B: OCEANcure05 study	1290
Treatment Response of IFN and Nuc in CHB Patients with Severe Liver Fibrosis or Cirrhosis (OASIS Subgroup Analysis)	1416	Semi-mechanistic PK/PD modeling and simulation of sequential siRNA and bepirovirsen treatment predicts added benefit in HBsAg response in support of Phase 2b dose selection	1295
Antiviral efficacy of tenofovir alafenamide versus entecavir in treatment-na&iuml;ve chronic hepatitis B: A Multicenter Longitudinal Study	1417	CLB-405 and CLB-505 combined with a saponin based adjuvant TQL-1055 exhibits a strong antiviral and enhanced immune responses in a mouse model of persistent Hepatitis B infection	1305
Risk of Cirrhosis and HCC in CHB Patients during IFN or Nuc Treatment (OASIS Subgroup Analysis)	1418	Sequential administration of siRNA with CLB-405 and CLB-505 HBsAg variants encoding clearance profile epitopes, combined with a novel adjuvant TQL-1055 exhibits significant anti-viral and T cell activity in an AAV/HBV mouse model	1307
<b>Hepatitis B</b>			
<b>Therapeutics: New Agents - Hep B</b>			
Dual-target (HBV and PD-L1 gene)+D62+A62:A2662+A62:A2664+A62:B2664+A62:C2664+A62:B2664+A62:A2664	61	Tolerability and immunogenicity of HBsAg variants, CLB-405 and CLB-505, combined with a novel semi-synthetic saponin adjuvant TQL-1055, in New Zealand white rabbits	1308
Robust and sustainable elimination of HBsAg by epigenome modulation enables seroconversion of chronic HBV infection in HBV mouse model	107	A Phase 1b, Open-Label Study to Evaluate the Safety and Efficacy of Novel Hepatitis B Virus Combination Therapies in Patients Living with Chronic Hepatitis B	1328
Tune-401 is a novel first-in-class epigenetic silencer developed for treatment of chronic Hepatitis B, with preclinical data showing strong, durable, and precise transcriptional repression of HBV DNA	152	Immune-Related Adverse Events With Low-Dose Nivolumab in Patients With Chronic Hepatitis B: Experience From 3 Clinical Studies	1332
BJT-778, anti-HBsAg monoclonal antibody, achieved 100% virologic response in subjects with chronic hepatitis D (CHD): phase 2 study results	239	Detection and Monitoring of Infant Drug Exposure: A Study on TFV Concentration in TDF and TAF	1333
Stimulating STING pathway leads to inhibition of HBV replication: insights into kupffer cell	1202	Immunologic Biomarker Dynamics in Chronic Hepatitis B: Insights From a Phase 2a Open-Label Study on Combination Therapies With Small Interfering RNA, Selgantolimod, and Nivolumab	1334
The role of Nucleoporin 214 in hepatitis B virus replication	1203	Pharmacokinetics and Safety of a Single Dose of Elebsiran (VIR-2218, siRNA) Subcutaneously Administered in Adult Participants with Moderate Renal Impairment	1340
Monotherapy with the Capsid Assembly Modulator, ALG-000184, Results in High Viral Suppression Rates in Untreated HBeAg+ and HBeAg- Subjects with Chronic Hepatitis B or Chronic Hepatitis B Virus Infection	1213	Establishment of HBx responsive quantitative cell culture reporter system for monitoring HBV infection	1346
Prognostic and therapeutic potential of imbalance between PD-1+CD8 and ICOS+regulatory T cells in advanced HBV-HCC	1221	Revelation of unknown confounding factors in functional HBV cure: a systemic review and meta-analysis	1363
The impact of Tenofovir Amibufenamide (TMF) on blood lipids during the process of anti-hepatitis B virus treatment - A real world prospective study	1223	Novel therapeutic hepatitis B virus vaccine using plasmid-launched live attenuated flavivirus vector immunization generates robust CD8 T cell responses that correlate with efficacy in a chronic hepatitis B model	1372
Outcomes of nucleos(t)ide analogue discontinuation in chronic hepatitis B participants treated with xalnesiran with and without an immunomodulator: 48 weeks of follow-up results from the phase 2, randomized, controlled, adaptive, open-label platform study Piranga	1228	Characterization of the direct antiviral effect of REP 2139 in 2D and 3D HDV infection models	1374
High-throughput screening for Antiviral Compounds using a Recombinant Hepatitis B Virus revealed the potent entry inhibitor, Skimmianine	1230	Safety Profile of Tobeivibart (VIR-3434) and Elebsiran (VIR-2218) for the Treatment of Chronic Hepatitis B and Delta (CHB and CHD)	1375
		Results From a Phase 2a, Open-Label Study to Evaluate the Safety and Efficacy of Novel Combination Therapies	1380



Containing VIR-2218, Selgantolimod, and Nivolumab for the Treatment of Chronic Hepatitis B		HIV coinfection accelerates HBV-induced liver fibrogenesis through an exosome and miR-103a-3p dependent pathway	1255
Soluble Immune Biomarker Profiling of Chronic Hepatitis B Subjects Treated with Imdusiran in Combination with Pegylated Interferon Alfa Reveals Phases of Immune Activation	1383	Effectiveness of adoptive cell transfer of antigen-specific T cells in mouse models of HBV infection	1259
Characterization of HDV RNA and HBsAg during pegylated interferon-alpha and ritonavir-boosted Isonafarnib combination therapy: The D-LIVR study	1385	Efficacy of Prophylactic Antiviral Therapy in Preventing Hepatitis B Reactivation in Patients with Anti-HBc Antibody Undergoing Daratumumab Treatment	1265
HBV Target Site for the RNA Interference Therapeutic Imdusiran is Highly Conserved in Chronic Hepatitis B Subjects	1391	The upregulation of GRP78 by HBV promotes the progression of hepatocellular carcinogenesis through the modulation of glucose uptake in host cells	1273
Bulevirtide monotherapy in patients with compensated cirrhosis and CSPH: a 96-week interim kinetic analysis of real-life setting	1393	NK cells function dvdfincreases, What is the cause of LLV occurrence?	1296
Immune Checkpoint Inhibitor (ICI) Treatment and Immune-related Adverse Events (IrAEs): Lessons Learned from Oncology for its Potential Use for Chronic Hepatitis B (CHB) Patients	1397	Patients with chronic HBV infection exhibiting significant inflammation and fibrosis should pay particular attention to the status of MASLD during antiviral therapy.	1303
Preclinical Pharmacokinetics of EDP-514, an Oral, Once-Daily Antiviral Treatment for Hepatitis B Virus	1407	Immunomodulators reinvigorate intrahepatic exhausted antiviral immunity in an immunocompetent mouse model of chronic hepatitis B	1304
Dose-Dependent Effects of Neutralizing Anti-HBs Monoclonal Antibody VIR-3434 on Hepatitis B Surface Antigen Composition	1409	Genome-wide off-target assessment of epigenetic modulation in human primary hepatocytes and HBV transgenic mice	1311
Pre-clinical Characterization of Cavrotolimod, a TLR9 Agonist for the Treatment of Chronic Hepatitis B	1414	HLA genotype regulates hepatitis B virus mutations associated with hepatocellular carcinoma.	1314
Mathematical modeling of acute HBV infection in humanized mice treated with HBs antibodies	1415	Single-cell profiling of HBV-associated hepatocellular carcinoma reveals novel HBV-related tumor-immune interaction	1320
		HBV/HIV coinfection before and during tenofovir-based therapy alters soluble immune profiles compared to HBV or HIV alone among adults in Zambia	1325
		Impact of hepatitis B surface antigen levels on regulatory T lymphocyte frequency: pooled analysis from single cell RNA sequencing datasets	1327
		Switching tenofovir-based antiviral to entecavir > 12 weeks by end of therapy in HBeAg-negative patients: a proof-of-concept study	1330
		Hepatitis B virus reactivation in cancer patients receiving Janus kinase inhibitors	1343
		Tracking B cell immunity during perturbation of hepatitis B infection induced by treatment withdrawal/Withdrawal of prolonged nucleos(t)ide analogue (NA) treatment can result in HBsAg loss in some subjects with chronic hepatitis B (CHB), potentially revealing immune correlates of functional cure. We aimed to assess whether there was any recovery of defective humoral immunity in those with loss of HBsAg, with or without development of anti-HBs antibodies, in this setting.	1352
		Circular RNA circSMAD2 inhibits autophagy via targeting miR-629/PDCD4 axis in Hepatitis B virus infection	1353
		Single cell RNA sequencing reveals exhausted adaptive immunity in utero to HBV exposed neonates born to mothers with high HBsAg titres persisting despite vaccination	1364
		Functional Analysis of Fumarylacetoacetate Hydrolase as a Hepatocyte Host Factor Gene Regulating Hepatitis B Virus Replication and Hepatocarcinogenesis	1366
		The impact of steatotic liver disease on HBV integration in patients with chronic hepatitis B virus infection	1376
		CCR2 of CD4+CD8+CXCR5+ T cell regulated IL-21 and TNF- $\alpha$ secretion in CHB patients	1378
		Innate immunity plays an important role in the inactive chronic HBV carriers with positive HBeAg and high HBV DNA during TAF treatment	1389
		★ Immuno-metabolic driven hepatitis B surface antigen seroconversion in mild and severe hepatitis B reactivation	1400
		Hepatic Steatosis is Associated With HBsAg Clearance in Patients With Chronic Hepatitis B Virus Infection	1403
		Single cell sequencing reveals rise in intrahepatic CXCL8, CCL4, and SELL expression with increased fibrosis in naive chronic hepatitis B patients with low HBsAg levels	1404

## Hepatitis B

### Virology, Pathogenesis, and Immunology - Hep B

The IFN-inducible MxB large GTPase attenuates HBV replication by activating the RIG-I innate immunity signaling pathway	82
★ Novel host factors in hepatitis B viral surface antigen production identified by genome-wide CRISPR-Cas9 knockout screen	155
A nucleosome switch primes Hepatitis B Virus infection	183
Post-transplant HBV vaccine compliance and seroprotection in thoracic organ transplant recipients	1205
Fuzheng Huayu Formula against HBV-induced Liver Fibrosis via Promoting Recruitment and Phenotype Polarization of CX3CR1+ Restorative BMDMs	1207
Hepatitis B virus subviral particle biogenesis relies on functional ubiquitin and proteasome pathways	1216
Large reductions of HBV integrations and viral transcripts in liver biopsies from functionally-cured CHB patients	1224
Cytokines Secreted by Macrophages Mediates the Interaction Between Hepatitis B and C Viruses	1226
HBV induces liver fibrosis through the generation of ROS in a pyruvate-PPAR $\alpha$ -dependent pathway	1227
Prevalence of hepatitis delta virus infection among hepatitis B positive individuals in Georgia: findings from the national seroprevalence survey, 2021	1234
HBV promotes hepatocyte binucleated polyploid formation through down-regulation of HDAC6 to maintain the stability of the cccDNA pool and promote viral replication	1238
Imatinib promotes HBV reactivation through oxidative stress-induced blockage of autophagic flux	1242
Immunological correlates of rapid HBsAg decline in chronic HBV hepatitis patients undergoing Tenofovir Amibufenamide treatment	1245
HIV coinfection destabilizes intrahepatic immunity at the single-cell level in Zambian adults starting treatment for chronic HBV infection	1254

Characterization of intrahepatic immune microenvironment in liver biopsies across different phases of untreated HBeAg-negative patients	1405
Uptake and T Cell Stimulation by BJT-778-HBsAg Immune Complexes: Insights into Anti-HBs Monoclonal Antibody Function.	1406
Predictors of HBsAg loss in HIV-HBV coinfecting patients receiving antiretroviral therapy: a systematic review	1411
Distribution of circulating T follicular helper 17 cell subsets altered in CHB patients	1412

## Hepatitis C

### Diagnostics and Biomarkers - Hep C

A serum biomarker-based score to evaluate HCC risk in HCV-cured patients with cirrhosis	128
High GGT levels is a risk factor for HCC development having potential to reflect mitochondrial dysfunction after HCV eradication	1423
Histological improvement of fibrosis in patients with hepatitis C who exhibit for 5 years a sustained virological response to antiviral treatment with direct-acting antivirals	1426
HCV Ab titer and ALT mark occult hepatitis C virus infection in treatment-naïve HCV Ab-positive and -negative patients, respectively: A 3-year prospective cohort study	1428
Closing The Gap: Implementing Hepatitis C Reflex Testing Within UNM Health System	1436
Stability of capillary whole blood (CWB) in microtainer, and Limit of Detection (LoD) for Hepatitis C Virus (HCV) (genotypes 1-6) in CWB versus Venous WB (VWB) using Cepheid Xpert HCV RUO System.	1443
Comparing baseline FIB-4 versus post-SVR12 FIB-4 to predict HCC occurrence following direct-acting antiviral attained SVR12	1444
Avoiding phlebotomy entirely: Validation of a point-of-care measure of APRI & FIB4 from finger-prick blood	1449
Multistep Hepatocarcinogenesis in Preneoplastic Nodules on EOB-MRI after Long-Term Sustained Virologic Response in Patients with Chronic Hepatitis C	1452
Methionine Sulfoxide, Methionine, and Ornithine as Biomarkers for Predicting Development of Hepatocellular Carcinoma after Hepatitis C Virus Elimination	1460
Transient Elastography in the ED Enhances Triage of Hepatitis C Virus Patients Compared to FIB-4	1477
Costs and outcomes of a one-step hepatitis C virus RNA point-of-care diagnostic strategy among people who inject drugs in the U.S.	1478
Successful Performance of the Xpert HCV test for Point of Care Detection of HCV RNA in a CLIA-Waived Setting	1480
Uncovering Oncogenic Effects of HCV in Non-Cirrhotic Hepatocellular Carcinoma: New Molecular Markers and Genetic Predispositions Identified by Whole Exome Sequencing	1482
Validation of an artificial intelligence model for prediction of hepatocellular carcinoma risk after oral antiviral therapy in patients with chronic hepatitis C	1491
Expert Evaluation of Guideline-Based Retrieval Augmented Generation vs. Supervised Fine-Tuning for Large Language Model Outputs: A Case Study in Hepatitis C Viral Infection Management	1507
Sex Disparities in the Rate of Delayed Hepatitis C Diagnosis in Patients With A Liver Complication-results of A Population-based Analysis	1508
Automated Screening Outcomes for Hepatitis B and C in the Preanesthesia Unit: A Hospital-Based Study	1509

## Hepatitis C

### Epidemiology, Prevention, Natural History

Long-term clinical outcomes after HCV elimination by direct-acting antivirals in patients with chronic hepatitis C: A large-scale, multicenter cohort study	1422
Scanvir: an ideal concept for eliminating hepatitis C	1424
Hepatic steatosis in chronic hepatitis C affects the risk of hepatocellular carcinoma mainly in women	1430
Fatigue in Chronic Hepatitis B (CHB) and C (CHC) is Associated with Impairment of Patient-Reported Outcomes (PROs) and Work Productivity	1431
Service Evaluation of Children with HCV and neurodevelopment delay; Incidental finding of high rates of learning and behavioural difficulties in UK children living with HCV	1433
Delineating gaps in the cascade of care among pregnant women with HCV: an observational retrospective analysis of real world data on a commercially insured cohort in the US	1434
Characteristics and Treatment Patterns of Transgender Men and Women Living with Hepatitis C in the United States	1439
Changes in Hepatitis C Virus Screening and Treatment Rates in Pregnant Individuals Before and After Implementation of Universal Screening Guidelines	1440
Long-term glycemic control in patients achieving sustained virologic response with direct-acting antivirals for hepatitis C virus infection	1447
Prevalence and Trends of Hepatitis C Infection in Pregnant Women in Xi'an, China: A 10-Year Retrospective Study	1453
Prevalence and risk factors for hepatocellular carcinoma (HCC) among patients with current and prior hepatitis C virus (HCV) infection in a real-world cohort in the post-DAA era.	1457
Trends in Care Utilization in Two Large Nationally Representative Datasets Reveal Important Disparities in Hepatitis C Access to Screening and Treatment	1458
Multi-collaboration contributes to HCV DBU Relink in Guangdong, China (First report)	1464
A review of phase 1 & 2 of the Joint United Kingdom Health Security Agency (UKHSA) & National Hepatitis C Paediatric Multi-Disciplinary Operational Delivery Network (pMDT ODN) National Hepatitis C Paediatric tracking project	1465
Strategic Approaches for HCV Micro-Elimination in Hemodialysis Population in Shanghai.	1468
Epidemiological Insights into Hepatitis B and C through Blood Samples from the Korea National Health and Nutrition Examination Survey	1469
Examination of factors predicting hepatic decompensation after elimination of HCV in patients with liver cirrhosis	1471
Metabolic dysfunction-associated steatotic liver disease is associated with liver fibrosis in hepatitis C	1472
The power of the Community Pop-up Clinic: Cascade of Care and HCV Treatment among Vancouver's inner-city Populations as a path towards elimination	1473
A Comparison of Sofosbuvir/Velpatasvir (S/V) and Glecaprevir/Pibrentasvir (G/P) for the Treatment of HCV infection Among HCV-Infected People Who Use Drugs (PWUDs)	1474
Hepatitis C Management of Women in the Third Trimester of Pregnancy in LA Bodega	1475
Hepatitis C Treatment Uptake Differs by Gender among a Commercially Insured Population in the United States	1476
Trends in HCV Screening, Follow-up Testing, and Treatment in Pregnant People and Infants in a Tertiary Care Center	1479
Long Term Outcome Following HCV Treatment With Glecaprevir/Pibrentasvir In People Who Use Drugs	1483
A disaggregated gender-based approach to understanding HCV among women: Descriptive analysis of The Canadian	1486

Network Undertaking against Hepatitis C (CANUHC) cohort from 2015 to 2023		Effectiveness of Glecaprevir/Pibrentasvir for 8 Weeks in People Taking Antipsychotics, Buprenorphine/Naloxone, or Illicit Drugs	130
Default Hepatitis C Screening and Proactive Linkage To Care Among Hospitalized Adults	1487	Safety, Tolerability, and Outcomes of Sofosbuvir/Velpatasvir in Treatment of Chronic Hepatitis C Virus during Pregnancy: interim results from the STORC study	222
Engaging community pharmacies within hepatitis C (HCV) test and treat networks to enhance access to care for key populations living with HCV: experience from Alberta, Canada.	1488	Sustained virologic response and posttreatment liver function are associated with 5-year survival after direct-acting antiviral treatment in decompensated cirrhotic patients with hepatitis C virus: A long-term follow up study of Japanese clinical trial cohort	1427
Chrono-Optimal Treatments for HIV/HCV Co-infection Yield Comparable Survival Outcomes with HCV Mono-infection	1492	A rare case of diffuse large B-cell lymphoma that developed after sofosbuvir-ledipasvir treatment for chronic hepatitis C	1429
Seizing the moment: Opportunistic screening impact on viral hepatitis prevalence in the Emergency Department over four years	1493	Close partnership with NGOs increases attendance and DAA treatment uptake in people who previously injected drugs (ex-PWID) with chronic hepatitis C	1432
Tailoring HCC risk stratification in chronic hepatitis C patients following viral eradication: a simple algorithm utilizing alpha-fetoprotein	1496	Factors associated with the aggravation of gastroesophageal varix in compensated and decompensated cirrhotic patients due to chronic hepatitis C virus infection after direct-acting antiviral therapy	1435
Positive Anti-HBC IGG is an Independent Risk Factor for Hepatocellular Carcinoma in A Cohort of Chronic Hepatitis C Patients	1497	Incidence of liver disease progression in patients with hepatitis C virus genotype 3 after SVR following DAA therapy	1438
Prevalence of HBV and HIV infection in anti-HCV positive individuals with a history of drug use	1499	Telehealth to increase healthcare access; perspectives of people who use drugs	1442
Bridging the gap between controlled human infection models and real-world testing using computational modeling of randomized hepatitis C vaccine trials	1500	Three for Two or One for Three: Evaluating HCV Treatment Regimens, Compliance, and Subpopulations	1445
HCV Reinfection Among People Who Use Drugs (PWUD) Treated For HCV Infection: A Long-Term View	1503	Sex and Race Disparities in Liver Listings and Transplants for Hepatocellular Carcinoma in the United States	1446
Implementing a Novel In-Hospital Hepatitis C Management Model: Advancing Towards the World Health Organization's 2030 Elimination Goal	1504	Sustained Virologic Response (SVR) in HCV-infected Patients with Hepatocellular Carcinoma (HCC): Real-world Outcomes and Predictors of Success	1448
The Impact of Homelessness on the Outcomes of Patients with Hepatitis C: An Analysis of a National Database	1510	Sofosbuvir/Velpatasvir Effectiveness in Treating Chronic Hepatitis C Genotype 3: A Real-World Study in Xinjiang, China.	1450
Analysis of the influencing factors of diagnosed but untreated HCV infected patients in Yunnan Province, China	1511	Implementation of Glecaprevir-Pibrentasvir treatment for children aged 3-12 years with chronic Hepatitis C: Multicenter real-world data	1451
Access to a primary care provider (PCP) both reduces the risk of untreated viremia and of incomplete diagnosis among patients with hepatitis C virus (HCV)	1512	Analysis of influence factors on antiviral efficacy in patients with chronic hepatitis C virus infection in Tianjin area	1454
A descriptive analysis of injection-related infections among people living with hepatitis C for direct acting antiviral (DAA) treatment received and naive individuals across pre- and post-treatment phases.	1513	The SVR10K study: A Real-World Data with Pangenotypic Direct-Acting Antivirals Across Multiple Diverse Regions	1455
		Evaluation of hepatitis C treatment and care model in primary healthcare centers in the country of Georgia	1456
		Glecaprevir/pibrentasvir in chronic HCV: An integrated analysis of patients on multiple concomitant medications	1459
		Directly observed DAA therapy comprising extended dispensation intervals as a unique approach to streamlined HCV microelimination for PWID	1461
		Including underserved populations in the global efforts against viral hepatitis - an Austrian approach to HCV elimination among homeless people without health insurance	1462
		Progress towards achieving hepatitis C elimination in the country of Georgia, April 2015 - March 2024	1463
		Bemnifosbuvir does not alter cardiac repolarization in healthy participants: results from a thorough QT study	1466
		Multiscale modeling of lead-in results from a Phase 2 study of an 8-week combination regimen of Bemnifosbuvir and Ruzasvir in patients with chronic hepatitis C virus infection	1467
		A multicenter real world study of sofosbuvir/velpatasvir for HIV/HCV coinfecting patients	1470
		Efficacy and Safety of Four-Week Glecaprevir/Pibrentasvir Treatment in Kidney Transplants from Hepatitis C Virus Positive Donors to Negative Recipients	1481
		Current Status of Hepatitis C Virus Infection and Treatment in Hemodialysis centers in Sichuan Province, China	1489
		A government-leading multi-organization collaborative model for HCV elimination in Chengmai County, Hainan Province	1490

## Hepatitis C

### Therapeutics: Approved and New Agents

Evaluating the safety and efficacy of SOF/VEL treatment and prophylactic use of TAF in patients with chronic HBV/HCV coinfection: A multicenter study	30
Factors associated with long-term risk of liver-related and non-liver-related death after sustained virologic response in patients with hepatitis C virus treated with direct-acting antiviral	53
Characteristics of persons treated for hepatitis C in the United States, 2014-2023	57
Liver stiffness as a predictive factor for hepatocellular carcinoma development after sustained virologic response by direct-acting antivirals for chronic hepatitis C	63
Predictors of Treatment Failure and Resistance Associated Substitutions in Patients with Chronic Hepatitis C Infections - HCV Elimination Experience from the Punjab Model in India	70
Primary Graft Dysfunction and Major Adverse Cardiac Events after Hepatitis C Viremic Heart Transplantation to Aviremic Recipients	85
Same Day and Rapid Start HCV Management in La Bodega Clinic	126



Exploration of influencing factors and predictive models for the decrease of non-invasive liver fibrosis indicators in patients with HCV infection treated with DAA	1494	★ Molecular Classification of Hepatocellular Carcinoma on Non-Cirrhotic Background: Integrating Immunohistochemistry Panel and Genomic Analysis'	197
Bemnifosbuvir Poses High Barrier for Resistance in both Preclinical and Phase 1b Monotherapy Studies	1501	Neoadjuvant Therapy Prior to Orthotopic Liver Transplantation (OLT) for Hepatocellular Carcinoma (HCC): Ablation and Radiation associated with a higher complete tumor necrosis rate than Chemoembolization	200
Transforming Hepatitis C Treatment: The Power of Large Language Model-Based Intelligent Agents in Clinical Decision Support	1502	Higher risk of proteinuria in atezolizumab plus bevacizumab than lenvatinib as a first-line systemic treatment in unresectable hepatocellular carcinoma	3350
Direct acting antiviral therapy is associated with increased one-year overall survival in patients with Hepatitis C related Hepatocellular carcinoma	1505	Locoregional treatments for bridging patients with hepatocellular carcinoma to liver transplantation	3351
<b>Hepatitis C</b>			
<b>Virology, Pathogenesis, and Immunology</b>			
Chronic hepacivirus infection in mice leads to progressive fibrosis and HCC	154	Analysis of factors predicting the real-world efficacy of atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma	3352
Mendelian randomization analysis reveals Hepatitis C infection is causally associated with extrahepatic cancer	1425	Developing and Validating a Machine Learning Model for Long-Term Prognosis Prediction in patients with BCLC0-A stage liver cancer	3353
Alterations in The Tryptophan Pathway During Hepatitis C Virus Infection Demonstrates a Shift Towards a Pro-inflammatory State	1437	Stereotactic Ablative Body Radiotherapy versus Ablation for the Treatment of Early-Stage Hepatocellular Carcinoma	3354
Impact of sustained virological response on long-term outcomes after curative resection in patients with of hepatitis-C-virus-related hepatocellular carcinoma in the era of direct-acting antiviral therapy	1441	The ASAP score demonstrates high sensitivity for hepatocellular carcinoma (HCC) and is feasible for use in HCC surveillance - a prospective study	3355
Virologic effect and hepatotoxicity of BCR-ABL tyrosine kinase inhibitors in cancer patients with chronic hepatitis C virus infection: a prospective study	1484	UCSF criteria and liver dysfunction predict hepatocellular carcinoma (HCC) recurrence after surgery for HCC: A large multicentre study	3356
Attempt to Predict Outcomes in DAA-Treated Patients Using Machine Learning with Hepatitis C Virus and Human Genetic Information	1485	Multi-omics analyses identify a novel HCC subtype with worse prognosis and better response to immune checkpoint inhibitor based therapies	3357
Changes in Portal Insulin and Insulin Homeostasis in Patients during and after Chronic Hepatitis C Infection	1495	FGF18, a potential predictive markers of immune combined with targeted therapy for primary liver cancer	3358
HCV Promotes Aging in HIV-Infected Individuals: Evaluating Immune Senescence using Telomere Length and DNA Methylation	1498	No Impact of Sarcopenia on Prognosis of Transarterial Chemoembolization for Hepatocellular Carcinoma	3359
<b>Hepatobiliary Neoplasia</b>			
<b>Clinical: Hepatocellular Carcinoma and Cholangiocarcinoma</b>			
Impact of Pre-Transplant Immune Checkpoint Inhibitors on Downstaging Outcomes: A Prospective Intention-to-Treat Analysis from a Multi-Center US Study	14	Risk of bleeding in hepatocellular carcinoma patients treated with atezolizumab/bevacizumab: A systematic review and meta-analysis	3361
Integrative Multiomics Unveils the Aggressive Mechanisms and Therapeutic Strategies of CA19-9 Positive Intrahepatic Cholangiocarcinoma	24	Evaluation of Prophylactic Esophagogastroduodenoscopy versus Beta Blockade in Hepatocellular Carcinoma Patients Undergoing Anti-Angiogenic Cancer Treatments	3362
Machine learning radiomics based on CT to predict response to lenvatinib plus PD-1 inhibitor for hepatocellular carcinoma	34	Restaging patients with early intrahepatic or systemic recurrence of hepatocellular carcinoma (HCC) following therapies with a curative intent: Is BCLC the ideal system?	3364
Camrelizumab combined with Lenvatinib and RALOX-HAIC for hepatocellular carcinoma (HCC) in BCLC stage B and C: a prospective, single-arm trial (Cal Era study)	52	Digitalized Precise Screening and Risk Stratified Management Improve Early Diagnosis of Hepatocellular Carcinoma (HCC) in China: a Multi-center Real-world Study	3365
Predicting Survival Among Patients with Early- to Intermediate-Stage HCC: Miami Liver cancer Estimator of Survival (MILES) Score	87	Non-viral Hepatocellular Carcinoma Has Similar Prognosis after Radical Treatment as Viral HCC: Analysis of a Nationwide Registry for Advanced Liver Diseases (REAL)	3368
Outcomes of Child-Pugh B patients treated with Single Tremelimumab Regular Interval Durvalumab (STRIDE) for unresectable hepatocellular carcinoma (uHCC) in a Real-World Cohort	120	TGF- $\beta$ Signaling Molecules in Circulating Tumor Cells as Prognostic Biomarker in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab	3369
RON0 resection for perihilar cholangiocarcinoma offers survival similar to transplantation: A multicentre pan-European study	182	Outcomes by baseline liver function in EMERALD-1: a Phase 3, randomized, placebo-controlled study of transarterial chemoembolization with durvalumab with/without bevacizumab in participants with embolization-eligible unresectable hepatocellular carcinoma	3371
		Comparison of liver function injury in intermediate and advanced hepatocellular carcinoma patients treated with hepatic arterial infusion chemotherapy versus transcatheter arterial chemoembolization combined with immune checkpoint inhibitors and tyrosine kinase inhibitors	3375
		Performance of a Multi-Cancer Early Detection (MCED) Test for Detection of Hepatocellular Carcinoma (HCC) in Patients with Cirrhosis	3377
		Prospective study on the improvement of prognosis and suppression of cancer development after administration of zinc preparation in patients with liver cirrhosis	3378

Fever after the administration of atezolizumab and bevacizumab predicts liver injury in patients with unresectable hepatocellular carcinoma: a prospective observational analysis using a multiplex bead-based immunoassay	3379	Five-year overall survival and overall survival by tumor response measures from the Phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma	3413
Analysis of Varix bleeding complication after Atezolizumab plus Bevacizumab for advanced Hepatocellular carcinoma patients	3380	Immune-related liver injury is a good prognostic factor in patients with hepatocellular carcinoma under atezolizumab plus bevacizumab therapy	3414
Multi-omics analysis of patients with hepatocellular carcinoma treated with anti-PD-L1 plus anti-CTLA-4 and locoregional therapy: Correlative study of Phase2 trial	3382	Circulating tumour DNA markers for prediction of sustained response following the cessation of targeted therapy and immunotherapy in hepatocellular carcinoma (HCC)	3416
Liver transplantation is the major determinant in achieving over 10-year survival for patients with early-stage hepatocellular carcinoma	3384	The Albumin-Bilirubin Score as an Indicator of Effective Immunotherapy in Elderly Patients with Unresectable Hepatocellular Carcinoma	3417
Maintenance of good liver function is important for good post-progression survival with atezolizumab/bevacizumab in advanced hepatocellular carcinoma	3386	Longitudinal trends in frailty among patients with hepatocellular carcinoma	3418
A comparative validation of clinical prediction scores for hepatocellular carcinoma in steatotic liver disease without cirrhosis	3387	Stem Cell Growth Factor- $\beta$ as a Predictive Biomarker of Response to Chemotherapy and Prognosis in Patients with Advanced-Stage Hepatocellular Carcinoma: A Retrospective Study	3420
Optimal subsequent therapy for unresectable hepatocellular carcinoma patients progressed on atezolizumab plus bevacizumab therapy, appropriate to the radiological progression patterns	3388	Prognostic value of combination of neutrophil to lymphocyte ratio and albumin- bilirubin grade in patients with hepatocellular carcinoma undergoing transarterial chemoembolization	3422
Outcomes by comorbidities with tremelimumab and durvalumab in the Phase 3 HIMALAYA study in unresectable hepatocellular carcinoma	3392	Real-World Study of Adjuvant Therapy After Complete Resection of Early-Stage Hepatocellular Carcinoma	3423
Trends in HCC deaths and contributing chronic liver disease etiologies - a contemporary analysis of national death certificate data	3393	Causal association of cholesterol metabolism-related proteins in HCC and MASLD: Mendelian randomization and drug repositioning	3424
Validation of a risk-stratified approach to screening for hepatocellular carcinoma following liver transplantation	3394	Impact of low level viremia on the efficacy of immune checkpoint inhibitors therapy in patients with unresectable hepatocellular carcinoma	3425
T cell receptor and immune gene expression pharmacodynamics for durvalumab monotherapy and in combination with tremelimumab or bevacizumab in unresectable hepatocellular carcinoma (uHCC)	3396	Peripheral Blood Inflammatory Score Using a Cytokine Multiplex Assay Predicts Clinical Outcomes in Unresectable HCC Patients Treated with Atezolizumab/Bevacizumab	3429
Emerald-Y90: a Phase 2 study to evaluate transarterial radioembolization (TARE) followed by durvalumab (D) and bevacizumab (B) for the treatment of participants (pts) with unresectable hepatocellular carcinoma (uHCC) eligible for embolization	3397	Changes in Bridging Therapy for Hepatocellular Carcinoma (HCC) by Region in the U.S. from 2018-2023: Reduction in Hepatocellular Carcinoma Risk with SGLT2 Inhibitors in Patients with Co-Existing Hepatitis C and Type 2 Diabetes: A Global Multicenter Propensity-Matched Study	3430
Non-viral etiology subgroup of the Phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma	3398	Systemic Immune Profiling Identifies Predictive Biomarkers for Response to Combination Immunotherapy in Hepatocellular Carcinoma	3433
Statin Use Reduces Tumor Recurrence in Hepatocellular Carcinoma After Curative Radiofrequency Ablation: A Propensity-Matched Analysis	3399	Phase I clinical trial of adjuvant therapy utilizing six tumor-associated antigen-derived peptides and autologous dendritic cells for hepatocellular carcinoma	3434
The optimal AFP threshold for HCC screening should be lower than 20 ng/mL in cured hepatitis C, ALD, and MASLD	3401	Multi-Omic Risk Prediction for Cholangiocarcinoma	3438
Nucleos(t)ide analogues in the treatment of long-term prognosis in patients with hepatitis B virus-related hepatocellular carcinoma after radical surgery: Interim analysis of the phase 3 multi-center prospective trial	3403	Analysis of atezolizumab antidrug antibody in HCC patients treated with Atezolizumab and Bevacizumab	3439
PIVKA-II as a prognostic factor for patients with hepatocellular carcinoma and with normal serum alpha-fetoprotein levels	3406	ACC2: A Novel Biomarker for Metabolic Dysfunction-Associated Steatotic Liver Disease-induced Hepatocellular Carcinoma with severe steatosis	3440
Machine learning-based decision-tree model demonstrating the prognostic value of PIVKA-II and AFP in patients with hepatocellular carcinoma	3407	Radiomics-based prediction of HCC response to atezolizumab/ bevacizumab	3441
Factors associated with type of first-line treatment received for unresectable hepatocellular carcinoma in the era of immunotherapy	3408	Critical Outcomes in Patients with Hepatobiliary Neoplasia during COVID-19: United States Nationwide Analysis	3443
Diagnosis Mode and Outcomes of Hepatocellular Carcinoma in Elderly Patients with Implications for Surveillance	3409	Phase II study of atezolizumab plus bevacizumab combination therapy in patients with unresectable hepatocellular carcinoma and Child-Pugh B: CHALLENGE trial	3445
Associations Between Metabolic Syndrome and Cholangiocarcinoma Risk: A Large-Scale Population-Based Prospective Study	3411	Hepatocellular Carcinoma Risk in Hispanics with Chronic Hepatitis B	3446
Serum soluble DR5 as a Novel biomarker predicts early recurrence of hepatocellular carcinoma in TACE-treated patients with chronic hepatitis B	3412	Impact of Prior Locoregional Therapy (LRT) on Outcome of Patients treated with Single-Dose Tremelimumab Induction Regular Durvalumab (STRIDE) Therapy for Unresectable Hepatocellular Carcinoma (uHCC) in a Real-World Cohort	3447
		Viral versus Non-Viral Etiology Does Not Impact Outcomes of Unresectable Hepatocellular Carcinoma (uHCC) Patients	3448



Treated with Single Tremelimumab Regular Interval Durvalumab (STRIDE) in a Real-World Setting		Curative Treatment after Immunotherapy Leads to Excellent Outcomes in Patients with Hepatocellular Carcinoma	3486
Unraveling immune-activated tumor microenvironment correlated with clinical response to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma	3449	Identification of Cytokines Predicting the Ineffectiveness of Atezolizumab Plus Bevacizumab Therapy.	3487
Re-classification of combined hepatocellular-cholangiocarcinoma and small duct type intrahepatic cholangiocarcinoma by genetic alterations	3452	Dendritic cell exosomes decorated with hepatocellular carcinoma-specific antigenic peptides combined with anti PD-L1 boost cancer immunotherapy	3490
Marijuana Use is not Independently Associated With the Incidence of Hepatocellular Carcinoma in Patients With Cirrhosis	3453	Atezolizumab combined with Bevacizumab versus Sorafenib and Lenvatinib for patients with unresectable hepatocellular carcinoma: A systemic review and meta-analysis for randomized controlled trials	3491
Incorporating Geriatric Nutritional Risk Index with ALBI Grade Improves Risk Stratification in Patients with Hepatocellular Carcinoma: Based on Korea Central Cancer Registry database	3454	A machine learning model to predict the treatment response of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma	3492
Outcomes of Combined Heart and Liver Transplants in Patients with Congestive Hepatopathy and HCC: Analysis of US National Database	3455	Risk stratification category is associated with differential risk-to-benefit ratio of liver cancer surveillance programs	3493
Causal association and prognostic value of tertiary lymphoid structure-related gene signatures in HCC	3456	Predicting end-stage hepatocellular carcinoma with the ECHO score: refining the definition of Barcelona Clinic Liver Cancer stage D disease in patients treated with immune checkpoint inhibitors	3495
Prevalence of Chronic Liver Disease in Cholangiocarcinoma: a Meta-Analysis	3458	Circulating exoPD-L1 predicts the outcome of patients with HCC who received atezolizumab-bevacizumab	3496
Escalating Burden of MASH associated HCC. An Updated Analysis of Global Burden of Disease 2021	3460	Burden of Liver Cancer and Other Major Gastrointestinal Cancers in The Eastern Mediterranean Region	3497
Real-world clinical characteristics and treatment patterns among patients with unresectable hepatocellular carcinoma (uHCC) amenable to locoregional therapy (LRT) in the United States (US)	3461	Beneficial effect of combined radiation therapy in atezolizumab plus bevacizumab treatment of hepatocellular carcinoma patients with main portal vein tumor thrombosis or bile duct invasion.	3498
MAFLD etiology and multidisciplinary treatment could achieve a good survival in advanced HCC with cirrhosis - a large retrospective data from India.	3464	Machine learning can accurately stratify risk of hepatocellular carcinoma in real-world data	3499
Recombinant human thrombopoietin (rhTPO) and platelet transfusion in patients with severe thrombocytopenia (sTCP) undergoing liver cancer ablation procedures: a retrospective study	3465	Activation of coagulation factors and impaired fibrinolysis in patients with primary sclerosing cholangitis and cholangiocarcinoma	3502
Safety analysis by treatment periods from EMERALD-1: a Phase 3, randomized, placebo-controlled study of transarterial chemoembolization with durvalumab with/without bevacizumab in participants with embolization-eligible unresectable hepatocellular carcinoma	3466	Evaluating Treatment Strategies in Hepatocellular Carcinoma: A Longitudinal Analysis of BCLC Recommendations and Patient Outcomes	3504
Risks of variceal bleeding in patients with hepatocellular carcinoma receiving immune checkpoint inhibitors and/or tyrosine kinase inhibitors (TKIs)	3467	Validation of prediction models for Hepatitis B Virus-related Hepatocellular Carcinoma Based on The Type of Antiviral Agents	3505
Risk factors for post-transarterial chemoembolization hepatic failure in patients with hepatocellular carcinoma: A Systematic Review and Meta-Analysis	3470	Initial trans-arterial chemo-embolization (TACE) is associated with similar survival outcomes as compared to upfront percutaneous ablation in those with single hepatocellular carcinoma (HCC) <= 3cm: results of a real-world propensity-matched multi-centre Australian cohort study	3507
Compound sarcopenia and physical frailty adversely impact outcomes in hospitalized patients with hepatocellular carcinoma in an age dependent manner.	3472	Efficacy and safety of Stereotactic body radiation therapy in elderly patients with cirrhosis and large advanced hepatocellular carcinoma	3508
High Proximity of Treg-CD8T/CD4T Cell Interactions in Spatial Omics Analysis Regulating Cancer Progression in Patients with Hepatocellular Carcinoma	3475	The role of adjuvant therapy in HCC treated with curative intent ablation: a step too far?	3509
Impact of CRAFTY score on Efficacy and Safety of First-line Atezolizumab plus Bevacizumab Therapy: Multi-center Retrospective Study	3476	Relationship between Immune Cell Infiltration and Outcomes in Cholangiocarcinoma	3510
Statin Use and Hepatocellular Carcinoma in Participants with Hepatic Fibrosis in the All of Us Research Program	3477	Trimethylamine N-oxide (TMAO) as a novel predictive biomarker in gallstone disease and gallbladder cancer: Insights from human and mice study	3513
Exploring the Influence of Aspirin on Hepatocellular Carcinoma : A Nationwide Inpatient Analysis	3478	Characteristics of HBV integration in patients with and without hepatocellular carcinoma	3515
Exosomal miRNA as a Valuable Indicator for Predicting the Response of Atezolizumab and Bevacizumab Combination Therapy in Patients with Advanced Hepatocellular Carcinoma	3480	Increased PD-1+TIGIT+TIM-3+ in peripheral circulating cells predicts outcomes and treatment response in HCC patients with Transarterial Chemoembolization	3516
The Composition of Circulating Immune Cells Following Treatment with Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma	3481	Sarcopenia impacts treatment tolerance and survival of patients with Hepatocellular carcinoma in cirrhosis	3517
Impact of COVID-19 on primary liver cancer-related mortality in the United States	3483	The Relationship between Fatty Acid Composition and Prognosis in Patients with Hepatocellular Carcinoma: Establishment of a New Nutritional Prognostic Score	3518
		The Steatosis- Associated Fibrosis Estimator (SAFE) Score Predicts Hepatocellular Carcinoma in a Cohort of Chronic Liver Disease of Mixed Etiology	3519
		A comprehensive study employing computational analysis and Mendelian randomization has revealed the impact of key genes on liver cancer	3520

Role of ALBI score in patients with hepatocellular carcinoma undergoing transarterial chemoembolization in Child-Pugh class A and low MELD score	3522	Towards precision oncological liver surgery: label-free multiphoton microscopy and machine learning for tumor recognition in hepatocellular carcinoma	188
Impact of the SARS-CoV-2 Pandemic on the Diagnosis and Follow-up of Patients with Hepatocellular Carcinoma at R&iacute;o Horteaga University Hospital	3523	Liver Stiffness Measurement and Hepatocellular Carcinoma Risk in Metabolic Dysfunction Associated Steatotic Liver Disease	225
ASAP score predicts HCC recurrence after complete radiological response to locoregional treatments	3524	Diagnostic Accuracy of Blood Plasma Spectroscopy for Early Liver Cancer Diagnostics in Obese Patients	3370
Survival after Removal from Liver Transplant Waitlist for Hepatocellular Carcinoma Progression: Effects of Immunotherapy and Therapy Type	3525	Intraindividual Comparison of Prognostic Imaging Features of Hepatocellular Carcinomas Between MRIs with Extracellular and Hepatobiliary Contrast Agents: Focus on Microvascular Invasion and Early Recurrence	3372
Efficacy and Safety of FGFR Inhibitors in Cholangiocarcinoma, A Systematic Review and Meta Analysis	3526	A Clinicopathological and Artificial Intelligence-Derived Screening Model as a Tool for Distinguishing Patients with Non-Hodgkin Lymphomas from Inflammatory Hepatic Diseases: A Multicentric Learning Approach	3391
Comparative Analysis of Imaging Modalities for Hepatocellular Carcinoma Surveillance	3529	Development of an ultra-sensitive TERT promoter mutant DNA detection method and its application in liquid biopsy	3400
Transarterial Chemoembolization Offers Survival Advantage Over Radioembolization in Early-stage Unresectable Hepatocellular Carcinoma	3530	Performance of the LI-RADS-based Milan criteria and its prognostic implication in potential transplant candidates with hepatocellular carcinoma	3419
Baseline liver histological characteristics in patients with chronic hepatitis B who developed into HCC 3- 5 years later	3532	Utility of the Gaad Algorithm in Hepatocellular Carcinoma Surveillance Among A High-risk Cohort	3426
Clinical and Imaging Factors Associated HCC Progression on the Liver Transplantation Waitlist	3533	Misclassification analysis of a multimodal image-based deep-learning model for predicting post-operative HCC recurrence: Implications for model improvement	3444
Sarcopenia and physical frailty result in worse outcomes in hospitalized patients with hepatocellular carcinoma than other solid organ cancers or hospitalized patients without cancer	3535	Novel miRNA Methylation Patterns Specific to Hepatocellular Carcinoma in the Post-SVR patients.	3457
Characterization of the immune microenvironment in hepatocellular carcinoma before selective internal radiation therapy and its prognostic role in treatment efficacy	3536	Prediagnostic CT radiomics features for Hepatocellular carcinoma (HCC) risk stratification among patients with cirrhosis	3473
Rising Disparate Trends in Hepatocellular Carcinoma Incidence: A 22-Year Analysis of National Centers for Disease Control and Prevention Data	3537	Differentiating Hemangiomas from Hepatocellular Carcinomas Using Sonazoid-Enhanced Ultrasonography: A Proposed Two-Step Diagnostic Algorithm	3485
Hepatocellular Adenomas: Malignant Transformation and Surgical Outcomes in a High-Volume Center	3538	AGAP-APRI as a proposed alternative to GALAD or Liver US with AFP for HCC screening in Filipinos	3527
Optimal Treatment Strategies for Hepatocellular Carcinoma: A Meta-Analysis Comparing Transarterial Chemoembolization (TACE) Plus Microwave Ablation (MWA) Versus Microwave Ablation Alone	3539	Prediction of Immune Checkpoint Inhibitor Treatment Response in Hepatocellular Carcinoma Using CT Radiomics	3543
Assessing treatment Response in Hepatocellular Carcinoma (HCC) after Trans-Arterial Chemo-Embolisation (TACE) - Incorporating degree of tumor necrosis to predict survival outcomes	3540		
Nonviral HCC is independently associated with poorer survival as compared to viral HCC: a U.S. population-based study	3542		
Tumor-derived circulating carbonic anhydrase 9 as a predictor of resistance to atezolizumab and bevacizumab in advanced hepatocellular carcinoma	3544		
Trends in the utilization of systemic therapy for treatment and palliation in patients with advanced HCC in the era of immunotherapy	3545		
Advancing Survival: A 45-Year Analysis Showing Improvement in Hepatocellular Carcinoma Treatment Outcomes	3546		
Complementing Locoregional Therapies with Immune Checkpoint Inhibitors in patients with advanced HCC is tolerable and improves disease-free survival: Real-World Data and Experience	3547		

## Hepatobiliary Neoplasia

### Diagnostics and Liver Imaging

Novel multiomics Biomarker Signature derived from blood circulating Hepatocyte-Extracellular Vesicles for the early detection of HCC	83
--	----

## Hepatobiliary Neoplasia

### Experimental Hepatocarcinogenesis

★ Targeting Macrophage-Mediated Mechanisms of Immune Evasion as adjuvant therapy in TACE-resistant Hepatocellular Carcinoma	15
★ Enhancing Cytotoxic CD8+ T Cell Response for Liver Cancer Treatment using poly(IC)-Containing Ionizable Lipid Nanoparticles via activating Hepatocellular Type I IFN pathway	41
Contribution of myeloid cell-derived HMGB1 to the development of hepatocellular carcinoma	84
Lysosomal autophagy-based degradation of hepatocellular carcinoma PD-L1 modulates tumor macrophage polarization to activate anti-tumor immunity	98
★ DNA methylation of tumor tissues and circulating tumor DNA in early detection of hepatocellular carcinoma	132
Liver cancer chemoprevention by targeting the histamine receptor 2 and using PLSec as a biomarker	138
★ Regnase-1 down-regulation contributes to myeloid cell intermediated ICC development	169

Multiplexed single-cell analysis reveals distinct tumor-immune microenvironment linked to premetastatic niche formation in steatotic liver	173	Hepatoma-derived growth factor (HDGF) is an oncogene on chromosome 1q in liver cancer	3459
Resveratrol and tanshinone IIA synergize to suppress hepatocellular carcinoma by modulating stromal cells to remodel tumor microenvironment	3360	DNA Methylation-Regulated TIPIN Promotes Hepatocellular Carcinoma Metastasis	3462
★ Cholangiocytes' Primary Cilia Regulates DNA Damage Response and Repair	3363	Manzamine A Inhibits Proliferation of Human Hepatocellular Carcinoma Cells by Suppression of Mitochondrial and Glycolytic Metabolism	3463
The Histone Lysine Acetyltransferase KAT2B Inhibits Cholangiocarcinoma Growth: Evidence for Interaction with SP1 to Regulate NF2-Yap Signaling	3366	A patient-derived hepatocellular carcinoma spheroid system harnessing patient serum to model the tumor microenvironment and treatment response	3468
RBM39 Enhances Cholangiocarcinoma Growth through Ezh2-Mediated Wnt7b/ $\beta$ -Catenin Pathway	3367	PFAS exposure as a risk factor for hepatocellular carcinoma: are all PFAS the same?	3469
Mechanism of hepatocarcinogenesis due to hepatitis B virus genome integration into host KMT2B locus	3373	TGF- $\beta$ /Smad3 dependent and Smad3 independent roles of SIRT6 regulation in blocking HCC	3471
METTL3-mediated m6A modification regulates the polycomb repressive complex 1 (PRC1) components BMI1 and RNF2 in hepatocellular carcinoma cells	3374	Multistep accumulation of mismatch repair deficiency-associated mutational signature during the hepatocarcinogenesis revealed by whole-genome sequencing analysis	3474
The Hippo Pathway Effector TAZ Is Required for Notch-Driven Cholangiocarcinogenesis via METTL3-mediated m6A modification	3376	Mutated- $\beta$ -catenin drives suppression of an immune-regulatory module of transcription factors altering expression of key chemokines involved in immune response in hepatocellular cancers	3479
Hypocrellin A, a Natural Small Compound, Exerts Anti-Tumor Effects via Multi-Target Inhibition of the PI3K-AKT-mTOR, MAPK, and STAT3 Signaling Pathways in Intrahepatic Cholangiocarcinoma	3381	In vivo experiments and omics analysis to explore the effect and mechanism of AnLuoHuaXian pills in alleviating the process of hepatitis to hepatocellular carcinoma	3482
Interaction of solute carrier family 39 member 1 and dynamin related protein 1 to facilitate development of hepatocellular carcinoma by impairing mitochondrial quality control	3385	Insights into the Role of Hepatocyte MLKL in MASLD-Driven Liver Cancer	3484
UBE2D3 negatively regulates hepatocarcinogenesis via suppression of STAT3 signaling	3389	Functional role of microRNA-491 in lenvatinib resistance in hepatocellular carcinoma	3488
RNA-Binding Protein Trx regulates alternative splicing and promotes metastasis of HCC via interacting with LINC00152	3390	Epigenetic Regulation of ACSM5 Expression in Hepatocellular Carcinoma	3489
Loss of BAP1 confers resistance to ferroptosis and promotes cholangiocarcinoma development	3395	★ DPP4 inhibition augments the anti-tumor effect of combined anti-PD-1 antibody/regorafenib in hepatocellular carcinoma	3494
The chemoprotective effects of genistein in a rat model of cirrhosis and hepatocellular carcinoma	3402	Targeting UBE2I-mediated protein hyper-SUMOylation halts cholangiocarcinoma progression and rewires the tumor-stroma crosstalk	3500
The role of HBV pregenomic RNA in influencing the development of hepatocellular carcinoma	3404	The involvement of microRNA-1297 in lenvatinib resistance in hepatocellular carcinoma cells	3501
Identification of PRMT5 as a therapeutic target in cholangiocarcinoma	3405	Transposon-based oncogenes integration in Abcb4 (Mdr2)-/- mice recapitulates high susceptibility to cholangiocarcinoma in primary sclerosing cholangitis	3503
RPL41 Promotes HCC Metastasis Via Transcription Factors RUNX2-Mediated EMT Mechanism	3410	NRF2-mediated immune cold tumor microenvironment contributes to resistance to atezolizumab and bevacizumab in advanced hepatocellular carcinoma	3511
Role of myeloid-cell derived osteopontin in hepatocellular carcinoma	3415	Lipophilic Statin Increases Sensitivity for Lenvatinib by Suppressing YAP/TAZ in Hepatocellular Carcinoma Cell Lines and Patient-Derived Organoids	3512
Investigation for a role of non-apoptotic cell death in the development of Hepatocellular carcinoma	3421	Novel Th17 lymphocyte populations, Th17.1 predicts survival of patients with Hepatitis B Virus - Associated Hepatocellular Carcinoma	3514
Identification of ITGB2 as a Novel MHC-II Neoantigen using Hepatocellular Carcinoma Organoids	3428	Genomic profiling and pathological differences in MASLD-related hepatocellular carcinoma with and without cirrhosis.	3521
Disruption of FGL2 induced TFEB-dependent lysosomal degradation of PD-L1 and Enhanced the efficacy of Anti-PD-1 therapy in Hepatocellular Carcinoma	3435	GalNAc-conjugated antisense oligonucleotides targeting DDR1 inhibit hepatocellular cancer	3528
Soluble FGL2-Fc $\gamma$ RIIB axis driven memory CD8+ T cells dysfunction in Hepatocellular Carcinoma	3436	Altered Cellular Energetics and Dysregulation of NK Cells in Hepatocellular Carcinoma	3531
★ Investigation for diagnostic value of circulating tumor DNA for the early HBV-derived HCC by profiling fragmentation	3437	Chemical inhibition of phosphoglycerate mutase 5 attenuates hepatocellular carcinoma viability	3534
Spatial Omics Analysis of the Proximity of PD-L1(+) Tumor-Associated Macrophage and CD8T cell Interaction Promoting Hepatocellular Carcinoma Progression	3442	Hepatocyte Specific ATP1A1 Knock-out Mice Develops Spontaneous Primary Liver Malignancy Associated With the Metabolic Disturbances of Mash- Related HCC.	3541
Identification of Erzhu Jiedu Recipe and its molecular mechanism underlying inhibited human hepatoma cells by UHPLC-MS/MS and network pharmacology	3450	Evolution of hepatocarcinogenesis induced with chronic administration of DEN and 2-AAF during 13 and 18 weeks in Wistar Rats	3548
DNA demethylation in promoter region restores CYGB expression and attenuates hepatocellular carcinoma progression	3451		

## Hepatotoxicity

### Drug Metabolism, Toxicity and Therapeutics

S-Adenosylmethionine Protects Against FOLFOX-Induced Liver Injury by Inhibiting Plasminogen Activator Inhibitor-1 in Mice	79
★ The Protective Role of Sulfiredoxin-1 (SRXN1) in Acetaminophen-Induced Liver Injury	93
Olanzapine-Induced Liver Injury: A Case Report	2424
Lipofuscinosis as a novel discriminating feature for drug-induced liver injury vs. autoimmune hepatitis	2425
Single-cell investigation of mercaptopurine-associated liver injury	2428
Deep learning-based diagnostic model of pyrrolizidine alkaloid-related hepatic sinusoidal obstruction syndrome based on CT: development and validation study	2429
'Shrooms' and Severe Hepatitis - A Unique Entity	2430
The Impact of COVID-19 and COVID-19 Vaccination on Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury Occurring During Clinical Trials: Consensus Recommendations from the IQ DILI Consortium	2432
Early Bile Drainage Saves Beagles from Amanita Subjunquillea-Induced Acute Liver Failure	2437
Drug-Induced Liver Injury due to Medications for Alcohol Use Disorder: Insights from the DILIN Prospective Study	2438
Drug induced liver injury: A unusual case of cholestatic hepatitis caused by highly active anti-retroviral therapy (HAART)	2444
Evolving Patterns of Potentially Hepatotoxic Botanical use in the United States: Results from NHANES 2003 - 2018 Surveys.	2445
Biodistribution of therapeutic nanoparticles depending on gender and progression of chronic liver disease	2446
The MetaHeps technology for drug causality assessment in patients diagnosed with idiosyncratic drug-induced liver injury (DILI)	2449
The Ongoing Problem of Mislabeling of Herbal and Dietary Supplements Implicated in Hepatotoxicity	2451
Safety of fomepizole with n-acetylcysteine in acetaminophen overdose: a case series	2452
Dual-mode action of scalable, high-quality engineered stem cell-derived SIRP $\alpha$ extracellular vesicles for treating acute liver failure	2453
Immune-mediated liver injury caused by immune checkpoint inhibitors exhibits distinct clinical features that differ from autoimmune hepatitis	2456
Clinical Outcomes of Idiosyncratic DILI are Improving in the United States: Results from the DILIN Prospective Study, 2004 to 2024	2459
Muscle steatosis significantly increases the risk of death in patients with cirrhosis - a retrospective cohort study	2460
Co-administration of Alcohol, Ritonavir and Lopinavir Affects Expression of the SET Cheperone Protein in Hepatocytes and Monocytes and HIV-1 Infectivity In Vitro	2462
Characterization of liver injury induced by CDK 4/6 inhibitors induced liver injury	2469
The burden of anti-cancer drugs in drug-induced liver injury in the French-speaking hepatotoxicity network	2470
Verbascoside Protect Against Oxidative Damage of Benzo[ $a$ ]pyrene Exposure on Hepatocellular Cells	2473
Efficacy of UDCA as first-line treatment for cholestatic checkpoint inhibitor-induced liver injury	2475
Trends and Outcomes of Acetaminophen-induced Hepatotoxicity: A 2016 to 2021 Analysis Using the National Inpatient Sample Dataset	2476

Decoding Acetaminophen Risks: A U.S. Inpatient Data Comparison of Acetaminophen toxicity in patients with Alcoholic and without Alcoholic Liver Disease	2479
Nilotinib Induced Hepatotoxicity with Decade Long Latency and Newly Discovered Pancreatic Head Mass	2482

## Hepatotoxicity

### Pathogenesis and Mechanisms

★ Hepatic Grp78/BiP Overexpression Protects Against Enhanced MASLD by Vinyl Chloride.	101
★ Single-Cell Imaging Mass Cytometry Defines Immune Cell Composition and Spatial Interactions with Apoptotic Hepatocytes in Immune-mediated Liver Injury from Checkpoint Inhibitors (ILICI) and Autoimmune Hepatitis (AIH)	157
Induction of Cyp2e1 contributes to asparaginase-induced hepatocyte sensitization to lipotoxicity.	2431
Nuclear factor erythroid 2-related factor 2 (NRF2) activation aggravates liver injury by causing mitochondrial dysfunction	2433
KEAP1 deletion rescues cell death associated with GPX4 knockdown in hepatocytes in acute models of liver injurydelta	2434
★ The liver-endocrine axis plays a mechanistic role in driving chemical plus diet-induced steatotic liver disease in females	2441
Interleukin-19 protects against acetaminophen-induced liver injury by limiting macrophage infiltration via enhancing C/EBP $\beta$ SUMOylation	2448
Sequential analysis of serum levels of ten intestinal permeability and inflammation markers in patients with drug-induced liver injury and other forms of acute liver injury	2450
Identification of Risk Profiles for Liver Injury in Adults With Multiple Sclerosis Using Artificial Intelligence Method	2457
The pivotal role of ABCB11 on genetic susceptibility to drug-induced liver injury from anabolic steroids	2463
CXXC-type zinc finger protein 5 deficiency in mice ameliorates acetaminophen-induced liver injury via the STAT1 signaling pathway	2465
Exposure to cigarette smoke aggravates hepatic damage in mice induced by ethanol or acetaminophen	2466
Low dose exposure to dioxins alters hepatic energy metabolism and steatotic liver disease development in a sex-specific manner.	2467
Correlation between decreased type 3 innate lymphocyte and deterioration of liver function in cholestatic drug induced liver injury	2468
SS-31 Protects from Vinyl Chloride and Western Diet-induced Hepatic Injury	2471
★ Targeted Deletion of Epidermal Growth Factor Receptor in Hepatocytes Mitigates Acetaminophen-Induced Liver Damage and Enhances Compensatory Regeneration in Mice	2472
Hepatic cell membrane synthesis is suppressed during liver regeneration after acetaminophen hepatotoxicity	2474
The role of 2'-5'-oligoadenylate synthase-like protein (OASL1) in cholestatic- and hepatotoxin-mediated liver fibrosis	2477
Maternal smoking exacerbates subsequent liver damage in offspring mice	2478
Aging promotes liver injury: Studies on C57Bl/6 mice	2481

## Hepatotoxicity

### Predictors of Drug Toxicity

Sankey Plots are Better than eDISH Based Plots for Initial DILI Assessment in Trials with Abnormal Baseline Liver Tests	91
nR-value Greater Than Five Is Better Than Alkaline Phosphatase (AP) Less than Twice Normal Criterion for Identifying Hy's Law Cases in Clinical Trials	92
Unveiling Preventable Liver Damage: Exploring LAAT and Hallas Tools in Hospitalized Patients Assessed with Updated RUCAM Scale	2427
Hepatic Sinusoidal Congestion Associated with Inotuzumab in Patients with B-cell Acute Lymphoblastic Leukemia: A Case Series Report	2435
Variability in Reference Ranges of Hepatic Biochemical Tests in Pediatric Populations: Implications for Monitoring and Assessment of Drug Induced Liver Injury	2436
Liver Injury in Clinical Trials of Biologic Agents Has a Lower Rate of Attribution to Drug-Induced Liver Injury (DILI) Compared to Non-Biologic Agents	2439
Impact of lipophilicity and daily dose on drug-induced liver injury in the Japanese cohort	2440
Intrathecal Methotrexate is Associated with Acute Transient Hepatocellular Liver Injury	2442
Elevated Baseline Serum CD8 and IL-2 Levels May Predict Systemic Anticancer Therapy Related Liver Injury	2443
Improving the Diagnostic Accuracy of the RECAM in North American Patients with Suspected Idiosyncratic Drug-Induced Liver Injury	2447
A Novel Machine Learning Model for Distinguishing Drug-Induced Liver Injury from Autoimmune Hepatitis: Development and Validation	2454
Higher pre-treatment ALT level and pre-existing liver disease are associated with increased risks of fluconazole related liver toxicity.	2455
TransDILI: a deep transfer learning based prediction for drug-induced liver injury through leveraging molecular structure images	2458
HLA-B*35:01 Allele is a Risk factor for Drug-Induced Liver Injury due to Anti-Hypertensives	2461
Exploring the Impact of Acetaminophen Overdose on Patients with Acute Alcoholic Liver Failure	2464

## Human Cholestatic and Autoimmune Liver Diseases

### Autoimmune Liver Disease

TNFalpha as a key inflammatory mediator in Autoimmune Hepatitis (AIH): molecular basis and successful proof-of-concept phase IIA clinical trial of infliximab induction therapy	185
Predicting outcomes in autoimmune hepatitis pregnancy	240
Clinical Presentation of Patients with Autoimmune Hepatitis Stratified by Immunoglobulin G Levels	4268
Quantitative MRCP+ measures predict advanced cholangiopathy in pediatric Primary Sclerosing Cholangitis (PSC)	4284
Autoimmune hepatitis - A disease with a manifold clinical presentation - Machine Learning to break it down?	4297
Metabolic risk factors and metabolic dysfunction-associated steatotic liver disease influence waitlist and transplant outcomes in autoimmune hepatitis patients	4299
Comparison of inpatient outcomes and characteristics of Autoimmune Hepatitis-Primary Biliary Cirrhosis Overlap	4300

Syndrome with Autoimmune Hepatitis, and Primary Biliary Cirrhosis in the United States 2016-2019: A nationally representative study	4303
Impaired hepatic regulatory T cells aggravate autoimmune hepatitis	4316
Multicenter study on Incidence and Risk Factors of Hepatocellular Carcinoma in Patients with Autoimmune Hepatitis	4319
Haploinsufficiency of A20 in Autoimmune Hepatitis Enhances Inflammatory and Fibrogenic Responses: Insights from iPSC-Derived Models	4325
Targeting of inflammatory monocytes via CCL2/CCR2 signaling as a therapeutic strategy against autoimmune hepatitis by using macrophage-derived extracellular vesicles	4329
A Multi-Platform Approach Identifies Novel Candidate Biomarkers of Relapse in Autoimmune Hepatitis	4332
Test-retest Repeatability of PSC specific imaging biomarkers from quantitative MRCP	4353
Association between NUDT15 Polymorphism and Thiopurine-induced Leukopenia in Patients with Autoimmune Hepatitis	4359
Enhancing the Detection of Autoimmune Hepatitis Onset through Natural Language Processing and Database Programming in a Large Health Record Database	4361
Autoimmune Hepatitis and Vitamin D Deficiency: A Nationwide Perspective	4370
Partial Living Donor, Whole Deceased, and Split Liver Transplantation in Autoimmune Liver Disease	4373
Is Half-Dose Corticosteroid Induction Therapy Effective in Achieving Therapeutic Response in Autoimmune Hepatitis?	4375
Recompensation is associated with improved outcomes in patients with decompensated cirrhosis from autoimmune hepatitis	4376
Predictors of Symptom Severity among Autoimmune Liver Disease patients in a Single United States Center	4377
Diagnostic Performance of Transient Elastography and Aspartate Aminotransferase-to-Platelet Ratio (APRI) in Autoimmune Hepatitis	4378
Burden of comorbid psychiatric illnesses among hospitalized patients with Autoimmune Liver Disease: A Nationwide cohort analysis	4380
What do specific markers of autoimmune hepatitis inform us about the variant presentations of autoimmune liver disease?	4384
The Effect of Race on Autoimmune Hepatitis Mortality Rates in the United States	4386
Impact of Vancomycin on Liver Fibrosis in Paediatric Patients with Primary Sclerosing Cholangitis	4387
How frequent is clinical concern for 'overlap' between primary biliary cholangitis and autoimmune hepatitis encountered in real world care?	4389
Label-free classification of cell type diversity in human livers distinguishes autoimmune hepatitis from disease controls	

## Human Cholestatic and Autoimmune Liver Diseases

### PBC/PSC and Other Cholestatic Disease

★ Fecal cytolyisin is associated with a poorer outcome in patients with primary sclerosing cholangitis	42
One-year treatment with elafibranor in the phase III ELATIVE trial improves GLOBE and UK-PBC prognostic scores	43
ASSERT-EXT: Final data from an open-label, phase 3 study of odeixibat in patients with Alagille syndrome	50
Alkaline phosphatase and fibrosis markers are prognostic for outcome in recurrent primary sclerosing cholangitis after liver transplantation	109



★ Biliary senescence drives hepatocyte VCAM-1 expression and liver neutrophil infiltration	116	Improving knowledge in PBC Management Beyond First-Line Therapy: Structured Learning Increases Competence and Confidence	4283
Quantitative MRCP metrics have utility in assessing changes in biliary tree health in PSC patients: a ten-year evaluation	133	Validation of the worst itch numerical rating scale (NRS) and related patient-reported outcomes (PROs) to assess severity and impact of pruritus in primary biliary cholangitis (PBC)	4285
Associations Between Biomarkers and Magnetic Resonance Imaging-Derived ANALI Score in Patients with Primary Sclerosing Cholangitis: Analysis from the Phase 3 PRIMIS Study	151	Pruritus impacts health-related quality of life (HRQoL) and sleep for patients with primary biliary cholangitis (PBC) in the patient-centric PicnicHealth registry	4286
Efficacy and Safety of Seladelpar in Patients With Primary Biliary Cholangitis and Compensated Cirrhosis in the Phase 3 Placebo-controlled Response Trial	164	Lipidomic profiling of blood and bile reveals an abundance of Lactosylceramides in patients with Primary Sclerosing Cholangitis	4287
Attenuation, Near Resolution, and Prevention of Pruritus in Patients With Primary Biliary Cholangitis Treated With Seladelpar: A Secondary Analysis of Patterns of Pruritus Change in the Response Trial	167	Clinically significant itch on the PBC-40 corresponds to moderate-severe itch on the worst itch numerical rating scale (NRS) in patients with pruritus and primary biliary cholangitis (PBC)	4288
★ Fibrate-Oca (FI-OCA) Study - a Global snapshot of PBC practice around the Globe	186	Real-world clinical significance of biochemical response and liver stiffness variation over time in patients with primary biliary cholangitis treated with Obeticholic acid.	4289
The effect of obeticholic acid on inflammatory markers and fibrosis scores in POISE incomplete responders: a retrospective review of POISE, a phase 3 trial of obeticholic acid for the treatment of primary biliary cholangitis	219	Insufficient control of cholestatic pruritus in primary biliary cholangitis (PBC) with current therapies: baseline data from the ongoing Phase 3 GLISTEN (Global Linerixibat Itch Study of Efficacy and safety in PBC) trial	4290
Diagnostic delay limits early recognition of Primary Biliary Cholangitis	4265	Periductal iron-corrected T1 is a predictor of adverse outcomes in large-duct primary sclerosing cholangitis	4291
Histological stage as predictor of the complications of primary biliary cholangitis	4266	Use of Machine Learning (ML) Models to Stratify Response Patterns to First-Line Treatment of Primary Biliary Cholangitis (PBC) with Ursodeoxycholic Acid (UDCA)	4292
Altered serum biomarkers in primary sclerosing cholangitis after proctocolectomy are consistent with improved prognosis and reduced gut microbial impact	4267	Liver stiffness measurement by transient elastography as a dynamic prognostic indicator for decompensation, transplant, or death in primary sclerosing cholangitis	4293
Deep learning analysis of magnetic resonance imaging accurately detects early-stage cholangiocarcinoma in patients with primary sclerosing cholangitis	4269	Unified or Unique? Transcriptomic Differences Between Patients with Primary Sclerosing Cholangitis, with and without Ulcerative Colitis	4294
The prevalence of Intestinal failure-associated liver disease (IFALD) in patients on long-term home parenteral nutrition	4270	Obeticholic acid treatment is associated with longer transplant-free and liver-related event-free survival in patients with primary biliary cholangitis from two large real-world cohorts	4298
Magnetic Resonance Cholangiopancreatography (MRCP) for Suspected Cholangiopathy in Children: a Multi-Reader Agreement Study	4271	Long-term Use of Fenofibrate as Second-line Therapy in Primary Biliary Cholangitis: A retrospective 12-year study of cholestatic markers and liver stiffness measurement	4301
Spatial heterogeneity of liver stiffness by MR elastography in patients with primary sclerosis cholangitis does not associate with clinical outcomes	4272	Sulfasalazine improves ANIT-induced cholestatic liver injury and regulates gut microbiota in rats	4302
Significance of heterogeneous biliary epithelial senescence as a possible target of new therapies in primary biliary cholangitis	4273	MRCP+ has a role in enhancing detection of high-grade strictures in primary sclerosing cholangitis	4304
Beyond the mean: exploring the impact of baseline alkaline phosphatase levels on endpoints in primary biliary cholangitis	4274	Whole exome sequencing for the diagnosis of genetic cholestasis in adults	4305
Treatment Response in Primary Biliary Cholangitis Based on Differing Criteria	4275	Cholangiocarcinoma Surveillance with Magnetic Resonance Cholangiopancreatography in Primary Sclerosing Cholangitis: Making our Hepatologists Feel Better	4306
Extent of bile duct loss correlates with clinical outcomes in hepatic graft-versus-host-disease	4276	Use of ursodeoxycholic acid can be optimized in a nationwide cohort of patients with primary biliary cholangitis	4307
Effects of odevixibat vs placebo on hepatic biochemical parameters and liver adverse events in patients with PFIC: Data from the PEDFIC 1 study	4277	Diabetes mellitus is associated with worse clinical outcomes in patients with primary biliary cholangitis	4308
An International Study of Circulating Fibrosis and Inflammatory Markers in Patients with Primary Sclerosing Cholangitis	4278	A disbalanced minority of patients with primary biliary cholangitis is managed in an academic health care setting	4309
Epidemiology and outcomes of primary biliary cholangitis patients undergoing liver transplantation - An Australian 37-year cohort study	4279	Non-PSC patients with cholangiocarcinoma have higher post-liver transplant mortality compared to PSC with cholangiocarcinoma	4310
A phase 1, open-label, fixed-sequence, crossover study to evaluate the interaction of multiple-dose odevixibat with the pharmacokinetics of single-dose combined oral contraceptive steroids in healthy female participants	4280	Investigating the Cholestatic Pruritus of Primary Sclerosing Cholangitis (ItCh-PSC): A cross sectional study of patients participating in the Consortium for Autoimmune Liver Disease (CALiD)	4311
Childhood Liver Disease Research Network (ChiLDReN) Prospective Observational Study of Primary Sclerosing Cholangitis (PSC) in Children: Cross-sectional characterization of the first 141 participants	4281	FOSB Aggravates Cholestatic Liver Disease by Disrupting Immune Microenvironment Balance	4312
Obeticholic acid for primary biliary cholangitis in the prevention of clinical events: a modeling study using real-world data	4282	Complication-Free Survival in a Real World Cohort of PBC Patients: Deep versus Adequate ALP Response to UDCA	4313

Diabetes is associated with poor liver related outcomes in patients with Primary Biliary Cholangitis	4314	Defining Acute Cholangitis as a Clinical Outcomes Endpoint in Adults with Primary Sclerosing Cholangitis (PSC): Results of a Multi-National Patient Survey to Develop a Patient-Reported Outcomes Measure (PROM)	4346
HLX92, a new molecular entity targeting gut microbiota-liver axis, confers therapeutic potential against cholestatic liver diseases	4315	Pilot study of volixibat co-administered with OCA for Primary Biliary Cholangitis (PBC) treatment: The VLX-602 trial	4347
Biomarkers Associate with Fibrosis Progression in Patients with Primary Sclerosing Cholangitis: An Ad-hoc Analysis from the PRIMIS Study	4317	Correlation Between The Pharmacokinetics of The Opioid Antagonist Nalmefene and Pruritus Relief in Patients with Cholestatic Pruritus	4348
Dysregulated Circular RNAs and Their Implications in the Pathogenesis of Primary Sclerosing Cholangitis	4318	Elafibranor has no impact on markers of renal function in primary biliary cholangitis: results from the phase III ELATIVE trial	4349
Establishment of an FXR-related PFIC mouse model carrying human-like bile acid composition by in vivo liver-specific gene deletion using adeno-associated virus and CRISPR/Cas9 system	4320	Characteristics of Patients with Primary Biliary Cholangitis Treated with Ursodeoxycholic Acid, Obeticholic Acid and Fenofibrate at Our Tertiary Liver Transplant Center	4350
Autoantibodies against carbonic anhydrase isoforms inhibit enzymatic function in primary sclerosing cholangitis and IgG4-related cholangitis	4321	Safety and efficacy of HK-660S versus placebo in patients with primary sclerosing cholangitis: A randomised, double-blind, placebo-controlled, phase 2a trial	4351
★ E-cadherin expression by CD8+ T cells is increased in patients with primary biliary cholangitis and promotes their invasion into biliary epithelial cells	4322	The Prognostic Role of Liver Stiffness Measured by Transient Elastography (TE) in Patients with Primary Biliary Cholangitis in Predicting Hepatic Decompensation	4352
The protective role of gallbladder presence and enlargement in patients with Primary Sclerosing Cholangitis: preliminary analysis of a multicentric study	4323	Circulating thrombospondin-2 (TSP2) predicts liver fibrosis and fibrogenesis in patients with primary sclerosing cholangitis	4354
Liver Transplantation for Primary Sclerosing Cholangitis in the United States by Donor and Recipient Sex and Race	4324	Real-world Evaluation of Alkaline Phosphatase Normalization in Patients with Primary Biliary Cholangitis Receiving Treatment	4355
The population with Primary Biliary Cholangitis is changing over time: milder disease and more metabolic comorbidities	4326	The clinical characteristics and validation of prognostic models for Primary Sclerosing Cholangitis: a multi-center population-based cohort study across mainland China	4356
The cyst microenvironment is spatially patterned to promote polycystic liver disease	4327	Primary Biliary Cholangitis Has the Worst Quality of Life When Compared to Autoimmune Hepatitis and Primary Sclerosing Cholangitis	4357
Serum Biomarkers of Cellular Senescence Show PSC Progression	4330	Economic burden of patients with primary biliary cholangitis and experiencing fatigue or pruritus in the United States	4358
The early dynamic changes of radiological and biochemical scores help identify a more aggressive PSC phenotype	4331	FXR agonist INT-787 inhibits inflammation, fibrosis, senescence, and apoptosis arrest in human cholangiocytes modeling PSC	4360
Understanding fatigue experiences through qualitative interviews with adults living with primary sclerosing cholangitis (PSC): An essential first step towards customizing a PSC-specific PROMIS measure	4333	Patients without baseline pruritus who initiate treatment with OCA have similar risk of developing treatment-emergent pruritus as those who are not on treatment with OCA	4362
Auto-antibody discovery in primary biliary cholangitis (PBC) using phage-immunoprecipitation sequencing (PhIP-seq)	4334	Pharmacokinetic and pharmacodynamic interaction of obeticholic acid and bezafibrate in healthy volunteers	4363
Performance of Ursodeoxycholic Acid Response Score in Predicting Treatment Response in A Single United States Cohort	4335	Longitudinal trends in hepatic biomarkers in patients who initiated treatment with obeticholic acid vs control patients in the HEROES study	4364
Transient Elastography Use in a Large Retrospective Cohort of Individuals with Primary Sclerosing Cholangitis: A Descriptive Study of Real-World Practice	4336	Clinical and Prognostic Factors Associated With Inflammatory Bowel Disease in Admixed Multiethnic Patients With Primary Sclerosing Cholangitis: Results From the Brazilian Cholestasis Study Group	4365
Identification of Novel Inflammatory Serum and Urinary Protein Biomarkers for PSC	4337	Effects of Elexacaftor-Tezacaftor-Ivacaftor treatment on liver stiffness, CAP values, and metabolic parameters in patients with cystic fibrosis	4366
Gallbladder Neoplasia is Associated With a Higher Risk of Biliary Neoplasia in Patients With Primary Sclerosing Cholangitis	4338	Identification and in vitro characterization of a novel BSEP and ABCB4 dual-acting positive functional modulator targeting the treatment of a broad range of hepatobiliary diseases	4367
Alkaline Phosphatase Changes With Seladelpar Across Subgroups of Primary Biliary Cholangitis Patients in the Response Trial	4339	Deep liver phenotyping in unexplained liver disease: the LIPHE algorithm	4368
FGFR signaling potentiates cholestatic liver fibrosis	4340	An Evaluation of Anti-IL23 Therapy in Primary Sclerosing Cholangitis	4369
Long-term Safety of Seladelpar 10 mg With up to 5 Years of Treatment in Patients With Primary Biliary Cholangitis	4341	Enhancing MRCP Precision: A Comprehensive Analysis of Intramuscular Glucagon Administration Impact on Biliary Visualization	4371
Seladelpar and Reductions in Lipids in Patients With Primary Biliary Cholangitis With and Without Statin use in the Phase 3 Placebo-controlled Response Study	4342	★ Primary Sclerosing Cholangitis in South Africa - a single centre experience	4372
Obeticholic Acid versus Fibrates as Second-line Therapy for Primary Biliary Cholangitis: a Systematic Review and Meta-analysis	4343	Primary sclerosing cholangitis in Afro-Caribbeans VS Non-Afro-Caribbeans	4374
Assessing the Health-related Quality of Life, Impairment and Productivity among Individuals with PBC and Pruritus: Results from the ITCH-E Study	4344		

Glycine-beta-MCA shows comparable anti-cholestasis but better anti-fibrosis efficacy than UDCA in female Cyp2c70 knockout mice	4379	Efficacy of Nitazoxanide (NTZ) in Pathogen-Associated Molecular Patterns (PAMPs)-induced disease models	2222
Aberrant cytokeratin 7 expression by hepatocytes can predict the ductopenia grade in primary biliary cholangitis	4381	Targeting Inflammation and Immune Dysregulation in Alcoholic Liver Disease with Graphene Oxide Nanoparticles	2229
Inflammatory Bowel Disease Burden Increases Over Time in Patients with Primary Sclerosing Cholangitis Post-Liver Transplant	4382	The effect of high-salt diet in the immunology and development of hepatocellular carcinoma	2230
Crude death rates for male and female populations due to hepatic diseases from 1999 to 2020: A comparative trend analysis and identification of statistically significant shifts.	4383		
Spatial Transcriptomic Analysis of Historical Fixed Primary Sclerosing Cholangitis Livers Reveals Distinct Signaling Pathways	4385		
Comparison of pathological features of patients with antibody-negative and positive primary biliary cholangitis	4388		
An elevated baseline level of alkaline phosphatase, alanine aminotransferase, and aspartate aminotransferase predict a lack of biochemical response to UDCA therapy among Hispanic patients living with Primary Biliary Cholangitis: A retrospective, propensity scored-matched, cohort study.	4390		
Normalization of alkaline phosphatase compared to conventional response criteria leads to lower liver related events and mortality in patients living with primary biliary cholangitis, treated with UDCA: A retrospective, propensity scored-matched, cohort study.	4391		

## Inflammation and Immunobiology

### Adaptive Immunity

The distinct expression patterns of ENO1 in malignant cells and CD8+ T cells play a crucial role in shaping the 'evolution tree' of HCC	17
A Pilot Study of the Combination of Sorafenib plus Nivolumab in Unresectable Hepatocellular Carcinoma (HCC): Safety, Efficacy, and Immune Cell Profiling in Child Pugh A and B Cohorts	2221
Glucocorticoid receptor expression in hepatocytes controls enclysis, responds differently to prednisolone and fenofibrate, and varies in explants from patients with autoimmune but not metabolic liver injury.	2223
Diet-Derived Fatty Acid Induces Dysfunctional Intestinal Tfh Cells via Elevated KLF2 that Impairs Intestinal Homeostasis and Exacerbates MASH	2226
Dendritic Cell MHC Class I Expression Regulates Diet-induced Obesity and Metabolic Dysfunction-associated Fatty Liver Disease	2227
SIRPα expressed in T lymphocytes triggers activation-induced cell death in hepatocellular carcinoma	2228

## Inflammation and Immunobiology

### Animal Models

Immune checkpoint B7-H4 promotes cholangiocarcinoma growth via TGFβ-induced stromal remodeling, unveiling a novel targetable tumor-stroma axis	31
Hepatocyte-specific Deletions of Autophagy-initiating Genes Result in Pronounced Hepatomegaly and Pathology	241
Metabolic dysfunction drives CD8 T cell hyperfunction and impaired tumor responses in mouse models of advanced liver disease	2218

## Inflammation and Immunobiology

### Innate Immunity

Alcohol-induced trained immunity contributes to dysfunctional immune responses involving PD1 and exacerbated inflammation in mice and human immune cells	10
Kupffer cell repopulation after toxic depletion results from propagation of embryonic KCs and not from maturation of monocyte-derived replacements	60
Cancer-Induced Reprogramming of Macrophage Nucleotide Metabolism Dismantles Anti-Tumor Immunity	75
Monocyte transcriptomic landscape and inter-organ crosstalk between the liver, brain and bone marrow in a model of alcohol misuse in aging	2219
Oxidative stress contributes to pro-inflammatory monocytes and an inflammatory profile of infiltrating macrophages in advanced liver fibrosis.	2225
The impact of PD-1+innate-like CD8+ T cells on the HBsAg reduction in active chronic hepatitis B patients receiving nucleos(t)ide analogue therapy	2231
NLRP3 activation in monocytes drives murine liver inflammation and fibrogenesis	2234
Exogenous arginine differentially regulates inflammatory cytokine and inducible nitric oxide synthase expression in macrophages.	2236
Liver disease in patients with CTLA 4 haploinsufficiency: an in vivo scenario to understand CPI related liver injury	2237
The Role of Heme in Sepsis-Induced Kupffer Cell Loss and Senescence	2238

## Inflammation and Immunobiology

### Mechanisms of Injury

Dietary Salt Intake Modulates Th17-Dependent Inflammation in Cirrhotic Patients and Exacerbates Liver Injury in Mice	47
The PNPLA3 I148M variant aggravates inflammation in macrophages through impaired nuclear receptors (LXR alpha, PPAR gamma, and GR alpha) signalling	2217
CD73 enhances the immunoregulatory functions of hepatic Tregs through enzymatic and nonenzymatic pathways in MAFLD development	2220
Interplay between CD40 and Integrin α5β1 Enhances Tumor Cell Survival in Poorly Differentiated Hepatocellular Carcinoma	2224
CLM-022, a potent inhibitor of NLRP3 inflammasome-mediated pyroptosis, as a potential treatment for acute and chronic inflammatory liver diseases	2232
High-throughput in vivo pooled screening of inflammation-related targets in hepatocytes predicts clinical outcomes	2233
Pyruvate-Driven B cell Effector Responses and IgG-Mediated Hepatic Stellate Cell Activation Exacerbate MASH Progression	2235

## Liver Fibrogenesis and Non-Parenchymal Cell Biology

### Basic Fibrosis Research and Stellate Cell Biology

CYP1B1+PRRX1+NR4A2+ hepatic stellate cells in alcohol-associated hepatitis	22
Wilms Tumor 1 and HIF-1 $\alpha$ induce hepatic stellate cell invasion that develops bridging fibrosis in chronic liver injury	35
Hepatic stellate cells regulate liver size, zonation, metabolism, injury and regeneration via R-spondin 3	65
Intrahepatic signaling by Netrin-1 exacerbates advanced fibrosis in nonalcoholic steatohepatitis	115
With no lysine kinase 1 (WNK1)-mediated metabolism promotes hepatic stellate cell activation in a spatial manner during in vivo liver fibrosis.	235
Activated Hepatic Stellate Cells (aHSCs) are required for recovery from toxic liver injury in mice.	3555
Hepatic stellate cells facilitates ammonia detoxification through GPT1-mediated alanine synthesis in hepatocellular carcinoma	3557
Hepatocyte-derived fibroblast growth factor 18 promotes hepatic fibrogenesis under dietary steatohepatitis in hepatocyte-specific Cflar deficient mice	3558
Anti-fibrotic microRNAs enriched in extracellular vesicles derived from mesenchymal stem cells suppress fibrogenesis of hepatic stellate cells by downregulation of RhoA signaling.	3560
Liver sinusoidal endothelial cell-derived extracellular vesicles contain catalase that induces senescence of activated hepatic stellate cells	3563
TNFAIP3 mediates JNK-dependent chemokine expression in hepatic stellate cells	3564
A novel FGFR inhibitor BF12 attenuates liver fibrosis by suppressing the PI3K/Akt and ECM-receptor interaction pathways	3565
Schistosomiasis-induced liver fibrosis is more severe in mice infected at a young age due to a higher egg burden	3566
Chemotherapeutic drugs induce hepatic stellate cell activation in hepatocellular carcinoma via ROS-dependent PI3K pathway	3567
S100A6 regulated by PATZ1 Promotes Liver Fibrosis by Activating Hepatic Stellate Cells	3572
HUC-MSCs exosome-derived miR-100-5p alleviates liver fibrosis by inducing autophagic death of hepatic stellate cells	3573
Fibromodulin selectively accelerates activated hepatic stellate cells apoptosis in liver fibrosis by upregulating interleukin 1 $\beta$ expression	3576
Altered chromatin accessibility in hepatic stellate cells reveals mechanisms of liver fibrosis	3577
A small molecule mimicking Tcf21, a deactivation factor of hepatic stellate cells, accelerates repair of injured liver by orchestrating crosstalk between deactivated stellate cells and other types of cells in the fibrotic tissue	3581
Itaconate mitigates liver fibrosis by elevating GDF15 production	3582
Exploring the mechanism of action of YGXJ in the treatment of liver cirrhosis through animal experiments and intestinal flora	3583
Targeting JAK2/STAT1 signaling to regulate CX3CL1 expression in biliary epithelial cells for interventional therapy in liver fibrosis	3584
ATP-Citrate Lyase Enables Hepatic Stellate Cell Activation: Implications for Fibrogenesis	3587
HGF upregulated the expression of hepatocyte NRP-1 via RARA to exacerbate liver fibrosis.	3588
CCL2-CCR2 axis inhibition reduces liver fibrosis by restoring the immune cell landscape	3589
Generation of Colec11-CreERT2 knock-in mice: a novel tamoxifen regulable cre-driver mouse specific to hepatic stellate cells	3592

Hepatic stellate cell-derived neurotrophin-3 supports liver regeneration after partial hepatectomy	3595
Unraveling the impact of hepatic stellate cell-derived CXCL12 on liver fibrosis: a study of TGF $\beta$ -mediated regulation and spatial redistribution	3596
Hepatic stellate cell-intrinsic role for cytoplasmic stress granule proteins in IRF3-mediated fibrogenic responses to TGF $\beta$	3598
Suppressing MASH Fibrotic Progression by Blocking Succinate-GPR91 Signaling Axis in Hepatic Stellate Cells	3599
In vivo anti-FAP CAR T cells that Target Fibrogenic Hepatic Stellate Cell Subsets Ameliorate Murine (MASH) Liver Fibrosis	3600
Hepatic Stellate Cell-derived THBS2 Promote Intrahepatic Inflammatory Infiltration by Regulating SPP1 Secretion During Liver Fibrogenesis	3602
LOXL1 G153D Mutation Is Associated with Non-regression of Liver Fibrosis During Viral Clearance in Chronic HBV Infection	3605
Lysyl oxidase inhibitor ameliorates ECM cross-linking and infiltrating macrophages in hepatocellular carcinoma with fibrosis/ cirrhotic background	3606
Mfap2 Ablation Retards Hepatic Fibrosis Regression by Orchestrating Extracellular Matrix and Inflammation	3607
Empagliflozin reduces liver fibrosis caused by CCL4: Understanding the mechanism	3609
Polarization of Cancer Associated Fibroblasts and Activated Myofibroblasts in the Tumor Microenvironment of Hepatocellular Carcinoma	3610
ECM1hiHSC subpopulation: as a master regulator in the reversal of liver fibrosis	3611
In vivo experiments and non-target metabolome analysis to explore the effect and mechanism of ShuXueNing injection in treating liver cirrhosis	3612
Carfilzomib Shows Therapeutic Potential for Reduction of Liver Fibrosis by Targeting Hepatic Stellate Cell Activation	3613
Translational potential role of Zeb2 in liver fibrosis and NAFLD	3615
Amniotic Fluid Reduces Epithelial-to-Mesenchymal Transition and Myofibroblast Activation in Hepatic Stellate Cells	3617
★ Deletion of ETS1 in hepatic stellate cells accelerates development of liver fibrosis	3620
ADAMTSL2 secreted by hepatic stellate cells promotes liver fibrosis through regulation of microfibril assembly	3621
LARP6 regulates translation of Collagen Type I/III mRNAs in activated Hepatic Stellate Cells (HSCs) from patient livers with MASH and MetALD	3622
Ethanol metabolites enhance TGF- $\beta$ signaling in hepatic stellate cells via mitochondrial DNA release and cGAS-STING-IRF3 pathway	3623
Glycolysis in hepatic stellate cells induces epigenetic histone 3 lysine 9 acetylation (H3K9ac) to promote liver fibrosis.	3624
Degeneration of liver sympathetic innervation accelerates liver injury and metabolic dysregulation due to impaired neuronal communication within the liver	3628
Network pharmacology and molecular docking reveal the mechanism of Ginkgo biloba extract against liver cirrhosis	3629

## Liver Fibrogenesis and Non-Parenchymal Cell Biology

### Clinical and Translational Fibrosis Research

Targeting the liver clock improves fibrosis by restoration of TGF- $\beta$ signaling	140
★ Unlocking EPHX1-Mediated Alterations in Eicosatrienoic Acid Metabolism: Novel therapeutic Targets in Liver Fibrosis	3550
Validation of the novel GLAS algorithm as an aid in the detection of liver fibrosis and cirrhosis based on GP73, LG2m, age, and sex	3551





combined with William's E culture media or University of Wisconsin (UW) solution			
Establishment and observation of a long-term viable allogenic murine liver transplantation model	2517	The Utility of Follow-Up Transthoracic Echocardiogram (TTE) to Screen for Severe Portopulmonary Hypertension (POPH) in Patients Granted POPH Model for End-Stage Liver Disease (MELD) Exceptions	2519
Metabolic reprogramming of bile acids ameliorates acute inflammatory injury of liver transplantation by regulating differentiation of macrophages	2542	Vibration-controlled Transient Elastography as A Non-invasive Tool to Exclude Hepatic Steatosis in Living Liver Donor Evaluation	2525
YAP in macrophages reduces sterile inflammation and hepatic injury during the liver ischemia-reperfusion stress.	2565	Calibrating Exception Points for Continuous Distribution: Why Matching HCC to Non-HCC Waitlist Dropout Falls Short	2528
Roles of mitoNEET in ischemia/reperfusion injury of diet-induced mouse steatotic livers	2592	Living Donor Liver Transplantation: The Role of Transplant Kinship on rejection rates and allograft survival, using genetic related vs unrelated live donors.	2530
The safety and tolerability of QEL-001, an autologous Chimeric Antigen Receptor (CAR) T regulatory (Treg) cell therapy, in liver transplantation - A safety cohort in the LIBERATE study	2597	Exercise stress echocardiography is a feasible alternative to pharmacologic stress echocardiography for cardiac risk evaluation in patients with cirrhosis prior to liver transplantation	2534
Machine Perfusion Strategies in Liver Transplantation: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials	2600	Sex and Race Disparities in Liver Listings and Transplants for Non-Hepatocellular Carcinoma Indications in the United States	2536

## Liver Transplantation and Liver Surgery

### Donor and Allocation Issues, Living Donor and Split Liver Transplantation, and Hepatobiliary Surgery

Geographic Disparities in Liver Transplant Waitlist Outcomes for Critically Ill Candidates: The Impact of Population Density amid the Acuity Circle in the United States	25	Predicting Liver Graft Discard Criteria: A Machine Learning Approach to Key Donor Characteristics	2549
★ Muscle mass, frailty and cardiopulmonary exercise testing: correlations and impact on liver transplant outcomes	105	Defining the role of living donor liver transplant in the era of machine perfusion for donation after circulatory death	2555
Current Burden and Geographic Disparities in Liver Mortality and Access to Liver Transplantation	174	★ Racial and Gender Disparities in Access to Living Donor Liver Transplantation Between 1999-2021	2556
The Operational Characteristics of Liver Transplant Programs Determine Growth, and Impact Where State Level Disparities in Transplant Access Exist	176	Research Trends in Liver Transplantation for Hepatocellular Carcinoma and Related Tumors: A Comprehensive Bibliometric Review (2000-2022)	2562
Racial Disparities in Access and Outcomes of Liver Transplant in the United States: An Update	207	Human versus artificial intelligence: Head-to-head comparison of predictive performance of MELD 3.0 and latest machine learning models	2567
Comprehensive deep learning-based assessment of living liver donor CT angiography: from vascular segmentation to volumetric analysis	2484	Outcome of utilizing MELD 3.0 from a Canadian perspective: a retrospective study in a single tertiary-care transplant centre	2569
★ The classification of portal vein thrombosis and a tactical algorithm based on it	2486	Albumin Infusions can Lead to Clinically Significant Changes in MELD 3.0 scores for Patients Waitlisted for Liver Transplantation	2571
★ Center-level Variability in Utilizing Normothermic Machine Perfusion and the Association with Recipient Insurance	2498	Utilization of donation after circulatory death liver grafts by procurement type and storage modality: A comparison of cardiac and non-cardiac donors in the US	2588
Tracking Long-Term Outcomes in ALPPS Procedure: A Follow-Up Study Analyzing Extended Survival	2499	Extended Criteria Donors in Donation After Circulatory Death: Can Abdominal Normothermic Regional Perfusion Safely Expand the Deceased Donor Pool?	2589
Clinical outcomes of TACE in patients listed for liver transplantation at a single center from 2018-2022	2500	Geographic distribution of US donor recovery facilities in relationship to liver transplant centers: Should we rethink the origin of donor allocation?	2591
Trends in Candidate HCV NAT+ Listing and Associated Impacts on Liver Transplantation Waitlist Outcomes	2501	One-third of liver donors for recipients of severe alcoholic hepatitis experience psychological distress.	2602
Etiology-specific trends of delisting for liver disease improvement and re-compensation among candidates on liver transplant list in the US	2502	Relationship between center-level extended criteria donor liver transplantation volume and recipient outcomes	2635
Inhibition of ferroptosis in fatty liver ischemia-reperfusion injury attenuates subsequent acute kidney injury	2504		
Analysis of the impact of female sex and sarcopenia on serum creatinine and waitlist priority for liver transplantation	2509		
One Year Post Transplant Outcomes in HCV Positive Donor to HCV Negative Recipient Liver Transplantation: A Descriptive Analysis of A United States Transplant Center's Experience	2511		
Early outcomes of robotic vs open living donor right hepatectomy in a US Center	2512		
High-Throughput Proteomics Analysis Identifies Changes in Circulating Proteome Signatures Across Different Stages of Liver Transplantation Surgery	2515		

## Liver Transplantation and Liver Surgery

### Immunosuppression, Outcomes, Complications

★ Abdominal Aortic Calcification - A Novel Cardiac Risk Prediction Tool in Liver Transplantation	33
The Liver Transplant Comorbidity Index (LTICI) : A Composite Index of Ambulatory Pre-LT Factors to Identify Patients at Increased Risk of Post-LT Mortality	129
Coronary artery disease risk after liver transplantation is 2-fold higher than the general population: A nationwide Swedish cohort study of 2925 patients.	136

Liver Transplantation for MetALD resembles ALD more than MASLD	192	Cholesterol Content and Expression of SREBF-2 and HMGR	2543
Health system and patient predictors of post-transplant short-term mortality and length of stay among liver transplant recipients	221	Predict Early Allograft Dysfunction and the Outcome of Human Liver Transplantation	
Frontal EEG Monitoring Reduces Anesthesia Requirement During Liver Transplantation	2483	Risk Factors and Outcomes of Rejection in Liver Transplant Recipients with Autoimmune Liver Diseases: A Comprehensive Analysis	2544
The Impact of Arrhythmias: Outcomes of Patients with Liver Transplantation and Atrial Fibrillation	2485	Epstein-Barr virus negative monotypic plasma cell infiltrates in liver allografts: a clinicopathologic review	2545
Risk Factors and Survival in Patients with De Novo Malignancies Following Liver Transplantation Alone or Simultaneous Liver-Kidney Transplantation	2487	Worse tumor biology, and not tumor size, is associated with lower post-liver transplant survival in recipients with hepatocellular carcinoma	2546
Outcomes of Simultaneous Liver-Kidney Transplantation vs Liver Transplantation Alone in Patients with Cirrhosis Requiring Renal Replacement Therapy	2488	The Difference in Liver Transplant Outcomes between Normothermic and Hypothermic Machine Perfused Livers	2548
Cystatin C vs. Creatinine: Who Wins in Cirrhosis?	2489	The Impact of Machine Perfusion on Transplanted Liver Grafts with Macro-Steatosis	2551
Frailty is associated with multiple negative clinical outcomes in patients referred for liver transplantation.	2492	The Role of Smoking in Post-Transplant Cancer Development: Insights from a Two-Decade Cohort Study	2552
Comparative Outcomes of Trans-arterial Chemoembolization and Radioembolization as Bridging Therapy for Hepatocellular Carcinoma in Liver Transplant Candidates.	2493	The Risks Associated with Thymoglobulin Use in Patients with Liver Transplant Rejection: A National Database Analysis	2553
Characterization and Post-Transplant Outcomes of Machine Perfusion Organs for Liver Re-Transplantation	2495	A Systematic Review of Treatment and Outcomes for Late Cellular Rejection, Chronic Ductopenic Rejection, and Antibody Mediated Rejection After Liver Transplantation	2554
Operational Time and Severe Postoperative Complications: Their Impact on Long-term Survival in Liver Transplant Patients	2496	Impact of Post-Transplant Body Mass Index Trajectory on Liver Transplant Outcomes	2557
Advancing Liver Transplantation into the Next Decade: Liver Transplant Outcomes in Patients 70 Years or Older	2497	Comparative Analysis of Liver Biopsy Complications across the United States: A Propensity Matched Study of Patients with Normal and Reduced Platelet Counts Using Inpatient Data	2558
Metabolic Vulnerability Index	2503	MRI-serum based score accurately identifies liver transplant patients without rejection avoiding need for liver biopsy: a multisite European study	2560
The impact of tacrolimus level and its inpatient variability on the development of chronic kidney disease following liver transplantation	2505	Acupuncture in the pre and post liver transplantation setting is safe, well accepted and improves quality of life.	2561
Predictive Power of Bubble ECHO for Diagnosis of Hepatopulmonary Syndrome	2510	Coronary Artery Disease Liver Transplantation (CAD-LT) score can accurately identify patients requiring invasive Coronary Angiography	2564
Sleep Disturbance is Associated with Frailty, Impaired Physical Function, Fatigue, Anxiety, and Depression in Liver Transplant Recipients: Results from the LivCog Cohort Study	2513	Social Determinants of Health Measured by SDI and ADI do not Impact Liver Transplant Outcomes	2566
Stress-Induced Cardiomyopathy in Liver Transplant Recipients: A Systematic Review	2514	Long-term Outcomes of Patients Transplanted for Acute Liver Failure in the United States: An Analysis of the Unos Database	2568
Serum and Urinary Metabolomics are Associated with the Development of De Novo Metabolic Syndrome after Liver Transplant: A Multi-center Longitudinal study.	2520	Liver transplant immunosuppression education in the US: a survey of transplant hepatology fellowship program directors	2570
Assessing Liver Transplant Rejection Using Paired Blood and Biopsy Samples	2521	The Patient And Kidney Graft Outcomes of Safety Net Kidney Transplants Are Similar to Kidney Transplant Recipients Without A Previous Liver Transplant: A Retrospective UNOS database Analysis	2572
Advancements in liver transplant outcomes from 1997 to 2023	2522	Post-liver transplantation renal dysfunction primarily driven by older age and MELD at listing rather than liver disease etiology type	2573
Incidence and outcome of rejection in hyperimmunized liver transplant recipients receiving an induction therapy	2524	Post-Transplant Predictors and Outcomes of Persistent Cholestasis after Liver Transplantation	2574
The Impact of Recipient Body Mass Index and Cold Ischemic Time on Post-Liver Transplant Biliary Strictures	2526	Plasma cell-rich rejection: potential role of non-HLA antibodies	2576
Risk Factors, Pregnancy and Transplant Outcomes Associated with Intrahepatic Cholestasis of Pregnancy in Liver Transplant Recipients	2527	Psychological Burden of the Liver Transplant Process	2577
Atrial Fibrillation Pre-Liver Transplant Associated with Increased All-Cause and Cardiovascular Mortality Post-Transplant	2529	Human Immune Organoids to Model Liver Transplant Rejection	2578
A 13-Year Nationwide Analysis of Nocardia and Actinomyces Infection Outcomes in Liver Transplant Recipients	2531	Palliative Medicine Utilization for Older Adults with End-Stage Liver Disease Referred for Liver Transplantation	2579
Outcomes of CABG Patients With and Without A History of Liver Transplant	2532	Improved Self-Efficacy in Post-Liver Transplant Patients in Management of Post-Transplant Metabolic Syndrome Through Behavioral Resources and Intervention Through Digital Group Education (BRIDGE): A Share Medical Appointment Program	2580
Liver Transplantation for MASH Cirrhosis Has Better Post-Transplant Outcomes Than Non-MASH Cirrhosis	2533	Post liver transplant resource utilization in early versus standard liver transplant in alcohol associated liver disease.	2581
National Trends of Bridging Locoregional Therapy in Liver Transplant Candidates with Hepatocellular Carcinoma.	2535	Survival Outcomes for Living versus Deceased Donor Liver Transplantation for PSC: A 2 decade multicenter experience	2582
Impact of Nosocomial Infections in Post-Liver Transplantation Patients	2537		
Anxiety and depression are significantly associated with worse health-related quality of life in liver transplant survivors	2538		
Early Extubation: A Promising Strategy to Mitigate Post-Liver Transplant Complications and Enhance Recovery	2539		





Alcohol use disorder treatment in patients with alcohol use after liver transplant seen in a multidisciplinary alcohol-associated liver disease clinic.	2550	States; 2Division of Metabolism and Endocrinology, Faculty of Medicine, Saga University, Japan; 3Department of Scientific Pathology Graduate School of Medical Sciences, Kyushu University, Japan	
Hepatocellular carcinoma recurrence after liver transplant: an Australian single-centre study	2559		
Tenofovir Alafenamide Monotherapy Is Effective in Suppressing Hepatitis B Virus After Liver Transplantation	2563	Comparative evaluation of zonal fibrosis patterns in pediatric and adult metabolic dysfunction-associated steatohepatitis biopsies using Second Harmonic Generation/Two Photon Excitation-based qFibrosis analysis	2012
Liver Transplantation for Short Telomere Syndrome: outcomes, and detailed histopathologic evaluation of explants.	2575		
Metabolic Dysfunction-Associated Steatohepatitis Emerges as the Leading Cause for Adult Liver Transplantation in Saudi Arabia: A single-center study	2584	Fibro-Scope: an artificial intelligence/neural network system is useful in predicting liver related events, cardiovascular events, and prognosis in Japanese patients with metabolic-dysfunction associated steatotic liver disease	2013
No initial increase in cancer risk with Glucagon like peptide-1 therapies following liver transplantation.	2596	Diagnostic Potential of FAST and AGILE3+ Scores for F2/F3 Fibrosis: An Analysis of the Phase 2 ENLIVEN Study	2014
<b>MASLD and MASH</b>			
<b>Diagnostics and Biomarkers – MASH</b>			
Prognostic value of the AASLD 2-step approach in the identification of advanced liver fibrosis in 16,603 patients with metabolic dysfunction-associated steatotic liver disease (MASLD) in the VCTE-Prognosis Study	23	Clinical management of discrepancies between FIB-4 and liver stiffness measurement in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)	2015
Validation of the Masef Score for its Diagnostic Enrichment Utility for At-risk Mash in the Nimble Project	49	The Diabetes Risk Index (DRI) Predicts Future Development of Type 2 Diabetes Mellitus in Euglycemic and Prediabetic Patients With Metabolic Dysfunction Associated Steatotic Liver Disease.	2016
Type 2 diabetes and glycaemic control are associated with liver stiffness progression in people with MASLD: A Multicenter Prospective Study	106	Validation of Microbial Signature for Advanced Fibrosis in A Global Multi-ethnic Cohort of MASLD	2017
★ The proteome differentiates MetALD from MASLD and identifies patients at risk.	114	Thrombospondin 2: A Key Player in Fibrogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease Uncovered by Multi-Omics Analysis	2018
Risk factors associated with decreased bone mineral density in patients with metabolic dysfunction-associated steatotic liver disease: a cross-sectional study at a health examination center	2001	Machine Learning-Facilitated Predictive Model for Liver-related Events in Type 2 Diabetes Mellitus	2019
Enhancing prediction of moderate fibrosis or higher in MASLD patients for Resmetirom treatment via machine learning	2002	Digital Pathology and AI single-nuclei liver issue panels reveal the quantitative parenchymal involvement of inflammation and steatosis in rodent models of MASH treated with Mannose	2020
Deep Learning Predicts Hepatocellular Carcinoma Development in Steatotic Liver Disease Using Digital Pathology	2003	The associations between circulating metabolic biomarkers on the risk of hepatocellular carcinoma development in the USA	2021
A novel steatosis liver disease (SLD) index with easy-to-use clinical parameters in primary care settings for steatotic liver disease	2004	Factors associated with obtaining lower IQR-CAP values in the detection of hepatic steatosis by transient elastography	2022
Allyl nonanoate, a bile metabolite, activated hepatic stellate cells through GPR 119 signaling in metabolic dysfunction associated steatosis disease (MASLD).	2005	Framingham Fibrosis Index for Metabolic Dysfunction Associated Steatotic Liver Disease: Validation in Large Nationwide Cohort	2023
Impact of Steatosis and Cardiometabolic Abnormalities on Plasma Free Amino Acid Levels and Potential Role of Amino Acid Modulation in MASLD	2006	Automated digital analysis of Shh-injured area correlates with conventional and digital pathologies in MASLD and MASH patients	2024
Screening for Advanced Fibrosis among Alaska Native peoples with Metabolic Dysfunction-Associated Steatotic Liver Disease	2007	Validation of the Diagnostic Enrichment Utility of NIS2+ for Varying Phenotypes of Metabolic Dysfunction Associated Steatotic Liver Disease	2025
Quantitative Analysis and Integration of Machine Learning for Biomarker Assessments and their Association with Treatment Response: Insights from the ENLIVEN Phase 2b Trial of Pegzofermin	2008	Performance Metrics of Spleen Stiffness Measurement (SSM) Obtained by Transient Elastography in Patients With Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD)	2026
Comparison of simulated vibration controlled elastography sample volumes and global measurements on MRE and MR-PDFE in patients with suspected MASLD	2009	Resmetirom Therapy of MASH-Associated Child Pugh A Cirrhosis Reduces Estimated Risk for Clinical Outcome Based on HepQuant RISK ACE Model	2027
Multiple DP/AI quantification approaches are complimentary in identifying histology features: Cross sectional study in a Japanese cohort. Vandana Gupta1, Ruixue Hou1, Hiroaki Yashiro1, Shuling Zhang1, David Cordover1, Simon Kim1, Mark Chen1, Erin Smith1, Maria Paraskevopoulou1, Yoshihito Kubotu2, Zoltan Dardak1, Paresh Thakker1, Shinichi Aishima3, Hirokazu Takahashi2.1Takeda Development Center Americas, Inc., Cambridge, MA, United	2011	The Oral Cholate Challenge Test Identifies the MASH Patients with > = F3 Fibrosis with Greatest Hepatic Impairment Who Show the Most Benefit from Short-term Rencofilstat Therapy	2028
		An automatic tissue folding detection algorithm to aid AI segmentation models.	2030
		An automatic out of focus detection model for enabling the assessment of liver biopsies.	2031
		Histological diagnostic tool for detecting and characterising portal tracts in liver disease using Artificial Intelligence.	2032
		The use of AI-assisted digital pathology in determining the inflammatory burden in liver disease.	2033

Identifying Health-to-disease Transitional Cell States in A 3D Human Organotypic Model of MASLD-MASH	2034	Developing a Brief Evaluation Index to Diagnosis Metabolic Dysfunction-Associated Steatotic Liver Disease	2058
Validation of the AGA AND AASLD Care Pathways for Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in A Prospective Cohort of Overweight and Obese Individuals	2035	The correlation between measurements obtained by the iLivTouch and FibroScan a multicenter randomized study in the US.	2059
The Oral Cholate Challenge Test Defines Likelihood of Large Esophageal Varices in an Overweight and Obese US Population	2036	Deep-learning-aided quantification of steatohepatitis-associated pathological findings in liver specimens	2060
Maintenance Therapy with GLP-1 Receptor Agonists Does Not Impact the Clearance of Orally Administered Isotopes of Unconjugated Cholate	2037	Comparison of liver fibrosis between MASLD in PLHIV and Non-PLHIV	2061
Multiple genetic polymorphisms are associated with the risk of metabolic syndrome, fatty liver, and airflow limitation: A Taiwan Biobank Study	2038	NIS2+, an effective monitoring tool for tracking disease evolution in patients with fibrotic MASH	2062
Enhancing Traditional Fibrosis Prediction Models with Machine Learning in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)	2039	NIS2+, an effective tool for monitoring MASH resolution and fibrosis improvement in patients with at-risk MASH	2063
Prevalence and Characteristics of High-Risk FIB-4 among Primary Care Patients with Pre-Diabetes (PreDM): Potential to Improve the Current State of Disease Under-Recognition	2040	Evaluation of Two Non-invasive Approaches to Assessing at-risk MASH in Clinical Practice: MASEF and FAST scores	2064
Performance of Noninvasive Tests in Identifying Appropriate Patients for Resmetirom Treatment: Real World Data from Four Tertiary Care Centers	2041	Independent Validation of Second Harmonic Generation/two Photon Excitation Imaging and Artificial Intelligence-based SNOF Index for Metabolic Dysfunction Associated Steatohepatitis Cirrhosis Assessment	2065
The diagnostic ability for hepatic steatosis using attenuation imaging and controlled attenuation parameter; a prospective multicenter study in Japan	2042	Identification of new exosomal microRNA markers for metabolic dysfunction-associated steatotic liver disease using artificial intelligence approach	2066
A Single-center, Observational Study to Evaluate the Utility of Ferritin as a Noninvasive Biomarker in Patients with MASLD	2043	Detecting MASH resolution and fibrosis improvement with NIS2 + in patients with at-risk MASH	2067
Misclassification and Discordance with Magnetic Resonance Elastography using FIB-4-based Stratification for at-risk MASLD	2044	Plasma proteome signatures associated with steatohepatitis in morbidly obese patients	2068
★ Identifying Candidates for Liver Biopsy in Metabolic-Associated Steatotic Liver Disease: Machine Learning-Based Predictive Models	2045	Pathological Significance of Intranuclear Lipid Droplets and Glycogenated Nuclei in Liver Biopsy	2069
Clinical utility and diagnostic accuracy of phosphatidylethanol for detecting and differentiating MetALD from MASLD: A prospective study	2046	T1-mapping in the liver: The need for standardization	2070
Evaluation of the consistency and heterogeneity of fibrosis assessment in adjacent virtual liver needle biopsies using AI-based qFibrosis	2047	A combined imaging and proteomic approach identifies inflammatory response proteins upregulated in MASH: results from the UK Biobank	2071
Serum IL-16 predicts visceral fat inflammation associated with metabolic dysfunction in patients with bariatric surgery	2048	Anthropometric Factors and Their Association with Fibrosis and MASH in Patients with MASLD in Japan and the United States	2072
Characterization of Intracellular Organelle Abnormalities in MAFLD	2049	A Prospective Study of the Circulating Lipidome in MASLD Reveals Distinct Profiles Associated With Fibrosis Progression and Regression	2073
Diagnostic performance of FibroScan's controlled attenuation parameter (CAP) and Continuous CAP in MASLD with PDDF as the reference: a multicenter study.	2050	Evaluation of the Performance of MASEF score in Patients with Metabolic Dysfunction Associated Steatohepatitis (MASH) under a Lipid-Lowering Medication	2074
The Efficacy of Measuring Natural Killer Activating Receptor Ligands to Predict the Pathogenesis of MASLD	2051	Improved diagnostic accuracy of Vibration-Controlled Transient Elastography based tests in Identifying Metabolic Dysfunction-Associated Steatohepatitis (MASH) and at-risk MASH in obese and lean individuals with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)	2075
Validation of FibroTest-T2D as a serum biomarker of early bridging fibrosis according to biopsy length, and sex-specific differences in large populations at risk of MASLD.	2052	Corrected T1 Mapping (cT1) outperforms in evaluating clinically significant and advanced fibrosis in non-obese Individuals with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Findings from a multi-ethnic Asian cohort with histologically confirmed MASLD	2076
The DiabetesLiver score: a non-invasive algorithm for advanced liver fibrosis and long-term liver-related outcomes in type 2 diabetes mellitus population	2053	Chitinase-3-like protein 1 based biomarker panel for early liver fibrosis assessment in patients with type 2 diabetes mellitus	2077
A Real World, Large Scale Application of the AGA MASLD Pathway. Pitfalls, Challenges and Success Story	2054	Adjusting for steatosis content in baseline and followup MASH biopsies can overestimate changes in fibrosis	2078
Liver virtual biopsy using CSE-MRI in patients with chronic liver disease: a comparative work with elastography and blood test.	2055	Simple noninvasive tests have poor diagnostic accuracy for MASLD F2-3 in a real world Canadian cohort	2079
Fib-4 score is an unreliable non-invasive marker to identify patients with cirrhosis due to MASLD	2056	Stain-free digital pathology imaging provides microarchitecturally-resolved insights into scar evolution and histological injury allowing direct clinical outcome prediction in metabolic dysfunction-associated steatotic liver disease	2080
A Machine Learning Approach Identifies Patients at Risk of Metabolic Dysfunction-associated Steatotic Liver Disease-related Complications at the Population-level	2057	Usefulness of serum microRNAs as biomarkers for pediatric metabolic dysfunction-associated steatotic liver disease (MASLD)	2081

Machine Learning based Predictive Modeling using Proteomic Signatures in Extracellular Vesicles as Diagnostic Indicators of Metabolic Dysfunction-Associated Steatohepatitis.	2082	The Diagnostic Performance of Agile 3+ Score for Detecting Advanced Fibrosis in Individuals with Chronic Hepatitis B and Concurrent MASLD: A Multicenter Study	2105
Development of a Machine Learning Model to Predict Progression of Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease	2083	PLIN2 and RAB14 are potentially useful biomarkers for monitoring treatment response post bariatric surgery	2106
Disparities in Non-invasive Testing-based Risk Stratification Among Hispanic Compared to Non-hispanic Individuals At-risk for Metabolic Dysfunction-associated Steatotic Liver Disease: Analysis of A Prospective Cohort of 358 Overweight and Obese Individuals	2084	Glycemic control predicts advanced fibrosis in patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): combined data from multiple therapeutic trials including more than 4,000 liver biopsy data	2107
Explainable Artificial Intelligence on Proteomics for the diagnosis of advanced liver fibrosis on MASLD patients using open data	2085	NF-TE Score: A Novel predictor for liver fibrosis in Metabolic dysfunction Associated Steatotic Liver Disease	2108
An Effective, Inexpensive, and Simple Alternative to Current AGA Guidelines for Risk-Stratifying Liver Fibrosis: MASHFIB-10 Machine Learning Model	2086	Diabetes Risk Index in Individuals with PCOS is Associated with Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD), Clinically Significant Fibrosis and Advanced Fibrosis	2109
Agile 3+ and Agile 4 Scores Predict Cardiovascular Events in a Large General Population Cohort	2087	Correlation of hepatocyte ballooning with fibrosis and repair in MAFLD - A novel expanded histological score and Sonic Hedgehog IHC based study	2110
Prevalence of Cardiovascular Events in MASLD, MetALD, and ALD Patients in a Large General Population Cohort	2088	Identification of Novel Circulating Exosomal miRNAs and mRNA Networks Contributing to the Progression from MASH to HCC	2111
Noninvasive assessment of steatotic liver disease in individuals with class 2 and class 3 obesity	2089	The Degree of Adiposity Enhances the Effect of THE PNPLA3 rs738409 on Hepatic Steatosis in Prepubertal Latinx Children	2112
PLIN2 expression is a reliable biomarker of MASH that is specifically associated with inflammation and ballooning rather than steatosis	2090	Efficacy of Non Invasive Tests (NITs) in differentiating Metabolic dysfunction-associated fatty liver disease (MAFLD) and Metabolic-Alcohol-associated Liver disease( MetALD)-META-ALD STUDY	2113
Artificial Intelligence (AI) in Metabolic dysfunction-associated steatotic liver disease (MASLD): a dual approach for innovating genomic analysis and development of risk prediction models	2091	Evaluating Impact of Weight Changes on Histological Patterns of Liver Fibrosis in MASH: Implications for Spatial Interrogation	2114
PLIN2 is a specific marker for MASH and is not a marker for cardiovascular disease or diabetes	2092	Model for Advanced fibrosis in MASLD-Informed by Inflammation (MAM-I): A Novel Model To Predict Advanced Fibrosis in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)	2115
Clinical comparison of the HeparDx™ diagnostic blood test with MyLab™ elastography of significant fibrosis in patients with non-cirrhotic MASH	2093	Differential patterns of liver and spleen stiffness in chronic viral hepatitis and metabolic associated steatotic liver disease	2116
Exploring the impact of mitochondrial biomarkers on HCC risk according to etiologic drivers: a multicenter study	2094	The ELF™ Test Improves Risk Stratification Versus Histological Staging for Prediction of Clinical and Histological Outcomes in MASH and Advanced Fibrosis	2117
Single-cell RNA Sequencing Reveals the Heterogeneity of Monocyte-derived Macrophages in Metabolic Dysfunction-associated Steatotic Liver Disease	2095	Interleukin-9 levels correlates with lean-MASLD in an ancestry-related fashion across a Latin American cohort of individuals with cirrhosis	2118
Clinically Significant Portal Hypertension by Non-Invasive Tests in Compensated Advanced Chronic Liver Disease due to Metabolic dysfunction-Associated Steatohepatitis (MASH) with Obesity and Overweight.	2096	Retrospective cross sectional evaluation of the LIVERFAST Test for staging liver fibrosis in MASLD patients in NIDDK studies' populations using liver biopsy	2119
A bayesian network identifies causal relationships of serum biomarkers with masld	2097	Comparison of transient elastography and magnetic resonance elastography for assessment of MASLD/MASH: a retrospective review	2120
Deep learning can predict MASLD-related genetic risk variants from liver magnetic resonance imaging	2098	Prognostic significance of ELF test compared to liver biopsy in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)	2121
MetaSight's Metabolic Dysfunction-Associated Steatohepatitis (MASH)-fibrosis score: A blood test enabling patient monitoring of liver fibrosis	2099	Feasibility of fat free liver volume as a biomarker in steatotic liver disease	2122
Comparisons of diagnostic performance according to the scoring systems using magnetic resonance elastography and transient elastography for discriminating patients with metabolic-associated steatohepatitis and significant fibrosis	2100	FIB-4 based referral pathways to identify liver fibrosis and incident advanced liver disease have poor clinical utility in two independent General population cohorts	2123
Screening for advanced liver fibrosis due to MASLD with VCTE alongside retina scanning in patients with type 2 diabetes: A cross-sectional study of 1005 patients	2101	Glycated hemoglobin and AST as Predictors of at-risk MASH across Fibrosis Stages: combined data from multiple therapeutic trials including more than 4,000 liver biopsies	2124
AGILE3+ encompasses the two-step approach needed to enhance diagnostic accuracy of advanced fibrosis in patients with suspected MASLD	2102	Comparative Diagnostic Accuracy of AGILE Scores and Common Non-Invasive Tests in Detecting Advanced Liver Fibrosis in Patients with Metabolic Dysfunction Associated Steatotic Liver Disease	2125
Differentiation of steatotic liver disease from advanced liver fibrosis/cirrhosis by breath volatile organic compound analysis	2103	The Diagnostic Utility Of The United States Fatty Liver Index For Metabolic Dysfunction Associated Liver Disease	2127
Baseline characteristics in well-compensated NASH cirrhosis patients diagnosed with or without a liver biopsy in MAESTRO-NASH-OUTCOMES, a clinical outcome Phase 3 study assessing the effect of resmetrom in well compensated NASH cirrhosis	2104		

Evaluating the Impact of Enhanced Liver Fibrosis (ELF) Testing on Identifying F2 and/or Advanced Fibrosis at a U.S. Veterans Affairs (VA) Healthcare System	2128	Incidence of Major Adverse Cardiovascular Events and Major Adverse Liver Outcomes Across the Spectrum of Steatotic Liver Disease: A National Cohort Study	2293
Assessment of the sensitivity and specificity of non-invasive scores for identifying at-risk-MASH patients	2129	Analysis of the distribution and severity of liver fibrosis stages among the local population within the Rio Grande Valley: identification of risk factors and accuracy of non-invasive diagnostic tools.	2294
Gut microbiome in the spectrum of metabolic-dysfunction associated steatotic liver disease (MASLD): from MASH to hepatocellular carcinoma	2130	The Effect of Diet Composition Exposome on the Natural History of Metabolic-Associated Steatotic Liver Disease in the Million Veteran Program Cohort	2295
Retrospective Analysis of a Cohort of Patients with Various Liver Diseases Followed At An Urban Clinic Who Underwent a Liver Biopsy Over The Past 25 Years. Pattern of Liver Biopsy Utilization and Pitfalls.	2131	Metabolic-Associated Steatotic Liver Disease in Relation to Food Behaviors in the Million Veteran Program Cohort: Eat Your Broccoli	2296
Further exploration of differences between lean and non-lean metabolic dysfunction-associated steatotic liver disease (MASLD) in Latino subjects: PNPLA3 frequency and lipidomic profiles	2132	Lifestyle habits significantly mitigate MASLD risk: Results from a prospective multi-center study	2297
An AI approach for automated and noninvasive in vivo liver sizing in mouse models	2133	Risk difference for long-term clinical outcomes in steatotic liver disease (MASLD, MetALD and ALD)	2298
Normal Fib-4 values do not exclude advanced fibrosis in 15% of patients with MASLD	2134	Evolution of MASLD/MASH Patient Experiences: Insights from 'The State of Steatotic (Fatty) Liver Care in America' Surveys 2022-2024	2299
Validation of the 2023 Diagnostic Criteria for Metabolic Dysfunction-associated Steatotic Liver Disease and the Role of PNPLA3 I148M Variant in Latin America	2135	Associations between Metabolic Dysfunction-Associated Steatotic Liver Disease and Abdominal Pain: A Single-Center Retrospective Study	2300
Rapid identification of resmetrom-eligible patients in a large healthcare system using database programming and natural language processing	2136	Synergistic Impact of Low Body Mass Index and Metabolic Dysfunction-Associated Steatotic Liver Disease on Incident Alzheimer's Disease Risk: A Nationwide Cohort Study	2301
GGT as A Biomarker for the Diagnosis of MASLD in Younger Than 12 Years Old.	2137	Exploring Predictors of Rapid Progression to Major Adverse Liver Outcomes in Metabolic Dysfunction-Associated Steatotic Liver Disease	2302
Ethnic Differences in ELF scores in a suburban MASH population	2138	Neighborhood-level social determinants of health are associated with MASLD burden, complications, and mortality	2303
Phase 1 of Impact of Nutritional Intervention on The Prevention of Metabolic Associated Steatotic Liver Disease in Central Valley College Students	2139	Economic Cost of Inaction for Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Germany, Japan, and the United States	2304
<b>MASLD and MASH</b>		Understanding Metabolic Dysfunction-Associated Steatohepatitis: Differences in Clinical and Demographic Characteristics Across Racial and Ethnic Groups	2305
<b>Epidemiology and Natural History, Prevention and Outcomes</b>		Validation and epidemiologic definition of the novel steatotic liver disease nomenclature in a national cohort with cirrhosis	2306
The Steatosis-Associated Fibrosis Estimator (SAFE) Score Predicts Liver and Cardiovascular Outcomes: A UK Biobank Study	143	Thyroid Disorders (hypothyroidism and hyperthyroidism) and their associations with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: A Study on Inpatient Outcomes, Incidence and Prevalence	2307
Utilizing FIB-4 and transient elastography to diagnose steatotic liver disease in patients with type 2 diabetes: Quality improvement project at a Veterans Affairs resident clinic	2284	Impact of Metabolic Dysfunction-Associated Steatotic Liver Disease on the Incidence of Osteoporosis	2308
Risk of incident extrahepatic cancers among Medicare patients with non-alcoholic steatohepatitis (NASH)	2285	Improved Liver Fibrosis Regression After Direct-Acting Antiviral Therapy in Hepatitis C Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease	2309
Risk of all-cause mortality and adverse outcomes from steatotic liver disease and its subgroups in the general population	2286	Characteristics and clinical outcomes in patients with cirrhosis due to metabolic dysfunction-associated steatotic liver disease (MASLD) in Sweden	2310
Racial Differences and Comparative Clinical Outcomes among Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease Hospitalized for COVID-19: Insights from the National Inpatient Sample Database.	2287	Clinical features of MetALD: database analysis of 108,446 subjects	2311
Prognostic value of the FIB-4 index for all-cause mortality in heart failure with steatotic liver disease: Results from the MyoVasc study	2288	Differences in prevalence of MASLD with clinically significant fibrosis by sex/menopause status in a large prospective US cohort of persons with HIV	2312
Pruritus is Common and Persistent in Patients with MASLD	2289	The Cumulative Impact of Concurrent Diabetes Mellitus and Obesity on Long-term Risks of Cirrhosis Among a National Cohort of U.S. Veterans with MASLD or MetALD	2313
Structural equation modelling identifies sex-specific classes to characterize subtypes of metabolic dysfunction-associated steatotic liver disease	2290	Longitudinal Risk of Cirrhosis Across the Spectrum of Steatotic Liver Disease Among a National Cohort of Veterans in the United States	2314
Clinical outcomes of steatotic liver disease in Japan	2291	Sexual Dimorphism in Metabolic Dysfunction-Associated Steatotic Liver Disease Among 1,472 People with HIV	2315
Gender Disparities in Metabolic Dysfunction Associated Steatotic Liver Disease: Transcriptomic results from the BARIA longitudinal cohort study	2292		



Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Severe Fibrosis have Worse Executive Function Performance	2316	Low Anti-Mullerian Hormone in Reproductive-Aged Women is Associated with MASLD in Midlife: Data from the Longitudinal CARDIA Cohort	2340
Significant sex/gender disparities in the prevalence, cardiometabolic risk profiles and management of MASLD: Results from a cohort of 24,888 Canadians	2317	Stability of the NASH-CHECK patient-reported outcome measure over time in patients with metabolic dysfunction-associated steatotic liver disease and stable clinical status	2341
Investigation of factors contributing to liver fibrosis in MASLD through serial MR elastography and MRI-PDFF	2318	Steatotic Liver Disease with Metabolic Dysfunction and Modest Alcohol Consumption Cumulatively Impact Survival in the Younger Populations.	2342
Metabolic-associated Steatotic Liver Disease and Infections: A Systematic Review and Meta-analysis	2319	Increasing liver fibrosis in MASLD is associated with higher risk of hip fractures in males	2343
Prognosis of lean and non-lean MASLD in a large-scale Asian population study	2320	Incidence of cirrhosis and extrahepatic manifestations among lean and non-lean individuals with Metabolic Dysfunction-associated Steatotic Liver Disease	2344
Liver-related outcomes over 15 years following metabolic dysfunction-associated steatohepatitis diagnosis	2321	Risk of Comorbid Mental Health Conditions in Children with Metabolic Dysfunction-Associated Steatotic Liver Disease	2345
Changes in Hemoglobin A1c and Body Weight are Strongly Associated with Changes in Liver Stiffness in Adults with Biopsy-Proven MASLD	2322	Metabolic dysfunction-associated steatotic liver disease (MASLD) and Associated Risk Factors in a Community-Based Sample of American Indians	2346
Impact of New Nomenclature on Hospitalization Outcomes: Comparing MASLD, MetALD, and ALD	2323	Impact of Surveillance on Overall Survival in Patients with MASLD-associated Hepatocellular Carcinoma: Results from a Multicenter Cohort Study	2347
The Global Profile of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Clinical Presentation, Histologic Stage, Non-invasive Tests and Mortality from the Global NAFLD/MASLD Registry	2324	Obesogenic Medication Use is Associated with Increased Risk of MASLD and Liver Fibrosis	2348
Association Between Metabolic Dysfunction-associated Steatotic Liver Disease and Dementia-Related Brain Structure in Elderly People Living in Japan: The Arao Cohort Study	2325	Predictive Models for Hepatocellular Carcinoma (HCC) development in Cirrhotic and Non-Cirrhotic Metabolic Dysfunction-Associated Steatotic Liver Disease patients	2349
Real-world experience of a multidisciplinary MASLD clinic	2326	Balancing the Booze: How Light to Moderate Drinking Affects Liver and Cardiovascular outcomes in Steatotic Liver Disease	2350
Association of staple foods intake with the risk of metabolic dysfunction-associated steatotic liver disease: a prospective community-based cohort study	2327	Association of BMI trajectory with Mortality Among Non-alcoholic fatty liver disease Individuals: a prospective cohort study	2351
Epigenetic age acceleration is associated with steatotic liver disease in adolescence and early adulthood: A 10 year cohort study.	2328	Association between use of anti-hypertensive drugs and risk of hepatocellular carcinoma (HCC) in metabolic dysfunction-associated steatotic liver disease (MASLD) patients with cirrhosis	2352
Current multi-dimensional view of non-alcoholic steatohepatitis (NASH)/ metabolic dysfunction-associated steatohepatitis (MASH) global epidemiological rates	2329	Real-world outcomes of patients with metabolic dysfunction-associated steatohepatitis (MASH) compensated cirrhosis at a large academic referral center	2353
Liver-related events and mortality in patients with Metabolic Dysfunction Associated Steatotic Liver Disease varies with the type of Cardiometabolic Risk Factor	2330	PNPLA3 rs738409 is significantly and independently associated with histological progression and regression in MASLD: A large paired and prospective liver biopsy study.	2354
Comparing Rates of Decompensation, Hepatocellular carcinoma, Overall and Liver-related death between MASLD, MetALD and ALD in a National Cohort	2331	Evaluating acute healthcare utilization post implementation of a primary care metabolic-associated steatotic liver disease risk stratification pathway: A large Canadian cohort study	2355
Independent risk factors for chronic kidney disease: The impact of SLD and obesity in a large-scale health checkup cohort	2332	Characteristics of adult MASH patients and factors associated with MASH-relevant clinical endpoints in a real-world US cohort	2356
Differential Exercise Requirements for Nonalcoholic Fatty Liver Disease Resolution Across Age Groups: A Longitudinal Study of Korean Military Officers	2333	Time to Disease Progression and All-Cause Mortality in Adult MASH Patients in a Real- World US Cohort	2357
A prospective assessment of the impact of decompensation of cirrhosis on patient-reported outcomes in metabolic dysfunction-associated steatotic liver disease	2334	Quantitation of Plasma Cells, Cytotoxic T cells, and Kupffer cells/Macrophages with Hepatic Fibrosis Stage in Metabolic Dysfunction-Associated Steatohepatitis (MASH)	2358
GLP-1's Role in Lowering HCC Risk in Patients with Metabolic Dysfunction-Associated Steatohepatitis and Type 2 Diabetes - A Multicenter Propensity-Matched Study	2335	Association of Steatotic Liver Disease (SLD) with Adverse Pregnancy Outcomes: Results from the Prospective Fatty Liver in Pregnancy (FLIP) Cohort.	2359
Impact of hemoglobin A1c (HbA1c) trajectory on the risk of liver-related complications in patients with type 2 diabetes mellitus (T2DM): A territory-wide cohort study	2336	Artificial Intelligence for Early MASLD Identification in the Electronic Medical Record	2360
Predicting hepatic decompensation in patients with metabolic dysfunction-associated steatotic liver disease-related cirrhosis: The ABID-LSM model.	2337	Clinical characteristics and FIB-4 risk stratification of primary care patients with obesity, diabetes, or both: real-world implications for adopting a FIB-4 referral algorithm to detect metabolic dysfunction-association steatotic liver disease (MASLD) with advanced fibrosis	2361
Examining Waitlist Mortality and Transplantation Probability in MASH Cirrhosis under the MELD 3.0 System. A SRTR/UNOS database Analysis	2338	Three gradient boosting machine-learning models in Indeterminate FIB-4 Score Are Superior to Noninvasive Tests in Predicting Cirrhosis: A National and VA Analysis	2362
CORONASH study: prospective study of prevalence and severity of metabolic dysfunction - associated steatotic liver disease (MASLD) in patients undergoing coronary angiography	2339	Smoking and Progression to Cirrhosis	2363
		The Effects of Visceral Adipose Tissue on Survival in MASLD	2364

Disparities in the Association between Metabolic Associated Steatotic Liver Disease and Visceral Adipose Dysfunction Across Sexes, Races, and Diabetes Status: A Cross-Sectional Study of US Adults.	2365	Health Goal Coaching is Associated with Higher Health Goal Motivation and Satisfaction in Participants at Risk for Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)	
Prevalence of Metabolic dysfunction-associated fatty liver disease (MAFLD) in patients with Diabetes Mellitus: A Clinical Investigation of Patients in Puerto Rico West area.	2366	Healthcare Providers' Perspectives on New Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) Nomenclature	2387
Sex differences in clinical outcomes of patients with metabolic dysfunction-associated steatotic liver disease -results of a nationwide real-world U.S. cohort	2367	Sodium-Glucose Cotransporter-2 Inhibitors and the Risk of Hepatocellular Carcinoma Among Patients with Type 2 Diabetes, Metabolic Dysfunction-Associated Steatotic Liver Disease, and Obesity: A Large Population-Based Cohort Study	2388
Cause-specific Mortality Among Australians With Cirrhosis Differs by Cirrhosis Etiology and Decompensation Status	2368	Primary Care Based Implementation of Electronic Clinical Decision Support for Metabolic Dysfunction Associated Steatotic Liver Disease Improves Care Delivery Independent of Patient Demographics and Clinical Factors: A Prospective Implementation Study	2389
Patterns of Dietary Supplement Use among Patients with Steatotic Liver Disease in the United States: Vitamins, Minerals and Botanicals	2369	All-cause mortality differs between steatotic liver disease subtypes: Results from a prospective cohort of 16,560 Adults in Canada	2390
Discordance of FIB-4 and SAFE scores for the prediction of advanced fibrosis in primary care patients with obesity, diabetes, or both	2370	Statin Use with Cardiovascular Disease and All-Cause Mortality in Patients with Hypertension, Metabolic Dysfunction-Associated Liver Disease, and Obesity: A Population-Based Cohort Study	2391
Differential Prognosis and Impacts of Cardiometabolic Risk Factors and Alcohol Intake in MASLD and MetALD Patients	2371	Fibrosis risk stratification in metabolic dysfunction-associated steatotic liver disease patients with diabetes in Taiwan- A multi-center cohort study	2392
Noncirrhotic metabolic dysfunction-associated steatotic liver disease increases risk of hepatocellular carcinoma and new cirrhosis, and overall death compared to other liver diseases among US Veterans	2372	Hepatic Fibrosis But Not Steatosis is Associated with Early-Stage/Sub-clinical Markers of Heart Failure in Metabolic Dysfunction-Associated Steatotic Liver Disease	2393
Population-based Steatotic Liver Disease Screening Recommendations Could Help Address Women's Health Inequities in the United States: A National Health and Nutrition Examination Survey Analysis	2373	Association of severity of metabolic dysfunction-associated steatotic liver disease with gut dysbiosis and shift in the metabolic function of the gut microbiota in people with HIV	2394
Racial Disparities and Higher Substance and Opioid Use Disorder in Lean patients with MASLD: Risk Factors and Mortality	2374	★ New steatotic liver disease diagnostic performance in a Chilean agricultural population cohort	2395
Association between metabolic dysfunction-associated steatotic liver disease and mortality: A nationwide cohort study	2375	Forecasted changes in tumor characteristics and survival of patients with nonviral hepatocellular carcinoma in the United States: a modeling study based on the SEER-Medicare database	2396
Green food for liver protection? Comparative analysis of fat sources and risk of liver disease and mortality	2376	Sex differences in long-term overall, liver and nonliver-related mortality of patients with metabolic dysfunction-associated steatotic liver disease: a real-world longitudinal cohort study	2397
MASLD and metALD: the amount of liver fat and number of cardiometabolic risk factors in relation to the risk of type 2 diabetes and cardiovascular disease	2377	Suboptimal diagnosis rate and peri-complication diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD) in the U.S.: A population-based study	2398
Minimal or Moderate Alcohol Use before Liver Transplantation for MASLD is not associated with Steatosis Recurrence or Survival	2378	Cost utility of bariatric surgery among obese patients with chronic liver disease	2399
Long-Term Vascular Outcomes and Mortality After Bariatric Surgery Among Patients with Obesity, Type 2 Diabetes, and Metabolic Dysfunction-Associated Steatotic Liver Disease	2379	Use of a Computerized Clinical Decision Support (cCDS) Tool in Primary Care Increases Rates of Confirmatory Testing in patients with Metabolic Associated Steatotic Liver Disease (MASLD) at Risk for Advanced Liver Fibrosis: A Pilot Study	2400
Association of Glucagon-Like Peptidase 1 Receptor Agonist With Liver and Non-liver Complications in Patients With Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease	2380	Increasing metabolic dysfunction-associated steatotic liver disease-related mortality rates in the United States from 2006 to 2023 and future forecast to 2040	2401
Cause-specific mortality in patients with metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study	2381	Global epidemiology and characteristics of MASLD in type 1 diabetes: an updated systematic review and meta-analysis	2402
Effect of Glucagon-like Peptide 1 Receptor Agonists on Metabolic Dysfunction-associated Steatotic Liver Disease in Adults With Type 2 Diabetes Mellitus and With Overweight or Obesity: A Target Trial Emulation Study	2382	Identifying social determinants of health and environmental factors associated with significant fibrosis in MASH patients enrolled in the Mount Sinai MASH Center of Excellence Registry and Biobank	2403
Change in nomenclature and definition from NAFLD to MASLD maintains the disease severity determining association between type 2 DM and MASLD - The results of multi-centre Indian Consortium on MASLD (ICOM-D).	2383	Clinical, Psychosocial and Social Determinants of Health Factors Associated with Degree of Hepatic Steatosis and Liver Stiffness Among Overweight and Obese Adults at Risk of Metabolic Dysfunction-Associated Steatotic Liver Disease	2404
Contemporary Etiologic Differences for Cause of Death in Patients with Cirrhosis	2384	Representation of sex, race and ethnicity in MASH trials: a systematic review and meta-analysis	2405
Cumulative Dose and Duration of Statin use are associated with a reduced risk of liver cancer after adjusting for age, FIB-4 score, and prior cirrhosis diagnosis in MASLD patients; a 10-year cohort study	2385	Unveiling the Reach: Estimating Resmetirom-Eligible Population Among US Adults	2406
	2386		

Patients with Advanced MASLD and Decompensation have Distinct Dietary Habits	2407	Decoding and Targeting Hepatocyte Senescence in MASLD: From Identification to Treatment	233
Cardiovascular Outcomes and Mortality in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Population-based Analysis	2408	Mechanosensitive regulation of LXR by YAP/TAZ determines hepatic cholesterol accumulation	1002
Non-invasive assessment comparison for liver disease screening: Utilizing Hepatoscope and FibroScan for the assessment of hepatic steatosis and fibrosis in Southern Arizona	2409	Liver single-cell RNA transcriptome evolution in response to diet-induced MASH/fibrosis	1003
The best cutoff for transient elastography as a predictor of liver outcomes in metabolic-associated steatotic liver dysfunction (MASLD) patients	2410	A novel HTR2A antagonist for the treatment of metabolic dysfunction-associated steatotic liver disease	1004
Association of NAFLD with and without Advanced Fibrosis with Fatal, Non-Fatal, and Combined Cardiovascular Events: A Systematic Review and Meta-Analysis	2411	Soluble Siglec-9 improves intestinal barrier function in a mouse model of metabolic-dysfunction associated steatohepatitis (MASH)	1005
Magnesium depletion score and mortality in individuals with metabolic dysfunction-associated steatotic liver disease over a median follow-up of 14 years	2412	A new therapeutic approach for MASLD/MASH treatment	1006
Examining the prevalence of hepatic steatosis and advanced fibrosis using multiple non-invasive measures in Canada: A national estimate using the Canadian Health Measures Survey (CHMS) from 2009-2019	2413	11 $\beta$ -HSD1 inhibition on non-alcoholic fatty liver disease: Investigating immune cell dynamics via single-cell mass cytometry	1007
Helicobacter pylori cagA/vacAs1-m1 strain is associated with high risk of fibrosis in metabolic-dysfunction-associated steatotic liver disease	2414	DGAT2 Inhibition Blocks Activation of SREBP-1 and Improves Hepatic Steatosis by Increasing ER Phosphatidylethanolamine	1008
Alcohol use is associated with increased mortality among those with steatotic liver disease: A population-based study	2415	Cytoplasmic export of circPOLD1 promotes metabolic dysfunction-associated steatohepatitis liver disease through interaction with HuR	1009
The interplay between Helicobacter pylori infection and rs738409 PNPLA3 in metabolic dysfunction-associated steatotic liver disease	2416	MRC2 Deficiency Alleviates the Development of HFD-Induced NAFLD via Downregulating CD147-Mediated TNF- $\alpha$ production in Macrophage	1010
Investigating the prevalence of MetALD in comparison to MASLD in patients previously diagnosed with NAFLD	2417	Liproxstatin-1 Mitigates Liver Damage by Inhibiting Ferroptosis in a MASLD Mouse Model	1011
The Burden of MASLD in South Asia (2017-2021): A Global Burden of Disease Analysis	2418	Hepatic chenodeoxycholic acid promotes MASH with HCC in high-fat/high-sucrose diet-fed mice with human-like bile acid composition	1012
Relationship between Alcohol Consumption and All-cause Mortality in patients with Steatotic liver disease: Findings from NHANES III	2419	A Novel MASLD model evaluates Diet and Alcohol induced Pathology and Behavior	1013
Assessing the prevalence of cardiometabolic risk factors in patients referred to a Steatotic Liver Disease clinic	2420	Fumarate Supplementation Ameliorates MASH Pathology in a Murine Model of MASLD by Targeting the TCA cycle	1014
Diabetic Microvascular Complications are Associated with Mortality in Individuals with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Type 2 Diabetes Mellitus: A Nationwide Study	2421	The role of BH3-only protein Noxa in metabolic dysfunction-associated steatotic liver disease.	1015
Frequent misclassification of MetALD results in underestimation of its prevalence and long-term prognosis	2422	The increased IL-1 $\beta$ secretion of macrophages accompanying autophagy dysfunction enhances the inflammatory chemokine expression of LSECs, contributing to the progression of MASH pathology	1016
High adherence to the Mediterranean diet is associated with lower Liver Risk Scores - Analysis of the NHANES 2017-2018 Cohort	2423	Automated shear wave elastography captures MASLD onset in C57BL/6NTac mice preconditioned on a modified Amylin liver NASH diet	1017
		TMEM41B as a Therapeutic Target to Enhance VLDL Secretion in MASLD/MASH Treatment	1018
		Extracellular vesicles derived from the iPS-derived mesenchymal stem cells ameliorated liver fibrosis and fatty deposition in MASLD-related cirrhotic mice.	1019
		A longitudinal study of MASH pathogenesis in a non-human primate model at single nucleus resolution	1020
		Generating hepatic cells expressing the various PNPLA3-1148M variants by prime editing.	1021
		Steatotic and fibrotic liver-derived TNF-alpha exacerbates skeletal muscle atrophy in senescence-accelerated mice	1022
		Validation of and Mechanistic Insights on A Bile Acid Signature of Fibrosis Progression in Metabolic Dysfunction Associated Steatohepatitis	1023
		Murine MASH livers display bias towards a hypertrophic mechanism of regeneration following partial hepatectomy	1024
		Endothelial-stellate cell crosstalk underlies fibrosis resolution in liver	1025
		A genome-wide CRISPR-Cas9 screen identifies modifiers of cellular cholesterol uptake	1026
		Impact of adult-onset, hepatocyte-specific, loss of the growth hormone receptor on MASH progression	1027
		Oxidized LDL's Role in MASLD: Insights from Liver Spheroid Transcriptomics	1028

## MASLD and MASH

### Experimental: Basic

NADH-reductive stress links the antioxidant Cullin3-RING E3 ligase-NRF2 axis to regulation of hepatic steatosis and insulin sensitivity	39		
The PNPLA3 I148M variant initiates metabolic reprogramming in macrophages	78		
★ Lipid induced Endothelial Intercellular Adhesion Molecule 1 (ICAM1) Promotes Liver Inflammation in Metabolic Dysfunction-Associated Steatohepatitis (MASH)	142		
★ Role of OGT-TFF2 axis in intrahepatic crosstalk and MASH pathogenesis	146		
Endogenous double-stranded RNA drives macrophage IRF3 activation promoting early metabolic dysfunction-associated steatohepatitis	193		

Circulating and liver tissues EMILIN1 levels are reduced and associated with metabolic dysfunction-associated steatotic liver disease in patients and mice models	1029	Manipulation of MiR-15a/16 in embryonic Kupffer cells promotes hepatic steatosis and inflammation by recruiting monocyte-derived Kupffer cells	1056
WFDC2 promotes MASH-driven HCC development by restraining intracellular fatty acid flux in hypoxia	1030	Western diet through Galectin-1-dependent manners affecting MASH-HCC development.	1057
Identifying Neurogenic Mechanisms for Metabolic Dysfunction Associated Steatohepatitis (MASH) After Spinal Cord Injury	1031	An Oral inhibitor of CBP/ $\beta$ -catenin signaling, C-82, improves liver steatosis, function, inflammation and fibrosis in the GAN diet-induced obese mouse model of MASH	1058
Hepatic PNPLA3I148M associates with skeletal fragility without high-fat diet exposure in DIAMOND mice	1032	Therapeutic Implications of DNA Methylation in MASLD Progression	1059
Role of STARD1 in Hepatic Mitochondrial-derived Oxysterols in the Development of Cardiovascular Dysfunction in MASH	1034	The beneficial effect of resmetirum on tumorigenesis associated with MASH in STAM mice	1060
Hepatocyte arginase-2 protects from metabolic dysfunction-associated steatohepatitis by regulating mitochondrial fatty acid oxidation.	1035	Human hepatic 3D spheroids as a model for metabolic dysfunction-associated steatotic liver disease (MASLD)	1061
Regulatory T cell: Friend or Foe in the progression from MASH to HCC?	1036	PUM1 knockdown aggravates lipid deposition in metabolic dysfunction-associated steatotic liver disease	1062
The pan-PPAR agonist lanifibranor improves liver inflammation, ballooning, and fibrosis in a diet-induced obese MASH hamster model of binge drinking	1037	Intestine-Specific Faf2 Depletion Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease by Impairing Lipid Absorption	1063
Neutrophil Depletion attenuated NLRP3-Induced Liver Inflammation and Fibrosis in NASH	1038	Systemic IgA accumulation due to dysfunctional plgR enforces neutrophil-mediated inflammation during steatohepatitis.	1064
A novel steatohepatitis model in the FAH-deficient swine	1039	Histone Methyltransferase G9a: Key Regulator in Hepatic Steatosis Pathogenesis and Potential Therapeutic Target Beyond Epigenetics	1065
The exercise-induced metabolite beta-aminoisobutyric acid regulates hepatic lipid metabolism and reduces hepatic metabolic dysfunction and fatty liver in a dietary obese mouse model	1040	The influence and mechanism of vitamin C on PM2.5 exposure metabolic dysfunction associated fatty liver disease	1066
Pharmacological characterization of EA3571: a novel dual inhibitor of enteropeptidase and trypsin with luminal action for metabolic dysfunction-associated steatohepatitis	1041	Targeting BRD4 mitigates hepatocellular lipotoxicity by suppressing the NLRP3 inflammasome activation and GSDMD-mediated hepatocytes pyroptosis	1067
Hepatocyte-Specific Deletion of the Novel Hexokinase, HKDC1, Protects Against MASH-induced Fibrosis in Female Mice.	1042	Ketohexokinase deficiency mitigates MASH/HCC progression	1068
Adipocyte activating transcription factor 3 is a gatekeeper in preventing non-alcoholic steatohepatitis	1043	Hepatic FOXA3 overexpression alleviates diet-induced metabolic dysfunction associated steatohepatitis and obesity in mice via TGR5.	1069
C/EBP $\beta$ -VCAM1 axis in Kupffer cells promotes hepatic inflammation in metabolic dysfunction-associated steatohepatitis	1044	Coagulation protease-activated receptor-2 (PAR2) promotes dyslipidemia, obesity and MAFLD through suppression of a hepatic pioneer factor	1070
Inhibition of visceral adipose tissue-derived pathogenic signals by activation of adenosine A2AR improves cardiac dysfunction of NASH mice	1045	★ Novel Hepatic Lipid-Induced Enhancer activation modulates Steatohepatitis via S100A11	1071
The Gene Expression Characteristic in MASLD-HCC Progression with Diet-Induced Metabolic Shifts	1046	Toll-like receptor (TLR)5 mediates deleterious effects of lipid injury and fibrogenic responses in metabolic dysfunction-associated steatohepatitis (MASH) and clinical outcomes	1072
Microvascularized Liver Microphysiologic System Models Key Features of Human Insulin Resistance	1047	Fatty acid synthase (FASN) inhibitor reduces atherosclerosis development in diet-induced dyslipidaemia LDL receptor knockout mice with MASH	1073
Carriage of multiple genetic risk factors for MASH stimulates an altered inflammatory secretome in a human stem cell-based in vitro model	1048	A PNPLA3-deficient iPSC-derived hepatocyte screen identifies pathways to potentially reduce steatosis in Metabolic Dysfunction-Associated Fatty Liver Disease	1074
Fam172a Gene Knockdown aggravates Hepatocyte Lipotoxic Injury through Activating the ERK Pathway	1049	Potential of Novel Regulatory Bile Acid, 3 $\beta$ -Sulfate-5-Cholestenic Acid (3SCA) in MASLD Therapy	1075
MASH and fibrosis related-HCC model mouse for immunology	1050	A Fructose-enriched diet consumption promotes a specific transcriptomic signature defining an aggressive phenotype.	1076
The effects of CSE deficiency on high-fat diet-induced nonalcoholic fatty liver	1051	Lutein Mitigates Lipid Accumulation in Hepatic Cells via TFEB Activation: A Potential Therapeutic Approach for MASLD	1077
Hepatic mitochondrial quality control regulates skeletal muscle adaptation to exercise through selenoprotein P in MASH-related hepatocarcinogenic mice	1052	In vitro cellular studies implicate HSD17B13 in lipid and immune associated pathways in cultured primary human hepatocytes	1078
Polycyclic aromatic hydrocarbons (PAHs) Aggravate HFD-Induced NAFLD through Increasing Hepatocyte Sphingosine-1-Phosphate	1053	Elucidating novel therapeutic targets for metabolic disease through high resolution epigenetic profiling of primary human adipocytes	1079
Real-Time, Non-Invasive Profiling of Live Cell Behaviour in Human Hepatic Health-to-Disease (MASLD-MASH) Transition Models using Electric Cell-Substrate Impedance Sensing (ECIS)	1054	Liver-derived extracellular matrix hydrogels augment the survival and function of primary rat liver sinusoidal endothelial cells	1080
★ Hepatic R-spondin 2 is a key suppressor of hepatosteatosis.	1055	CARD9 Deficiency exacerbates diet-induced steatotic liver disease	1081
		Impact of ex-vivo expanded CD34-positive cells on tumor formation in hepatocarcinogenic mice with metabolic dysfunction-associated steatohepatitis	1082
		Role of bile acids in pathogenic intestinal permeability and fibrosis in a co-culture model	1083



Glucagon engagement is essential for the direct anti-inflammation and anti-fibrosis effect of efocipegrutride in TAA-induced mouse model of liver injury and fibrosis	1084	Neutralizing the OX40L-OX40 axis attenuates fibrosis and recruitment of monocyte-derived macrophages in murine metabolic dysfunction-associated steatohepatitis.	1108
Sulfonated albumin activates hepatic stellate cells to accelerate NASH liver fibrosis	1085	MAP1LC3B Protein Interactome in a Hepatocyte Mitochondrial injury model identifies novel targets relevant to Steatotic liver diseases.	1109
Phocaeicola coprocola alleviates metabolic dysfunction-associated steatotic liver disease by modulating lipogenesis	1086	EphA2 promotes inflammation and alters hepatocyte metabolism to enhance metabolic dysfunction-associated steatotic liver disease	1110
An ex-vivo approach to model metabolic dysfunction associated steatohepatitis (MASH) using patient-derived induced pluripotent stem cells.	1087	Glycogen Synthase Kinase 3 $\beta$ Hepatocyte Deletion Ameliorates Murine Metabolic Dysfunction-Associated Steatohepatitis	1111
Streptococcus salivarius mitigates metabolic dysfunction-associated steatotic liver disease by modulating NLRP3 inflammasome pathway.	1088	Genetic control of the MASLD/MASH transition	1112
Reproducible therapeutic effects of semaglutide in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH	1089	JiGuCao capsule alleviates metabolic dysfunction-associated fatty liver disease by regulating the gut microbiota and lipid metabolism	1113
Reproducible therapeutic effects of resmetirom in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH	1090	The effects of hydroxynonenal on hepatocytes and its association with the pathogenesis of NAFLD	1114
Estrogen-related receptor-alpha plays a role in ROS production by regulating lipid metabolism in the liver.	1091	Modelling Health-to-Disease Transition in MASLD-MASH: Development of a Dynamic Microfluidic Human Liver-on-Chip System	1115
NSR $\beta$ 70 deficiency worsens metabolic dysfunction-associated steatohepatitis by regulating lipogenesis	1092	Blockade of CXCR3 attenuates CD4 T cell-mediated liver injury in murine metabolic dysfunction-associated steatohepatitis	1116
Unravelling MASLD heterogeneity at single cell level in the switching towards progressive disease	1093	Hepatocyte-specific (pro)renin receptor knockout attenuated diet-induced steatosis in mice with improved insulin resistance and metabolic rates	1117
High frequency ultrasound shear wave elastography for preclinical liver investigation: a pilot study on an OGT mouse model	1094	Peripheral blockade of CB1 signaling improves liver fibrosis	1118
New steps forward in learning about the use of DGAT1 and DGAT2 inhibitors for metabolic dysfunction-associated steatotic liver disease (MASLD) management: benefits for their single or combined application	1095	Targeting EFHD1 to reduce liver damage in MASH	1119
AKT Isoform Specific Regulation of Hepatic Steatosis Induced by Bioactive Lipids	1096	Expression of hepatic drug metabolizing enzymes is altered by concomitant obesogenic lipids and ethanol in mice and adult human hepatic organoids	1120
Treatment with the CCR2/CCR5 antagonist Cenicriviroc does not affect MASH and fibrosis development in Ldlr $^{-/-}$ .Leiden mice, translational to clinical phase 3 trial results	1097	Modulation of Gut Microbiota and Metabolic and Histological Improvements through Methyl Group Donor Supplementation in a MetALD model	1121
Liver fibrosis induced by CDAHFD and surfactant Polysorbate 80	1098	The Role of MicroRNA-122 in Metabolic Dysfunction-Associated Steatotic Liver Disease	1122
Highly sensitive metabolic flux analysis using $^{14}\text{C}$ -microtracers combined with accelerator mass spectrometry - A proof of concept study on de novo lipogenesis	1100	Retatrutide improves steatohepatitis in a new accelerated mouse model of diet-induced steatohepatitis with a fructose binge	1123
Hepatoprotective effects of longer-term treatment intervention with Semaglutide and Tirzepatide in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH	1101	Insight to the efficacy of clinical anti-fibrotic compounds using digital pathology with artificial intelligence analysis in a 3D multicellular primary human MASH model	1124
Synergistic hepatoprotective effects of semaglutide and resmetirom combination therapy in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH	1102	CDS2 Deletion Leads to SREBP Dysregulation and Fatty Liver Induction	1125
Treatment with retinoic acid improves diet-induced MASLD in male mice	1103	Differential role of SERPINE1 in hepatocytes and Hepatic Stellate Cells in metabolic dysfunction-associated steatohepatitis	1126
Liver-specific CAPN4 knockdown protects the liver from diet-induced MASH in mice	1104	Characterization of human liver spheroids using stable isotope tracing	1127
Jiang Li1, Charis-Marie Vanderpuye1, Pooja Muddasani1, Sudrishti Chaudhary1, Sam Taborski1, Lorien Walker1, Juliane I Beier1,2, Ian Sipula3, Michael Jurczak3, Michael L Merchant4 and Gavin E Arteel1,2		The Role of Smoothed (SMO) in Hepatocyte Senescence and Ferroptosis in MASLD	1128
1Department of Medicine, 2Pittsburgh Liver Research Center, 3Division of Endocrinology and Metabolism, University of Pittsburgh, Pittsburgh, PA, USA. 4Department of Medicine, University of Louisville, Louisville, Kentucky, USA.		ENTPD1/CD39 regulates inflammatory process in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)	1129
Understanding how HMGCS2-derived ketone body metabolites impact MASLD progression	1105	Single nuclei RNA-seq analysis suggests that human MASLD is a ciliopathy	1130
Toll-like receptor ligands pattern in alcohol-related liver disease and metabolic dysfunction-associated steatotic liver disease patients	1106	Machine learning on multiple modalities of clinical and cellular datasets of liver and hepatocyte fat content reveals unique targets, subsequently validated in preclinical models	1131
Tenofovir disoproxil fumarate reduces hepatic de novo lipogenesis by downregulating the ChREBP/SCD1 pathway	1107	Longitudinal tracking of response to therapy in a diet-reversal MASH mouse model	1132
		Examination of Predictors of Metabolic Steatotic Liver Disease (MASH/MASLD) among Women on Oral Contraceptives (OCPs) Using the National Inpatient Sample: A 10-year Retrospective Analysis	1133

In vivo experiments and network pharmacology to investigate mechanisms of JiGuCao capsule for metabolic-associated fatty liver disease	1134	Impact of Glucagon-Like Peptide-1 Receptor Agonists on Metabolic Health in Liver Transplant Recipients	1539
Reduced HNF4 $\alpha$ Expression in MASLD iPSC-Derived Hepatocytes and Associated Epigenetic Modifications	1135	Deep learning model to predict steatotic liver disease diagnosis and staging in pregnant individuals	1540
Frataxin deficiency induces hepatocyte ferroptosis and liver injury in metabolic dysfunction-associated steatotic liver disease	1136	Serum Noninvasive Testing Scores and Modeling to Predict Intermediate or High Risk for Advanced Fibrosis due to Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in a Type 2 Diabetes (T2D) Population Cohort.	1541
Rap1a activation suppresses MASLD and MASH development via regulating the amino acid mediated mTORC1 activation	1137	Safety and Efficacy of Endoscopic Sleeve Gastroplasty after Orthotopic Liver Transplantation	1542
Manipulating bile acid pool size to target dietary fat absorption in MASLD	1138	Hepatocellular carcinoma and lifestyle: How do dietary patterns differ in those with metabolic and non-metabolic dysfunction associated steatotic liver disease?	1543
Unlocking S-Pindolol's Potential for MASLD: Beneficial effects on muscle mass and function and liver histology in western-diet fed mice	1139	Degree of Metabolic Dysfunction is linked to Steatohepatitis (MASH), Fibrosis, and Higher Cardiovascular Risk in Patients with Metabolic Dysfunction-Associated Steatotic liver disease (MASLD)	1544
Regulation of TM6SF2 by microRNA-432: a Potential Therapeutic Target	1140	Using Panel Management to Identify Adult Patients With High Risk MASLD/MASH Fibrosis in a Primary Care Clinic: A Pilot Study	1545
Enhanced muscle mass mitigates MASLD in myostatin knockout mice without impacting exercise performance.	1141	MASLD is a night-time disease driven by nocturnal hepatic, adipose, and skeletal muscle insulin resistance	1547
Nuclear sequestration of Y box-binding protein 1 reprograms hepatocytes for adipogenicity	1142	Lean Non-Alcoholic Fatty Liver Disease Is Not A Distinct Pathophysiological Entity	1548
		Biomarker response in metabolic dysfunction-associated steatohepatitis (MASH) patients with high-risk baseline FAST scores: Observations from the ENLIVEN Phase2b trial with pegozafermin.	1549
		The Interplay Between Coagulation Imbalance and PNPLA3 Mutation in MASLD Diabetic Patients: Impact on Hepatic and Vascular Complications	1550
		Analysis Of Cardiovascular Risk Factors During The Treatment Of Metabolic Dysfunction Associated Fatty Liver Disease With A Low Carbohydrate Diet	1551
		Plasma immune profile associated with MASLD in persons with HIV	1552
		Muscle function correlates with quality of life and disease severity in patients with MASLD	1553
		Improving Screening of Metabolic-Dysfunction Associated Liver Disease (MASLD) in Patients with Type 2 Diabetes Mellitus: A Quality Improvement Initiative	1554
		Comparison Of Steatosis Assessment Between VCTE-CAP Score and Ultrasound In Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) In A Canadian Cohort	1555
		Association Between US Abdomen, FIB-4, And VCTE Determined Steatosis and Disease Severity in A Canadian Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) Cohort	1556
		Diabetes Is a Risk Factor for Sarcopenia of Patients With Metabolic Dysfunction-Associated Steatohepatitis-Driven Cirrhosis	1557
		Novel Insights into the Accuracy of FIB-4 and FibroScan Scores Compared to Liver Biopsy in the Assessment of Liver Fibrosis in Patients with MASLD	1558
		A Phase 1/2a Single-Center Randomized Placebo-Controlled Study of Oral Idebenone to Treat Metabolic Dysfunction-Associated Steatohepatitis	1559
		Spatial transcriptomics maps the metabolic zonation of hepatocytes in MASLD I148M-PNPLA3 carriers	1560
		Application of artificial intelligence algorithm as a vascular evaluation tool for intra-stage assessment in the cirrhotic patients with metabolic dysfunction-associated steatotic liver disease	1561
		Lower Prevalence of MASLD in Non-Hispanic Black Patients Is Not Explained by Higher Hepatic Fat Oxidation	1562
		Pegozafermin reduced progression to cirrhosis: A post-hoc analysis from the Phase 2b ENLIVEN study	1563
			1564

## MASLD and MASH

### Experimental: Clinical

★ Clinically Distinct Metabotypes of Pediatric Metabolic Dysfunction-Associated Steatotic Liver Disease: An Unsupervised Machine Learning Analysis of Children Enrolled in NASH CRN Studies	1
Pharmacokinetics, Safety and Efficacy of the Novel Non-bile Acid FXR Agonist FXR314 in Patients With Metabolic Dysfunction-associated Steatohepatitis: Results From A Phase 2 Study	37
Novel DGAT2 antisense inhibitor demonstrates significant histological benefit in biopsy-proven MASH patients with advanced liver fibrosis stage F3: Subset analysis of a 51-week multicenter randomized double-blind placebo-controlled phase 2 trial	44
Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) is Significantly Associated with Biological Age and its Acceleration as Assessed by Methylation Clock	147
Validation of polygenic risk scores to predict MASLD Activity Score (MAS) and Advanced Fibrosis in a large cohort of patients with biopsy-proven MASLD	160
AI-based digital pathology shows that denifanstat improves multiple parameters of fibrosis and reduces progression to cirrhosis in MASH patients with F2/F3 fibrosis - results of the FASCINATE-2 study	170
First-in-Human Phase 1 Study of EA3571, which is a novel dual inhibitor of enteropeptidase and trypsin with luminal action, in Healthy Adult Participants	1535
DNA methylome analysis reveals epigenetic alteration of complement genes in advanced MASLD	1536
Effects of various genetic polymorphisms in f metabolic dysfunction-associated steatotic liver disease in Japan and their appropriate use in risk assessment of liver-related events	1537
NAFLD does not affect the effectiveness of tenofovir alafenamide in patients with chronic HBV infection after expanding the antiviral indications: A real-world multicenter, retrospective cohort study from Eastern and Central China	1538

Semaglutide improves liver enzymes and fatty liver index in patients with obesity and cardiovascular disease - results from the SELECT trial		therapy in the MAESTRO-NASH 52 week serial liver biopsy study	
Metabolic dysfunction-associated steatotic liver disease is associated with impaired health-related quality of life in people with HIV	1565	★ GLP-1 Receptor Agonists have a potential to improve disease activity in Pediatric Metabolic Dysfunction-Associated Steatotic Liver Disease	166
Free Fatty Acid induces Apoptosis via lncRNA NEAT1/miR-26a/PTEN Axis in Hepatic Cells	1566	Use of glucagon-like peptide 1 receptor agonists (GLP-1 RA) in patients with MASLD in a real-world setting is associated with slower disease progression and lower all-cause mortality	203
The combination of fatty acids desaturase 2 rs174583 and PNPLA3 rs738409 polymorphisms is a risk factor in advanced fibrosis in metabolic dysfunction-associated steatotic liver disease	1567	SGLT2 Inhibitors Suppressed the Onset of Esophageal Varices and Extrahepatic Cancer Compared to DPP4 Inhibitors in Type 2 Diabetic Patients with MASLD: A Nationwide Medical Claims Database Study in Japan	3167
Fibroblast Growth Factor 15/19 (FGF15/19) Regulates Circadian Energy Metabolism in Shift Workers	1568	Identification of Candidates for MASLD Treatment with Indeterminate Vibration-Controlled Transient Elastography	3168
Effect of Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, on Plasma Lipidomic Profiles in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)	1569	Effects of Luseogliflozin on MASLD in Patients with Type 2 Diabetes Mellitus: A Pooled Meta-analysis of Phase III Clinical Trials	3169
Steatotic liver disease in people living with hepatitis C virus following viral eradication with direct-acting antiviral therapy	1570	Changing Prescription Pattern of Anti-diabetic Medications and Improvement in Glycemic Control in Patients with T2DM, with and without Cirrhosis: a territory-wide cohort study in Hong Kong from 2000-2023	3170
Lipidomic and eicosanoid profiles in individuals with steatotic liver disease in pregnancy, gestational hypertension, and preeclampsia.	1571	Evaluation of MASH drug efficacy using liver organoids based on drug target pathways	3171
Exploring an Unlikely Association: Outcomes of MASLD Patients Hospitalized with Upper Gastrointestinal Bleeding	1572	Long-term outcomes of GLP-1 analogues treatment in MASLD patients with type 2 diabetes	3172
VLDL lipidomics capture signatures of MASLD-associated genetics and disease progression through a novel acyl chain distribution analysis	1573	Real World Data Shows Meaningful Improvement in Liver Fibrosis in Veterans Enrolled in Multi-Disciplinary Liver Weight Management Clinic on GLP-1 Receptor Agonists	3173
Development and validation of a natural language processing tool to extract steatohepatitis diagnoses from liver biopsy pathology reports	1574	The association between levothyroxine and its potential preventative effect on liver conditions, particularly in MASLD and MASH	3174
The Prognostic Implications of Dietary Vitamin D Intake Among Patients with Metabolic Dysfunction-associated Steatotic Liver Disease: An Analysis of the NHANES Database	1575	Effects of Saroglitazar in Compensated MASLD Cirrhosis: A Magnetic Resonance Elastography-Based (MRE) Based Single Arm Prospective Study	3175
The long-term prognostic effects of caffeine intake in patients with metabolic dysfunction-associated steatotic liver disease: An analysis of the NHANES Database	1576	Real-world Assessment of Glucagon-like Peptide 1 Receptor Agonist (GLP-1RA) in the Management of Patients with MASLD with Different Stages of Liver Fibrosis	3176
National Trends in the Costs Associated with Metabolic Dysfunction-Associated Steatotic Liver Disease-Related Admissions Stratified by Patient Demographics: An Analysis of US Hospitals	1577	A real-world evidence, phase 4, multicenter, open-label, single-arm study to evaluate the safety and efficacy of saroglitazar 4 mg in patients with non-alcoholic fatty liver disease with obesity, type 2 diabetes mellitus, dyslipidemia, or metabolic syndrome	3177
A1c Goals Reconsidered: Lower A1c Targets Can Improve Progression to Cirrhosis Despite Worsening Mortality for Patients with Type 2 Diabetes and MASLD	1578	The 5-Year Mortality Rate in MASLD Patients Undergoing Pharmacologic versus Bariatric Interventions	3178
Unlocking the Heart-Liver Connection: Exploring Diastolic Heart Failure Risk in MASLD Patients Devoid of Cardiovascular History	1579	A Phase I trial to determine lowest effective dose of betaine for improvement of ALT in metabolic dysfunction-associated steatotic liver disease	3179
Unveiling the Hidden Connection: Exploring the Interplay Between Pericarditis and Metabolic dysfunction-associated steatohepatitis (MASH)	1580	Patterns of Practice for Screening and Management of Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD). Report of a Global Survey.	3180
		Comparing Major Adverse Cardiovascular Event (MACE) incidence in MASLD patients undergoing pharmacologic versus bariatric interventions	3181
		Therapeutic Horizons in Metabolic Dysfunction-Associated Steatotic Liver Disease(MASLD) & Metabolic Dysfunction Associated Steatohepatitis(MASH): A Systematic Review of Current Treatment Option	3182
		Validating pre-identified morphological baseline features for predicting fibrosis progression in MAESTRO-NASH	3184
		Resmetirom protects against diet-induced MASLD and reduces atherosclerosis development in obese Ldlr <sup>-/-</sup> .Leiden mice	3185
		Accurate prediction of liver fat reductions across range of weight loss by quantitative systems pharmacology modeling	3186
		Screening and comparison of current clinical candidates in MASH using human liver spheroids.	3187
Resmetirom effects on NASH with liver fibrosis in patients with NASH genetic risk alleles	4		
A randomized, double-blind, placebo-controlled phase 2 trial to evaluate the efficacy and safety of Chiglitazar in NASH patients	54		
Long-term Liver-related Outcomes and Liver Fibrosis Progression of Statin Usage in Steatotic Liver Disease.	89		
Effect of resmetirom or placebo in NASH fibrosis patients with < 5% or > = 5% weight loss and/or on baseline GLP-1	112		

## MASLD and MASH

### Therapeutics: Approved/available agents

Resmetirom effects on NASH with liver fibrosis in patients with NASH genetic risk alleles	4		
A randomized, double-blind, placebo-controlled phase 2 trial to evaluate the efficacy and safety of Chiglitazar in NASH patients	54		
Long-term Liver-related Outcomes and Liver Fibrosis Progression of Statin Usage in Steatotic Liver Disease.	89		
Effect of resmetirom or placebo in NASH fibrosis patients with < 5% or > = 5% weight loss and/or on baseline GLP-1	112		

The Impact of Liraglutide on Patients with Metabolic Dysfunction Associated Fatty Liver Disease	3188	The Safety and Efficacy of Resmetirom for MASH: A Systematic Review and Meta-Analysis of Randomized Controlled Trials	3206
Pemafibrate improves liver function with alteration of bile acid composition in patients with steatotic liver disease	3189	Oral mannose supplementation dampens liver fibrosis in murine MASH model by reducing activated hepatic stellate cells	3207
Use of non-invasive tests to diagnose and follow NASH with liver fibrosis patients treated with resmetirom	3190	Efficacy and Safety of Resmetirom in Treating Patients with Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): a Systematic Review and Meta-analysis	3208
Differential class effects of oral anti-diabetic drugs on cardiovascular events in patients with metabolic dysfunction-associated steatotic liver disease	3191	Genetic and pharmacological targeting of hepatic oxalate overproduction ameliorates metabolic dysfunction-associated steatohepatitis	3209
Comparison of Bariatric Surgery vs. GLP-1 Receptor Agonists on Cardiovascular Outcomes and Mortality in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease, Diabetes, and Obesity: A Large Population-Based Cohort Study	3192	A small molecule inhibitor of fibroblast activation protein (FAP) blocks enzymatic activity and improves liver histopathology in cynomolgus monkeys with MASH and F1/F2 fibrosis	3210
Saroglitazar is more effective than simvastatin in reducing steatosis in patients with Met-ALD.	3193	TGF- $\beta$ Signaling Targeting Peptide BTI615 Attenuated Liver Fibrosis by Modulating Fibrotic Niche in CCl <sub>4</sub> -induced Mouse-model	3211
Long-Term Hepatoprotective Effects Of GLP-1RA in Obese Patients with Type 2 Diabetes: A Retrospective Cohort Study	3194	Assessment of resmetirom efficacy (80 mg vs. 100 mg) stratified by baseline body mass index and weight in patients from the MAESTRO-NASH trial	3212
		Impact of Resmetirom on Statin Pharmacokinetics and Safety in Phase 1 studies and MAESTRO-NASH	3213
		Engineered Macrophages Expressing Fibrosis-Modifying Transgenes Ameliorate Liver Fibrosis in Preclinical Models	3214
		Metabolism and Therapeutic Effects of N-acyl Amino Acids in Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Atherosclerosis	3215
		First-in-human phase 1 study of the safety and pharmacodynamic effects of OA-235i, a PAR2 pepducin, in adults with metabolic-associated steatotic liver disease (MASLD) and steatohepatitis (MASH)	3216
		ETX-312, a GalOmic™ siRNA, for the Treatment of MASH	3217
		Evaluation of Efficacy of Berberine Ursodeoxycholate (HTD1801) Compared to Ongoing Use of GLP-1 Receptor Agonists in Patients with MASH and T2DM	3218
		Time Course of Onset, Incidence and Prevalence of Gastrointestinal Adverse Events with HTD1801 (Berberine Ursodeoxycholate) in Patients with MASH and T2DM	3219
		Liver enzymes reductions from baseline over time in resmetirom treated patients in a Phase 3 study, MAESTRO-NASH	3220
		A Systematic Review on Resmetirom: Arresting MASH/MASLD Progression	3221
		Efficacy and Safety of Pegbelfermin in MASH Cirrhosis- A Meta-Analysis and Systematic Review of Randomized Controlled Trials	3222
		Enhancement of de novo NAD <sup>+</sup> biosynthesis by ACMSD inhibition counters DNA damage in MASLD/MASH	3223
		Mimeret, a novel mitochondrial-targeted drug, improves hepatic steatosis by stimulating mitochondrial fatty acid beta-oxidation to prevent lipid accumulation	3224
		Sigma1 regulation of hepatic lipid metabolism in response to diet-induced obesity	3225
		Nonclinical Toxicology Profile of ALG-055009, a Novel and Potent Thyroid Hormone Receptor $\beta$ Agonist, for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)	3226
		Massively parallel single nucleus transcriptomics-based in vivo screening identifies novel drug targets to treat MASH	3227
		Durable Upregulation of P1-isoform Hepatocyte Nuclear Factor 4 alpha (HNF4 $\alpha$ ) using Novel Epigenomic Controllers	3228
		★ Real World Data Assessing the Impact of Glucagon-like Peptide-1 Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease	3229
		Improvements in Non-invasive Markers of MASH and Fibrosis Were Associated With Histological MASH Resolution With Tirzepatide Treatment of Non-cirrhotic MASH	3230
Analysis of Non-Invasive Liver Biomarkers in a Phase II Trial of the Glucagon and GLP-1 Receptor Dual Agonist Survodutide in People with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis	94		
Efruxifermin Significantly Improved Liver Fibrosis at Week 96 in the HARMONY Study Across Subgroups and Improvements Were Associated With Changes in Biomarkers	158		
Denifanstat significantly improves liver fibrosis in difficult-to-treat metabolic dysfunction-associated steatohepatitis (MASH) patients. Results from conventional and AI-based pathology from the Phase 2b FASCINATE-2, a 52-week randomized, double blind, placebo-controlled trial of fatty acid synthase (FASN) inhibitor denifanstat, in F2/F3 MASH	3195		
Therapeutic Activity of Resolvin D1 (RvD1) in Murine MASH	3196		
A genome-first approach to coding variants in GPAM reveals an increased risk of steatotic liver disease in the presence of altered lipoprotein profiles across three biobanks	3197		
Comparative efficacy of pharmacologic therapies for MASH in reducing liver fat content: Systematic review and network meta-analysis	3198		
A Therapeutic Human Plasma Fraction Reverses Liver Aging and Steatosis Transcriptome and Improves Liver Regeneration	3199		
CVI-2742, a novel THR-beta selective agonist, exhibits enhanced liver-targeting properties in non-human primates and potent anti-NASH activity in mouse NASH model	3200		
SkQ1, a mitochondria-targeted ferroptosis inhibitor, demonstrates efficacy against steatosis, ballooning and fibrosis in preclinical models of MASH	3201		
Fibrosis Regression After Tirzepatide Treatment of Non-cirrhotic MASH for 52 Weeks Occurred in A Zone-dependent Manner	3202		
Dual Silencing of YAP1/WWTR1 as A Novel Therapeutical Approach for Liver Fibrosis	3203		
Efficacy and Adverse Events of Resmetirom 80 mg in Metabolic Dysfunction-associated Steatohepatitis (MASH): A Systematic Review and Meta-analysis	3204		
Metabolomic and Lipidomic Analysis of Patients with Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treated with the Selective Glucocorticoid Receptor Modulator Miricorilant	3205		

## MASLD and MASH

### Therapeutics: New Agents



Selective Inhibition of Ntrk3 on Hepatic Stellate cells by a Small molecule (LOXO195) Attenuates HCC and Fibrosis in Advanced Mouse MASH and Human Liver Slices	3231
Functional dynamics of MASH Regression Associated Macrophages (RAM)	3232
MASH 2B TRIALS- A SYSTEMATIC REVIEW	3233

## MASLD and MASH

### Treatment: Non-pharmacologic

Aerobic exercise training leads to MASH resolution as defined by the MASH Resolution Index without body weight loss	28
Bariatric surgery improves MRI-determined hepatic proton density fat fraction and metabolic dysfunction-associated steatohepatitis in patients with obesity: A systematic review and meta-analysis	4510
Mediterranean diet and low-fat diet are equally effective in MASLD resolution regardless of PNPLA3 genotype: A randomized controlled trial	4511
Systematic review of exercise for the treatment of pediatric metabolic dysfunction-associated steatotic liver disease	4512
Patient preferences towards attributes of drugs designed to target metabolic dysfunction-associated steatohepatitis: a non-interventional interview study	4513
Moderate-intensity aerobic exercise training improves metabolic syndrome severity in adults with MASLD	4514
Carbohydrate restriction delivered via remote care improves liver markers in individuals with obesity or overweight and abnormal alanine transaminase	4515
Feasibility, Safety and Acceptability of Different Doses of Aerobic Exercise Training in Adults with Histologically-Confirmed MASLD	4516
The Impact of Pomegranate Consumption on Clinical Parameters in MASLD: A Meta-Analysis and a Systematic Review	4517
Unhealthy plant-based diets are associated with hepatic steatosis in young adults.	4518
Evaluating the Impact of DASH diet on Metabolic Associated Steatotic Liver Disease (MASLD): A Systematic Review and Meta-Analysis of Randomized Controlled Trials	4519
Prospective Validation of the Mediterranean Diet Adherence Screener (MEDAS) for Point-of-care Assessment of Diet Quality in Patients with Metabolic Dysfunction-associated Steatotic Liver Disease	4520
Rapid Assessment of Modifiable Risk Factors (RAMS): A Lifestyle Risk Score Based on Open-Source Questionnaires for Clinical Management of Metabolic Dysfunction-associated Steatotic Liver Disease	4521
Effects of the very low energy diet compared to a mediterranean diet on hepatic and metabolic outcomes in metabolic associated steatotic liver disease: A randomised control trial	4522
Multomics analyses decipher intricate changes in the cellular and metabolic landscape of steatotic livers upon dietary restriction and sleeve gastrectomy	4523
Weight Reduction with Intra-gastric Balloon Placement is safe and effective in Obese Decompensated Cirrhosis Patients- An Observational Study	4524
Impact of laparoscopic surgery versus open surgery on long-term outcomes and healthcare utilization in patients with metabolic dysfunction-associated steatotic liver disease and severe obesity	4525

## Metabolic and Genetic Disease

### Hemochromatosis, Wilson Disease, and $\alpha$ -1 Antitrypsin Deficiency

The plasma proteomic profile of subjects with the SERPINA1 Pi*ZZ genotype correlates with liver disease signatures: an analysis of population-level data from the UK Biobank Proteomics Project	16
Convergent evolution of somatic escape variants in the liver in alpha-1 anti-trypsin deficiency.	72
ARBM-101 rescues fulminant Wilson Disease	81
Advances in Prime Editing enable in vivo therapeutic correction of the ATP7B p.H1069Q and p.R778L mutations causing Wilson's disease	201
Liver-directed gene therapy normalizes toxic bile acid metabolite levels in the blood and brain of mice with cerebrotendinous xanthomatosis	230
Evolving Treatment Paradigms in Wilson Disease: Impact of Micro CME on Physician Knowledge and Confidence	4450
N-end Rule-Mediated Proteasomal Degradation of ATGL Promotes Lipid Storage	4451
In Patient Analysis and Outcomes of Liver Transplantation in Patients with Alpha 1 Antitrypsin Deficiency: Study from 2016-2019	4452
Concordance of histological and liquid chromatography mass-spectrometry-based intrahepatic Z-alpha-1 antitrypsin (Z-AAT) burden assessments in patients with alpha-1 antitrypsin deficiency-associated liver disease	4453
Digital image quantification of collagen proportionate area correlates with METAVIR fibrosis stage and liver stiffness measurement via FibroScan in alpha-1 antitrypsin deficiency-associated liver disease	4454
Long-term safety and efficacy of fazirsiran in patients with alpha-1 antitrypsin deficiency-associated liver disease enrolled in the phase 2 placebo-controlled SEQUOIA trial	4455
Prevalence estimates of genotypes associated with alpha-1 antitrypsin deficiency: a retrospective cohort study in the USA	4456
Disease progression in adult patients with alpha-1 antitrypsin deficiency-associated liver cirrhosis: a retrospective cohort study of the US Veterans Affairs Health Database	4457
Comparative Management Practices of Wilson disease among Californian and Italian providers	4458
Plasma proteomic profiling identifies protein level changes associated with Alpha-1 antitrypsin deficiency liver disease pathways	4459
Exchangeable copper quantification falls below normal range in a high proportion of patients with Wilson disease during follow-up.	4460
RNA editing for the treatment of Alpha-1 antitrypsin deficiency	4461
Prediction of hepatic and pulmonary endpoints in a longitudinal cohort of individuals with homozygous alpha-1 antitrypsin deficiency (Pi*ZZ genotype)	4462
Metabolomic studies of Wilson's disease Metabolomics studies of Hepatolenticular degeneration disease	4463
Liver Elastography measurement is pertinent for fibrosis assessment and estimation of the severity of cirrhosis in patients with Wilson's disease	4464
Clinical and laboratory profile of adult patients with idiopathic cholestatic liver disease according to the presence of MDR3 mutations	4465
Thrombocytopenia predicts the long-term liver outcomes in Wilson's disease	4466
Targeting Sphingosine 1-phosphate Signaling to Ameliorate Hepatic Injury in Wilson Disease	4467

BMN 349, a small molecule for alpha-1 antitrypsin associated liver disease, stabilizes human Z-AAT and reduces severity of liver disease in the PiZ mouse model	4468	Liver Lymphatic Changes in Biliary Atresia from Diagnosis to Transplant	4429
Hepatic Manifestations in an Adult Cohort of Patients with Telomere Biology Disorders.	4469	The relationship between serum bile acids and event-free survival following the use of maralixibat for Progressive Familial Intrahepatic Cholestasis: Data from MARCH/MARCH-ON	4432
Bioanalytical methods to assess pharmacokinetics and pharmacodynamics of BMN 349, a small molecule therapeutic for alpha1 antitrypsin deficiency	4470	Portal Vein hypoplasia is present in patients with biliary atresia at the time of diagnosis	4435
The Alpha-1 Foundation Research Registry: Liver Profile and Diagnostic Disparities Among Alpha-1 Antitrypsin Deficiency Patients in the United States	4471	Bile acid subspecies are correlated with pruritus and bilirubin improvement in PFIC patients treated with maralixibat: Data from MARCH and MARCH-ON	4436
Comprehensive genetic testing of Wilson Disease patients with only 0 or 1 known pathogenic ATP7B-variant.	4472	Prognostic Value of Quantifying Time to Achieve Normal Bilirubin Levels after Kasai Portoenterostomy in Biliary Atresia	4444
[64Cu]-Methanobactin (SB2) biodistribution and excretion examined in pigs by whole-body PET/CT - pharmacokinetics of a potential new treatment for Wilson disease	4473		
Modulation of a Mouse Model of Metabolic Dysfunction-Associated Steatohepatitis by Trientine Tetrahydrochloride (TETA 4HCL)	4474		
Real-World Utility of Zinc Monotherapy in a Large Cohort of Individuals with Wilson Disease	4475		
Long-term metabolic, phenotypic, and neuropathological characterization of the Cyp27a1-/- mouse model of cerebrotendinous xanthomatosis	4476		
PAS-D Globules are Prognostic of Liver Disease in Heterozygous Alpha-1 Antitrypsin Deficiency	4477		
Performance of Non-invasive Tests to Predict the Risk of Development of Hepatic Events in Patients with Alpha-1-Antitrypsin Pi*ZZ Deficiency	4478		

## Pediatric Hepatology

### Biliary Atresia and Neonatal Cholestasis

★ Intrinsic NF- $\kappa$ B activation controls cellular defects, viral susceptibility, and macrophage activation in biliary atresia cholangiocytes	123
Improvements in pruritus are associated with improvements in growth in patients with progressive familial intrahepatic cholestasis: Data from the MARCH-ON trial	184
Human Disease is Recapitulated by A Novel Biliary Atresia Through Targeted Endothelial Destruction System	215
★ An Ultrasound Approach to Visualize the 'Duct at the Hilum' in Infants Undergoing Evaluation for Biliary Atresia	232
MMP-7 elevation in neonates with congenital heart disease and cholestasis	4396
Increased Hepatic Cellular Senescence at Diagnosis in Biliary atresia is Associated with Longer Duration of Survival with Native Liver	4397
Biliary atresia in the developing world: urgent need of changing track to improve outcome.	4399
Interleukin 8-CXCR2 Mediated Neutrophil Extracellular Trap (NET) Formation in Biliary Atresia Associated with NET-Induced Stellate Cell Activation	4407
Drug Induced Liver Injury in Biliary Atresia: Development of Monitoring Guidelines for Interventional Clinical Trials using Prospective Longitudinal Data from over 1200 Children	4413
Complement receptor C5ar1 controls liver macrophage oxidative-antioxidant balance and inflammasome assembly in biliary atresia	4423
Revisiting NK cells in biliary atresia: Complement receptor C5ar1 licenses NK cells to recognize and kill cholangiocytes	4424
Serum Values in Biliary Atresia Patients as Indicators for Native Liver Survival: A Systematic Review and Meta-Analysis	4426

## Pediatric Hepatology

### Metabolic and Genetic Diseases

Plasma Multi-omics Indicate that Mitochondrial Stress and Altered Amino Acid Metabolism Contribute to Sarcopenia in Children with Genetic Cholestatic Liver Disease	58
A first-in-class tool to predict future risk of portal hypertension, liver transplant and death in children with alpha-1-antitrypsin deficiency based on prospective data from the Childhood Liver Disease Research Network	153
Clinical Status and Liver Histology at Liver Transplantation in Progressive Familial Intrahepatic Cholestasis - Experiences from the Childhood Liver Disease Research Network.	161
Liver Disease Screening Disparities in Hispanic and Publicly Insured Children with Cystic Fibrosis	4392
Ambient Air Pollution Exposure is Associated with Advanced Liver Stiffness Among Latino Youth with Preexisting Risk Factors for Liver Damage	4394
Extracellular Vesicle miRNA analysis from Adolescents with MASLD with and without Obstructive Sleep Apnea/Chronic Intermittent Hypoxia	4408
Deep Phenotyping of a North American Cohort of Bile Acid Synthetic Disorders	4415
Required dose and effects of NTBC treatment for hereditary tyrosinemia type 1: confirmations and surprises from a novel, representative human model	4431
Bile Salt Exporter Pump (BSEP) deficiency in children from Indian PFIC registry: differences from the NAPPED cohort	4438
Missense variations in FADS1 and SCD1 genes oppositely affect lipid profile and epicardial fat thickness in Italian children with MASLD: a possible monitoring tool also in adults?	4439
Patient characteristics, management, and progression of lysosomal acid lipase deficiency (LAL-D) in France using real-world data from the National Health Data System (SNDS)	4440
Metabolic Dysfunction-associated and Alcoholic Cirrhosis Drive Distinct Stellate Cell Phenotypic Patterns	4443
Improvement in sequelae of chronic liver disease in patients with Alagille Syndrome treated with maralixibat	4445

## Pediatric Hepatology

### Pediatric Liver Disease - Basic Science

Defining the liver immune microenvironment of Indeterminate Pediatric Acute Liver Failure with single-cell transcriptomics	177
--	-----

★ Noninflammatory macrophages drive a fibrogenic gene program of periductal fibroblasts in pediatric primary sclerosing cholangitis.	196	Combined T and B cell mismatched epitope load as a prognostic biomarker of prolonged DSA-free survival in pediatric liver transplantation.	4447
Mechanism of Lauric Acid-mediated hepatobiliary protection during acute inflammatory cholangiopathy in mice	4404	Pediatric acute liver failure with concurrent aplastic anemia: a multicenter retrospective case series	4449
Macrophage-specific HIF1 $\alpha$ inhibition activates hepatic STAT6 and protects from Parenteral Nutrition-Associated Cholestasis	4405		
Mechanism of STAT3 role in the protective effects of FXR agonist in chronic mouse model of inflammatory cholangiopathy	4406		
Multi-omic Analysis of Pediatric Acute Liver Failure Identifies Immunomodulatory and Exhaustive Phenotypes that Predict Survival with Native Liver	4422		
The impact and treatment possibilities of neddylation in pediatric liver cancer: hepatoblastoma	4428		
Correlation between liver biopsy histopathology and liver ultrasound, elastography and laboratory data in patients status-post Fontan procedure	4434		

## Pediatric Hepatology

### Pediatric Liver Transplantation

Identification of Novel Class I HLA Alleles and T-cell Repertoire Features Associated with Indeterminate Pediatric Acute Liver Failure	2
Characterizing the Onset and Clinical Manifestations of Chronic Liver Disease in Patients with Post-Fontan Physiology.	4395
Adenovirus infection following pediatric liver transplant: incidence and outcomes.	4398
Impact of Maralixibat on Caregiver Burden for Patients with Alagille Syndrome and Progressive Familial Intrahepatic Cholestasis	4400
Assessment of Liver Fibrosis through Shear Wave Elastography in Pediatric Liver Transplant Recipients	4410
Fontan-associated liver disease: the role of liver elastography assessments pre and post orthotopic heart transplant	4411
Acute-on-Chronic Liver Failure (ACLF) in children with cirrhosis is associated with worse post-transplant survival and increased resource utilization.	4412
Association of abnormal global longitudinal strain with waitlist decompensation and mortality in children with biliary atresia	4416
To investigate the roles of gut microbiota and their metabolites in modulating the pediatric liver transplant outcomes	4417
Improving Time to Antibiotics for Febrile Pediatric Liver Transplant Patients - An Emergency Department Based Quality Improvement Intervention	4418
Real-world Use of Maralixibat in Biliary Atresia: A Case Series	4419
Tailoring Immunosuppressive Treatment Through the Follow-up Liver Biopsy Program in Pediatric Liver Transplant Recipients	4420
The use of a single procedure biodegradable stenting to treat biliary anastomotic strictures in pediatric liver transplantation	4421
Utility of fungal biomarker, Beta-D-glucan (BDG) for the diagnosis and antifungal usage in pediatric liver and multivisceral transplant recipients	4425
Merging Surgical and Medical Expertise in a Pediatric Liver Intensive Care Unit	4433
Impact funding for pediatric liver transplantation reduces the incidence of financial toxicity for patient families	4437
Ferroptosis Regulation by Deferoxamine Protects Against Ischemia Reperfusion Injury in Marginal Donor Livers	4442

## Pediatric Hepatology

### Viral and Autoimmune Liver Disease

★ Circulating Activated Tissue Resident Memory CD8+ T cell Population is a Unique Feature of Pediatric Activated T-cell Acute Liver Failure and Hepatitis Associated Aplastic Anemia	36
Decline of Pediatric Acute Hepatitis of Unknown Etiology During the Coronavirus Disease 2019 Pandemic in Japan.	56
★ Serum IgG reflects histological activity in children with autoimmune hepatitis	76
Clinical Factors Impacting the Health-Related Quality of Life of Children and Young Adults with Autoimmune Liver Disease	172
Children With Chronic Hepatitis C Have A High Prevalence of Neurodevelopmental Disorders	4401
Advanced hepatic fibrosis by MR Elastography is associated with abnormal serum liver biochemistries in pediatric Primary Sclerosing Cholangitis (PSC).	4409
Exploring disease-associated genetic variants in Japanese pediatric patients with autoimmune liver disease: a multicenter study	4414
Neonatal acute liver failure secondary to enteroviruses: clinical characteristics and outcome	4427
Characteristics of HBV integration in pediatric patients with chronic hepatitis B infection	4441
SURFASA Score for prediction of steroid response in children and adolescents with severe autoimmune hepatitis	4446
Longitudinal liver stiffness measurement by vibration-controlled transient elastography in pediatric patients with primary sclerosing cholangitis	4448

## Portal Hypertension and Other Complications of Cirrhosis

### Ascites, Renal Dysfunction, and Hepatorenal Syndrome

Point-of-care Ultrasound (POCUS) to assess impact of +D8+A8: B2662+A8:B2251+A8:B2254	7
Carvedilol is Associated with Lower Mortality than Other Nonselective Beta Blockers in Patients with Cirrhosis	32
Measurement of effective albumin concentration significantly improved prediction of one year mortality in patients with acutely decompensated cirrhosis without acute-on-chronic liver failure	48
★ Carvedilol does not prevent decompensation in patients with compensated cirrhosis without high-risk varices with clinically significant portal hypertension defined by non-invasive tests: a randomised controlled trial	68
Targeting lower serum albumin with long term albumin administration improves outcomes of recurrent ascites in patients with decompensated cirrhosis- Final results of the randomised controlled trial	190

Carriage of the Z allele of the SERPINA1 gene as a predisposing factor for the development of hepatorenal syndrome in patients with decompensated liver cirrhosis	211	A Decision Aid for the Timing of Paracentesis for Patients with Cirrhosis and Ascites: A Single Center QI Initiative	4132
Conjugated, Sulfated, and Amphipathic Bile Acids are Associated with Acute Kidney Injury Recovery in Patients with Decompensated Cirrhosis: An Untargeted Metabolomics Study	218	Statin Use in Cirrhosis Can Decrease Risk of Portal Hypertension and Mortality	4152
A multi-scale computational model of the hepatic circulation applied to predict the portal pressure after transjugular intrahepatic portosystemic shunt (TIPS)	4064	Ascites Care in Academic versus Community Setting: Are they Equal or Not the Same?	4154
Comparative Analysis on the Healthcare Disparities and In-Patient Mortality of Hepatorenal Syndrome among Different Liver Cirrhosis Etiologies: Insights from the National Inpatient Sample 2020 Database	4066	The characteristics and long-term outcomes of etiology-specific cirrhosis: a 15-year study of Stanford Cirrhosis Cohort	4155
Proteomic and Metabolomic Analysis from the CONFIRM Trial shows Biomarkers that Predict HRS Reversal without Vasoconstrictor Therapy	4067	Alfapump System in Refractory Ascites: Results from the POSEIDON Study at 24 months	4157
Acute kidney injury development is associated with mortality in Japanese patients with cirrhosis: Impact of amino acid imbalance	4068	Exploring the impact of leaky gut syndrome marker sCD14 on treatment outcomes in liver cirrhosis with water retention	4159
Sarcopenia as an Independent Factor for Mortality in Liver Cirrhosis Patients with Spontaneous Bacterial Peritonitis	4074	Serum N-glycans as Predictive Biomarkers for Recompensation in Patients with Chronic Hepatitis B and Decompensated Cirrhosis	4165
ADAMTS13 Deficiency Exacerbates Acute Kidney Injury in Acute-on-chronic Liver Failure Mouse Model	4079	Thrombospondin-1 as a Predictive Biomarker for Recompensation in Patients with Chronic Hepatitis B and Decompensated Cirrhosis	4168
Diagnostic accuracy of the neutrophil/lymphocyte ratio for diagnosing spontaneous bacterial peritonitis.	4082	Efficacy and Safety of Tenofovir Alafenamide in Patients with Decompensated Hepatitis B Cirrhosis	4169
SGLT2 inhibitor is promising as a novel agents for resolving cirrhotic ascites	4087	★ Rising Mortality Trends Among Adults with Chronic Kidney Disease and Cirrhosis in the United States (1999 to 2020): A Study of Health Disparities	4170
The impact of pre-existing chronic kidney disease on the updated definition of AKI-HRS.	4088	Observational longitudinal study divulges biological pathways and predictive biomarkers by urinary proteomics in patients with acute kidney injury in decompensated cirrhosis.	4172
Flinders Albumin in the Home (FAITH): A Feasibility Study	4090	Renal resistive index - a novel predictor of contrast-induced acute kidney injury in cirrhosis	4190
The impact of terlipressin treatment on liver transplantation rates in patients with hepatorenal syndrome-acute kidney injury (HRS-AKI) in the context of the changing MELD score definitions	4092	Epidemiology and Outcomes of Ambulatory Community Acquired Acute Kidney Injury: A Nationwide us Veterans Study	4195
Patience is a Virtue: Evidence for Waiting Until Day 4 and After 12 Doses of Terlipressin Before Evaluating Treatment Response in Patients with HRS-AKI	4094	Sociodemographic Characteristics and Outcomes of Patients Hospitalized With Hepatorenal Syndrome. A Nationwide Analysis	4199
The Effect of Obesity on the Clinical Response to Terlipressin in Patients With Hepatorenal Syndrome: Retrospective Assessment From a Pooled Patient Cohort	4095	The Physiological Determinants of Symptom Burden in Cirrhosis with Ascites	4202
Role of High Versus Standard Dose of Terlipressin in Reversing HRS-AKI: Pooled Analysis from Phase 3 Clinical Trials	4096	Impact of Intravenous Albumin Infusion on 28-Day Mortality and Complications in Patients with Acutely Decompensated Cirrhosis: A Propensity Score Matching Analysis	4213
PHIN-214: Phase 1 study in compensated and decompensated patients with cirrhosis - a novel treatment to manage complications of portal hypertension with subcutaneous, once-daily self-administration.	4100	Impact of sarcopenia on complications of liver cirrhosis: A National Inpatient Sample study (2018-2020)	4221
Paracentesis Exceeding Three Liters Increases Risks of Acute Kidney Injury Even in Cirrhotic Patients with Albumin Infused Refractory Ascites	4106	Intravascular volume overload in patients with decompensated cirrhosis and associated with a lower tolerability of intravenous albumin and worse outcomes, a single center, prospective, cohort study.	4224
★ Impact of the different stages of acute kidney injury in cirrhosis - a prospective multicenter cohort study	4107		
Effect of Pro-Dopamine Oral Docarpamine on Ascites: An open-label phase 2a study to assess safety and effectiveness in patients with Refractory Ascites due to Liver Cirrhosis	4108		
Peritoneal myeloid-derived suppressor cells characteristics define outcomes of patients with decompensated liver cirrhosis	4109		
Comparative Prognostic Value of MELD, MELD-Na, and MELD 3.0 in Predicting Survival After TIPS Placement	4115		
Global Socioeconomic Disparities Affect Acute Kidney Injury Outcomes in Hospitalized Patients with Cirrhosis: An Analysis of the International Club of Ascites GLOBAL AKI Study.	4127		
Practice Heterogeneity and Diagnostic Yield of Routine Outpatient Paracentesis Fluid Studies in Patients with Cirrhosis	4130		
The Association Between Albumin Administration and Acute Kidney Injury Outcomes in Patients Hospitalized with Spontaneous Bacterial Peritonitis	4131		
		<b>Portal Hypertension and Other Complications of Cirrhosis</b>	
		<b>Encephalopathy, Infections, and Other Complications</b>	
		Major Variations in 90-day Mortality post-hospital Discharge among Inpatients with Cirrhosis: A Prospective Cohort Study for the CLEARED Consortium	55
		Efficacy of Carvedilol + Ivabradine vs Carvedilol alone for left ventricular diastolic dysfunction in cirrhosis and impact on decompensation, cardiac function and survival; an open label randomized controlled trial.	144
		Child-Turcotte-Pugh (CTP) score-based Modified Anti-Tubercular Treatment (ATT) in Patients with Decompensated Cirrhosis with Tuberculosis: A Two-year Single Centre Retrospective Observational Study from a Hepatologist in North India.	4055
		Clinical Impact of Respiratory Alkalosis in Liver Transplantation Candidates	4056

## Portal Hypertension and Other Complications of Cirrhosis

### Encephalopathy, Infections, and Other Complications

Major Variations in 90-day Mortality post-hospital Discharge among Inpatients with Cirrhosis: A Prospective Cohort Study for the CLEARED Consortium	55
Efficacy of Carvedilol + Ivabradine vs Carvedilol alone for left ventricular diastolic dysfunction in cirrhosis and impact on decompensation, cardiac function and survival; an open label randomized controlled trial.	144
Child-Turcotte-Pugh (CTP) score-based Modified Anti-Tubercular Treatment (ATT) in Patients with Decompensated Cirrhosis with Tuberculosis: A Two-year Single Centre Retrospective Observational Study from a Hepatologist in North India.	4055
Clinical Impact of Respiratory Alkalosis in Liver Transplantation Candidates	4056



Causes of Markedly Elevated Aminotransferases in Patients with Cirrhosis	4057	Systematic Review and Meta-Analysis of Randomized Controlled Trials	
Association Between Pre-operative TIPS and Post-Operative Mortality in a Veterans Affairs Cohort	4059	Increased rates of ACLF and liver-related death in patients with alcohol-related cirrhosis and ongoing alcohol use after TIPS placement	4136
Hepatic Encephalopathy Defined using Hospitalizations significantly Adds to Risk Prediction for 90-day and 1-year mortality above the MELD3.0 and MELD-Na scores in a National Cohort of Veterans.	4061	Muscle composition is associated to frailty, physical performance, and quality of life in patients undergoing MRI-based HCC surveillance - baseline data from the multi-center cirrhosis cohort study ACCESS-ESLD	4137
Arginine glutamate injection for the treatment of mild hepatic encephalopathy: an open label, randomized, controlled, non-inferiority trial	4062	Hyperammonemia Increases Susceptibility to Oxidative Stress in Skeletal Muscle via Impaired Keap1-Nrf2 Pathway Function	4138
Blood metabolomics predict 6-month hospitalizations in a multi-center prospective North American cohort of outpatients with cirrhosis	4071	The prophylactic antibiotics do not influence the clinical outcomes of patients with Child A cirrhosis and acute variceal bleeding	4140
Sleep Related Breathing Disorders in Liver Transplant Candidates with Cirrhosis	4072	WFA+-M2BP is a useful biomarker for identifying the risk of minimal hepatic encephalopathy in cases with high MR elastography values	4141
Elevation of Conjugated Bile Acids and IL-6 in Chronic Liver Diseases Regulates Muscle Types and Inflammation	4073	Frailty and nutritional risk significantly increase liver disease-related adverse clinical outcomes in patients with cirrhosis - a single centre, prospective cohort study	4142
The dedicated TIPS stent was associated with a reduced risk of post-TIPS hepatic encephalopathy	4076	Community Acquired Sepsis Mortality Trends in a National Cohort of Patients with Cirrhosis	4145
The prognostic significance of serum thyroid hormones levels in patients with liver cirrhosis requiring hospitalization.	4078	Digital phenotype varies by alcohol use history and hepatic encephalopathy	4146
Interactions between sarcopenia, frailty and resting energy expenditure in patients with cirrhosis and portal hypertension	4080	Distribution of Organisms in Patients with Spontaneous Bacterial Peritonitis: A Veteran's Health Cohort Study	4147
Ammonia is an independent predictor of mortality in acutely decompensated cirrhosis patients: Time to change the paradigm?	4083	Baseline Satisfaction Scores for Patients with ESLD in PAL-LIVER Cohort Similar between VA and Non VA centers and Different Etiologies of Liver Disease	4148
Ascites Fluid Calprotectin Level and Ratio of Calprotectin to Total Protein for the Diagnosis of Spontaneous Bacterial Peritonitis: A Systematic Review and Meta-Analysis	4084	Assessing the Impact of Age on the Outcomes in Patients Presenting with Spontaneous Bacterial Peritonitis	4158
Inflammatory Sarcopenia in Chronic Liver Disease: A Novel Concept and Its Prognosis	4085	Lactulose-induced hypervolemia in cirrhotic patients with hepatic encephalopathy	4160
Predictors of In-Hospital Mortality for Patients with Cirrhosis After Index Episode of Spontaneous Bacterial Peritonitis	4091	Efficacy of Lactulose Alone versus Lactulose with Polyethylene Glycol in the Treatment of Hepatic Encephalopathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials	4161
Prognostic Value of Sarcopenia on the Recurrence of Hepatic Encephalopathy	4093	Postoperative Survival in Cirrhotic Patients: The Role of Sarcopenia	4162
Role of Zinc in Managing Covert Hepatic Encephalopathy during the Latency period of Abnormal Ammonia Metabolism in Cirrhosis	4099	Understanding the Impact of the Weekend Effect on Patients Presenting with Spontaneous Bacterial Peritonitis	4164
Percutaneous cholecystostomy tube placement for acute cholecystitis in patients with liver cirrhosis is associated with morbidity, healthcare burden, and patient mortality.	4103	Analysis of Thromboembolic Events in Patients with Cirrhosis	4166
Serum ammonia as a predictor of 6-month clinical outcomes in patients with liver cirrhosis	4111	Significant differences in in the overall and cause-specific survival rates across subgroups of patients with cirrhosis	4167
Risk of Hepatic Decompensation and HCC in Patients with Cirrhosis Significantly Differs by Liver Disease Etiology	4112	Disseminated Coccidioidomycosis in Patients with Chronic Liver Disease: A Single-Center Experience	4174
Reduced REM Sleep Measured by Wearable Technology is Associated with Poor Overall Wellbeing in Cirrhosis	4113	Rifaximin Improves Frailty In Patients With Decompensated Cirrhosis: Randomised trial	4175
Assessing the Role of 'The Weekend Effect' on Patient Outcomes Following TIPS Procedure in a North American Tertiary Care Center	4114	Assessment of the Relationship Between MRI-Based Intramuscular Fat Indicating Sarcopenia in Various Muscle Groups Among Patients with Chronic Liver Disease	4176
Sleep Disturbance and Impact on Health-Related Quality of Life, Frailty, and Minimal Hepatic Encephalopathy in Thai Cirrhotic Patients: A Cross-Sectional Study	4122	Increased Stool Urease activity is an Independent Predictor of Overt HE in Cirrhosis	4177
Survival of patients whose initial acute decompensation was hepatic encephalopathy	4124	Rifaximin Claim Rejections Resulting in Delayed Treatment among Patients with Overt Hepatic Encephalopathy: An Analysis of Prescriber Specialty	4180
Chronic Pulmonary Aspergillosis on a rise in liver disease patients: Study of prevalence, antifungal profile and predictors of mortality from tertiary care centre in India	4126	Skeletal Sarcopenia is Associated with Decreased Interventricular Septal Thickness in patients with Cirrhosis: Findings from a Dual-Center Study	4181
Impact of NOD2 genotype-guided antibiotic prevention on survival in patients with cirrhosis and ascites: results of the double-blind randomized controlled INCA trial	4128	Hyperammonemia induces an ATM-mediated DNA damage response in cerebellar and hippocampal neurons	4182
Intercostal Chest Tube Placement to Manage Hepatic Hydrothorax: Increasing Trends Despite Negative Impact on Patient Morbidity and Survival	4129	Impact of an inpatient 'quality bundle' on post-discharge mortality in patients with spontaneous bacterial peritonitis	4183
Evaluating the Impact of Branched-Chain Amino Acid Supplementation and Exercise on Sarcopenia in Cirrhosis: A	4135	Reduction of unnecessary CT head use in cirrhotic patients presenting with hepatic encephalopathy	4186
		Ablation of neuronal senescence attenuates the cognitive deficits observed in a mouse model of Type C HE	4187
		Patients With Cirrhosis and a History of Overt Hepatic Encephalopathy Experienced Lower 6-Month All-Cause	4192

Mortality Rates With Rifaximin Monotherapy Versus Lactulose Monotherapy		Endurance exercise promotes favorable gut microbiome composition during hyperammonemia	165
Assessment of sarcopenia with ultrasound-based measurements in patients with chronic liver disease.	4193	Targeting Liver Lymphatic Drainage: A Novel Approach to Treat Liver Cirrhosis and Portal Hypertension	223
Sarcopenia Exacerbates Liver-Related Complications in Patients with Cirrhosis and Hepatic Encephalopathy: A Nationwide Analysis Highlighting Inpatient Outcomes and Gender Differences.	4196	Liver sinusoidal endothelial cell responses to hepatic congestion instigate $\beta$ -catenin dependent proliferative responses in peri-central hepatocytes	224
Healthcare Utilization, Outcomes, and 30-Days Readmissions of Patients With Malnutrition in Decompensated Cirrhosis.	4197	Glucagon-like peptide-1 receptor agonist, semaglutide prevents liver cirrhosis-induced skeletal muscle atrophy in diabetic mice	4054
Rifaximin Soluble Solid Dispersion Immediate-Release Tablets for Prevention and Delay of the First Episode of Hepatic Encephalopathy: RED-C Phase 3 Study Design	4198	Evaluating ChatGPT-4o's Real-Time Clinical Assessments and Recommendations in Complex Hepatology Cases Using Voice Prompts	4077
Short-term primary rifaximin prophylaxis has no beneficial role in patients with cirrhosis.	4200	Tofogliflozin Ameliorates Portal Hypertension Along With Liver Fibrosis Progression by Inhibition of Sinusoidal Capillarization in Rats With Liver Cirrhosis	4081
Predictors of outcomes of bacterial infections in patients with advanced liver disease	4203	Post procedural complications of transjugular and percutaneous liver biopsies performed by hepatologists at a transplant center	4102
Determinants and impact of impaired aerobic capacity on survival in patients with cirrhosis: results from a 2600 patient cohort.	4204	Exploration for non-invasive surrogate markers for hepatic venous pressure gradient in portal hypertension and stratification of long-term prognosis	4119
Utilization of Endoscopic Ultrasound-Guided Liver Biopsy with Portal Pressure Gradient Measurements for Risk-Stratification of Liver Disease in Solid Organ Transplant Candidates - A Single Center Experience	4205	Relationship between portosystemic shunts and life prognosis of chronic liver disease and PoPH.	4123
Albumin administration and hypoxia in patients with cirrhosis	4207	Exercise during hyperammonemia activates adaptive skeletal muscle ammonia metabolism	4149
The Diagnostic Value of Speckle Tracking Echocardiography in Cirrhotic Cardiomyopathy	4208	Novel Cannabinoid -1 receptor (CB1R) antagonist Genistein restores hepatic microvascular function, reduces liver fibrosis and ameliorates portal hypertension	4171
Accuracy of Noninvasive Tests in Detecting Endoscopically or Radiographically Identified Clinically Significant Portal Hypertension in Compensated Cirrhosis	4209	Exosome Therapy in Hepatic Osteodystrophy Management: Evaluating Therapeutic Efficacy Across the Bone-Liver Axis	4179
The frailty component of hepatic encephalopathy - exploring physical and cognitive function in advanced chronic liver disease.	4210	Sweat Interleukin-6 Is Associated with Reduced Transplant-Free Survival in Veterans with Decompensated Cirrhosis	4185
The Impact of Zinc Deficiency and Nutritional Status on the Development of Overt Hepatic Encephalopathy in Cirrhosis Patients: A Prospective Cohort Study	4212	Increased EUS-Guided Portal Pressure Gradient Measurements Predicts Hepatic Decompensation in Compensated Cirrhosis	4211
Echocardiographic parameters of diastolic cirrhotic cardiomyopathy and post-liver transplant outcomes in patients with chronic liver disease and acute alcohol associated hepatitis	4214		
Simplifying sarcopenia assessment: The potential utility of cystatin C to serum Creatine ratio as a simple laboratory predictor of outcomes among patients with advanced cirrhosis.	4215		
Increased risk of Clostridioides difficile infection in patients with cirrhosis on secondary prophylaxis for spontaneous bacterial peritonitis: A retrospective matched cohort study	4216		
Simvastatin ineffective in improving hepatopulmonary syndrome in cirrhosis patients (HEPSIM Trial) - results of a double-blind randomized controlled trial [NCT05187715]	4217		
Pentoxifylline improves hepatopulmonary syndrome - results of a double-blind randomised placebo-controlled trial [PENHELPS Trial] [NCT05373134]	4219		
Outcomes of TIPS in Native Americans: A Single-Center Experience	4220		
Immunometabolic profiling of the hepatic encephalopathy model mouse	4222		
Differential immune response in Cirrhotics with COVID-19 associated Mucormycosis compared to COVID-19 and healthy controls	4226		
<b>Portal Hypertension and Other Complications of Cirrhosis</b>		<b>Portal Hypertension and Other Complications of Cirrhosis</b>	
<b>Experimental</b>		<b>Varices and Bleeding</b>	
Injured hepatocytes-secreted extracellular vesicles promote cirrhosis-associated skeletal muscle injury through mtDNA-cGAS-STING axis	45	Preemptive TIPS: the new standard for gastric variceal bleeding in patients with cirrhosis? Results of a large multicenter randomized controlled trial	5
		★ The Portal Decompenation Score - A Validated Predictive Model of Portal Hypertension Related Liver Decompenation events in Cirrhosis	27
		Three-dimensional MR Elastography Predicts Clinically Significant Portal Hypertension in patients with cirrhosis: A Prospective Multicenter Study	88
		The risk of portal vein thrombosis in patients with portal hypertension taking beta-blockers: A retrospective comparative study from a multi-institutional database.	100
		Natural history and predictors of outcomes in patients with liver cirrhosis after index variceal hemorrhage from fundal varices	187
		Spleen stiffness is reliable in assessing hemodynamic response and prediction of rebleeding on beta-blocker therapy for secondary prophylaxis of variceal bleed-BETA-RESPONSE study.	231
		Technical feasibility and efficacy of transjugular intrahepatic portosystemic shunt via middle hepatic vein access in patients with cirrhosis and portal hypertension	4058
		Simultaneous liver biopsy and endosonographic portal pressure measurement can safely be performed without use of antibiotics	4060

## Portal Hypertension and Other Complications of Cirrhosis

### Experimental

Injured hepatocytes-secreted extracellular vesicles promote cirrhosis-associated skeletal muscle injury through mtDNA-cGAS-STING axis	45
---	----

## Portal Hypertension and Other Complications of Cirrhosis

### Varices and Bleeding

Preemptive TIPS: the new standard for gastric variceal bleeding in patients with cirrhosis? Results of a large multicenter randomized controlled trial	5
★ The Portal Decompenation Score - A Validated Predictive Model of Portal Hypertension Related Liver Decompenation events in Cirrhosis	27
Three-dimensional MR Elastography Predicts Clinically Significant Portal Hypertension in patients with cirrhosis: A Prospective Multicenter Study	88
The risk of portal vein thrombosis in patients with portal hypertension taking beta-blockers: A retrospective comparative study from a multi-institutional database.	100
Natural history and predictors of outcomes in patients with liver cirrhosis after index variceal hemorrhage from fundal varices	187
Spleen stiffness is reliable in assessing hemodynamic response and prediction of rebleeding on beta-blocker therapy for secondary prophylaxis of variceal bleed-BETA-RESPONSE study.	231
Technical feasibility and efficacy of transjugular intrahepatic portosystemic shunt via middle hepatic vein access in patients with cirrhosis and portal hypertension	4058
Simultaneous liver biopsy and endosonographic portal pressure measurement can safely be performed without use of antibiotics	4060

Baseline patients' characteristics from NAVIGATE, a seamless adaptive Phase 2b/3 trial of Belvectin in MASH cirrhosis and portal hypertension.	4063	Vascular Phenotyping for Predictive Assessment of Transjugular Intrahepatic Portosystemic Shunt (TIPS) Therapy in Portal Hypertension	4143
Safety and Tolerability of Simvastatin 40mg in a Prospective Multicenter Randomized Blinded Controlled Trial of Child-Turcotte-Pugh A Patients with Clinically Significant Portal Hypertension	4065	Validation and comparison of non-invasive prediction models based on spleen stiffness measurement to identify cACLD patients with gastroesophageal varices	4144
Gastroesophageal Balloon Tamponade for Acute Variceal Hemorrhage is Associated with High In-hospital Mortality and Infrequent Palliative Care Consultation	4069	Validating and expanding the Baveno 'Rule of Five' criteria for stratifying risk of portal hypertensive complications	4150
Predicting high risk for decompensation events in patients with compensated cirrhosis using easily accessible patient data	4070	TIPS and Variceal Embolization in Pediatric Patients with Variceal Bleeding Secondary to Portal Hypertension: A Retrospective Study	4151
Cardiac Failure following Transjugular Intrahepatic Portosystemic Shunt in patients with cirrhosis	4075	Transfusion of blood products in the setting of a variceal bleed is associated with higher risk of TIPS, intubation, hospital re-admission, and mortality	4153
Analysis of risk factors for lower extremity deep venous thrombosis in patients with liver cirrhosis complicated with gastrointestinal bleeding	4086	Esophageal Varices Screening in Patients With Cirrhosis: Hospital-Affiliated GI Clinic VS Private Practice GI Clinic	4156
The SpleenPlatelet score for screening of high-risk varices by two-dimensional shear wave elastography in patients with compensated advanced chronic liver disease: A prospective multicenter study	4089	Six-week mortality after acute variceal bleeding is higher in non-alcohol-related etiologies of cirrhosis: An International Multicenter Study	4163
Pilot Study of a Model Based on Noninvasive Assessments of Portal-Systemic Shunting (HepQuant DuO), Hepatic Fibrosis (FibroScan), and Splenic Congestion (Platelet Count) for Accurate Prediction of Portal Hypertension and Clinically Significant Portal Hypertension	4097	Acute hemodynamic response to Carvedilol in cirrhotic children with clinically significant portal hypertension.	4173
★ Comparison of 1 Day Versus 5 Days of Octreotide Infusion Along With Endoscopic Therapy in Preventing Early Rebleeding and Mortality From Esophageal Varices: A Nationwide, Multicenter, Non-inferiority, Randomized Control Trial	4098	The impact of esophageal varices on the prognosis of patients with cholangiocarcinoma: A single center retrospective study	4184
To evaluate the efficacy of TIPS combined with embolization of large spontaneous portosystemic shunts in treating cirrhotic portal hypertension with esophagogastric variceal bleeding	4101	Significance of neutrophil-to-lymphocyte ratio in bleeding and prognosis after endoscopic treatment of cirrhotic patients with esophageal varices	4188
Real-world performance of vibration-controlled transient elastography with liver stiffness measurement and spleen stiffness measurement in a tertiary center.	4104	A Prospective Assessment of Beta Blocker response(BB) using Non invasive tests (NITs) in patients with Acute variceal bleed (AVB) using Artificial Intelligence Driven prediction Models-BLOCK BLEED MODEL	4191
The estimation of Portal pressure model with non-Newtonian fluid dynamics in liver cirrhosis	4110	A Meta-Analysis and Systematic Review on Comparison of Outcomes Between Early TIPS and Standard therapy.	4194
A Prospective, Single-center, Randomized, Open-Label Study to Investigate the efficacy and long-term outcome of cyanoacrylate glue for obliteration of all gastric varices (GOV1, GOV2, IGV1) versus obliteration of gastric varices with stigmata of recent haemorrhage in cirrhotic patients presenting with first episode of variceal bleed	4116	pTIPS is associated with better outcomes in patients with acute variceal bleeding and severe alcoholic hepatitis	4201
Safety of stopping non-selective beta-blockers (NSBBs) according to Baveno VII consensus in patients with cirrhosis and well-controlled liver disease etiology	4117	Prognostic performance of the new MELD 3.0 score, relative to MELD, MELD-Na and CLIF-C AD scores for emergent vs non-emergent TIPS creation	4218
Evaluation of esophageal and gastric varices in cirrhotic patients with portal hypertension: a central evaluation system for clinical research	4118	Exploring non-acute decompensation of cirrhosis and its long-term trajectories and outcome	4223
Lower Risk of Gastrointestinal Bleeding in Patients with Cirrhosis Who Have Received Direct Oral Anticoagulants (DOACs) Compared to Warfarin: A Territory-wide Cohort Study	4120		
In patients with compensated MASH cirrhosis with platelet count < 150,000/ $\mu$ L and radiologic findings of portal hypertension, a third are identified with esophageal varices on screening Esophago-Gastroduodenoscopy	4125		
Increasing comorbidities and medication burden in patients with cirrhosis and variceal haemorrhage from 2000 to 2020	4133		
Machine learning-based development and validation of a novel FIB-6 score for screening high-risk varices in compensated cirrhosis: an international multicenter study	4134		
Non-invasive diagnosis of HVPG $\geq$ 20 mmHg in cirrhotic patients based on spleen volume	4139		

## Vascular Liver Disease, Hemostasis and Thrombosis

### Hemostasis and Thrombosis

Low shear induced hepatic kallikrein-kinin system activation regulates intrahepatic vascular adhesion and develops pro-thrombotic microenvironment	246
Hematological long-term complications of COVID-19 in patients with compensated cirrhosis: A U.S. Based Analysis	1516
Defibrotide and its role in thrombin induced platelet activation and endothelial cell protection via PAR-1	1519
Thromboembolic Event Risk Factors in Patients with Liver Abscesses: Development of a Predictive Nomogram	1522
Assessment of Thrombin Generation in Cirrhosis Patients Before and After Liver Transplantation: Impact of Clinical Parameters on Endogenous Thrombin Potential	1525
Safety and outcomes of an on-demand transfusion strategy versus prophylactic transfusion of platelets in patients with liver cirrhosis and severe thrombocytopenia undergoing high-risk invasive procedures	1528
S100A8/9 is Upregulated in Platelets and Platelet-Derived Microparticles in Alcohol-Associated Hepatitis and Can Mediate Endothelial Inflammation	1530
Galectin-3 Binding Protein May Act Via Platelet-Derived Microparticles to Promote Hepatic Stellate Cell-Monocyte	1532

- Crosstalk Leading to Disease Progression in Alcohol-Associated Cirrhosis
- Preprocedural Thromboelastography Decreases Need For Blood Product Transfusion Prior to Endoscopy for Upper Gastrointestinal Bleeding in Cirrhotics: A Retrospective Review
- Portal vein thrombosis in cirrhosis, etiological spectrum, risk profile, and outcome.

1533  
1534

## Vascular Liver Disease, Hemostasis and Thrombosis

### Liver Sinusoidal Endothelial Cells

- Hepatic congestion promotes liver pathogenesis through the activation of Integrin  $\alpha$ V-YAP/TAZ-CTGF axis in LSECs

1520

## Vascular Liver Disease, Hemostasis and Thrombosis

### Vascular Liver Disease

- ★ Hepatic Artery Flow-Induced Portal Tract Remodeling and Fibrosis in Portal Hypertension: The Role of VCAM-1 and Osteopontin-Expressing Macrophages

6

- The Impact of Pre-Transplant Portal Vein Thrombosis on Post-Transplant Patient Survival
- Presentation and malformations associated with extrahepatic congenital portosystemic shunts
- Ursodeoxycholic acid improves liver enzymes in patients with obliterative portal venopathy - a pilot study
- Porto-sinusoidal vascular disorder and sinusoidal obstructive syndrome in patients treated with thiopurines: a systematic analysis
- Liver Nodules including Hepatocellular Cancer Rather than Impaired Liver Function are the Primary Clinical Challenge in Management of Patients with Fontan Associated Liver Disease
- Porto-sinusoidal vascular disease: A new nomenclature different from Idiopathic non-cirrhotic portal hypertension
- ★ Machine Learning of CT Images for Noninvasive Discrimination of Porto-sinusoidal Vascular Disease from Cirrhosis in Patients with Portal Hypertension
- Association of hemostatic status with portal venous system thrombosis in porto-sinusoidal vascular disease
- SARS-CoV-2 infected liver pericytes stimulate vWF expression by portal endothelial cells and an angiogenic response in the pulmonary endothelium
- The liver and spleen stiffness measure by transient elastography a promising tool for the clinical management of patients after Fontan-type surgery circulation
- Reliability of splenic stiffness in prediction of variceal bleeding and high-risk varices in non-cirrhotic portal fibrosis (NCPF)

1514  
1515  
1517  
1518  
1521  
1523  
1524  
1526  
1527  
1529  
1531